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ABSTRACT
An investigation has been conducted into factors influencing inter-particulate 
forces in pressurised metered dose inhalers (pMDI). Colloid probe atomic 
force microscopy (AFM) measurements of inter-particulate interactions were 
correlated with physico-chemical properties, theoretical surface energy 
calculations and the in vitro deposition characteristics of suspension based 
pMDI formulations.
Since pMDI formulations are rather complex, with various interactions being 
influenced by many variables, specific areas of pMDI formulation science 
were investigated. These included particle interactions in single formulations; 
particle interactions in combination drug systems; interaction of drug 
particulates with pMDI canister wall materials; and the influence of stabilizers 
on drug interactions.
The underpinning tools used to study such factors was AFM and surface 
energy measurements. AFM measurements were achieved by preparing 
colloid drug probes of micronised drug particulates of salbutamol sulphate 
(salbutamol) budesonide and formoterol fumarate dihydrate (formoterol) via a 
micromanipulation technique. Interactions between the AFM ‘drug probes’ 
and specific formulation surfaces (drug or canister material) were conducted 
in situ in a model propellant system.
A series of surface energy measurement techniques were utilised during the 
course of the study. Contact angle measurements were chosen to assess the 
dispersive (apolar), acid and basic (polar) components of the surface energy 
of the components used. The interfacial free energy of interactions for drug- 
drug and drug-device interactions were also theoretically predicted using the 
extended-DLVO theory and applied using the surface component approach 
(SCA).
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The force of interaction between each drug probe and a series of canister 
materials was compared with the predicted work of adhesion (calculated from 
the SCA). The force of adhesion, measured by AFM, was shown to correlate 
well with the predicted work of adhesion using the SCA. Moreover, the linear 
relationship between the work of adhesion and AFM measured adhesion was 
shown to be highly dependent on the polar contributions of the surface free 
energies of the interacting materials.
The force of interaction between a series of drug probes of a material and 
atomically smooth surfaces of each drug material (produced using controlled 
crystallisation) were compared with the predicted work of adhesion or 
cohesion from the SCA. The use of atomically smooth drug substrates 
allowed direct comparison between the adhesion/cohesion of each drug 
probe as the contact geometry remained constant. In general, comparison of 
the predicted adhesion/cohesion ratio (calculated using SCA) correlated well 
with the AFM measurements. In particular, salbutamol had a high cohesion 
force when comparing interactions between budesonide and formoterol. In 
addition, a series of in vitro studies, comparing the aerosolisation efficiency of 
both single and combination formulations of each drug were in general 
agreement with predicted and fundamental measurements of the interfacial 
interactions.
To investigate the potential of reducing inter-particulate cohesion in 
salbutamol sulphate pMDI formulations, the use of solubilised stabilisers was 
investigated. It was found that an increase in chain length (MW 200-600) and 
concentration (0.05 - 0.5 %v/w), of low molecular weight polymers 
(polyethyleneglycol), added to the model propellant resulted in a decrease in 
a significant decrease in particle adhesion by AFM measurements. 
Furthermore, the addition of polyvinylpyrrolidone, at low concentrations 
(0.001 %v/w) resulted in a significant decrease in adhesion, regardless of PEG 
concentration (P<0.05). These observations correlated well with theorised 
hypothesis regarding inter-particulate stabilisation using non-ionic polymers.
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The AFM colloid probe technique, in combination with physico-chemical 
characterisation and theoretical calculation, has successfully been employed 
to predict particle-particle and particle-substrate interactions specific to pMDI 
based inhalation technology. Furthermore, the correlation between 
theoretical, fundamental and in vitro behaviour may provide a rapid screening 




Localised delivery of pharmaceutical drug particulates to the respiratory tract 
has become an essential and effective therapeutic method for treating a 
variety of pulmonary disorders, including asthma, COPD (Chronic obstruction 
pulmonary disease) bronchitis and cystic fibrosis (British Thoracic Society et 
al., 1997). Such popularity can be related to the relative small dose required 
for effective therapy, reduced systemic exposure and minimised side effects. 
Furthermore, the large surface area for absorption at the terminal bronchioles 
and alveoli (-100 m2) provides a portal entry for systemic drugs (Patton, 
1996).
Drug distribution and deposition in the respiratory tract depends on many 
factors including: physico-chemical properties of a formulation (particle size, 
particle shape (Tang et al., 2004)), its delivery characteristics (aerodynamic 
diameter (Patton, 1996)), charge (Glover and Chan, 2004), density (William 
III et al., 1998; Steckel and Brandes, 2004) and hygroscopicity (Price et al., 
2002), anatomy of the respiratory tract and the co-ordination and breathing 
manoeuvre of a patient (Hickey and Martonen, 1993; Timsina et al., 1994).
The pressurised metered dose inhaler (pMDI) remains the most common 
prescribed device for therapeutic aerosol delivery (Ross and Gabrio, 1999). 
However, following the Montreal protocol in 1987, which has resulted in the 
gradual phasing out of chlorofluorocarbon (CFC) propellants, several new 
and unexpected challenges in the reformulation of hydrofluoroalkane (HFA) 
propellant based pMDI formulations have arisen. Of these, dispersion 
stability and particle interactions have been of utmost importance (Ranucci et 
al., 1990; Fu and Riman, 1993; Ruckenstein, 1993). With the ultimate aim of 
delivering a reproducible dose of medication to a target site, an 
understanding of particulate interactions within propellant based systems and 
their influence on formulation stability is of critical importance.
1.1 STRUCTURE OF THE AIRWAY
The human respiratory tract consists of a series of bifurcating airways, 
starting at the oropharynx and finishing at the alveolar sacs. The airway 
anatomy consists of the oro, nasopharynx, larynx, trachea, two main bronchi, 
five lobar bronchi (three on the right, two on the left) and fifteen to twenty 
dichotomous branching of the bronchi and bronchioles down to the level of 
the terminal bronchioles and the alveoli. A schematic diagram of a human 















Figure 1 Diagrammatic representation o f the structure o f a human lung 
(Copyright © 1996 Johns Hopkins University)
The portion of the airways that participates in gas exchange with the 
pulmonary capillary blood is the respiratory bronchioles, and the alveoli 
themselves. The alveoli act as the primary gas exchange units of the lung, 
especially as the gas-blood barrier between the alveolar space and the 
pulmonary capillaries are extremely thin, allowing rapid gas exchange.
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Oxygen can subsequently diffuse via the alveolar epithelium (a thin interstitial 
space) and the capillary endothelium.
The surface area provided by the respiratory bronchioles and alveoli for gas 
exchange is tremendous. It is estimated that the adult human lung has over 
300 million alveoli with a total surface area of approximately 100 m2 (Patton, 
1996). In simple terms, this provides a high surface area, low surface fluid 
coverage, thin diffusion layer and sluggish cell surface clearance by 
macrophages. These properties provide an alternative delivery system to the 
more conventional gastrointestinal, nasal, buccal or transdermal delivery 
routes (Patton, 1996).
However, the delivery of medicaments to the respiratory tract is not a simple 
process. The entrainment and efficient delivery of particulates to the lung is 
regulated by three intrinsic physiological factors: inertial impaction, 
gravitational sedimentation and diffusion (via Brownian motion) (Hinds,
1999).
When designing and formulating a delivery system, consideration of the 
many factors which influence the deposition of drug particles needs to be 
understood. The main factors are the properties of the aerosol particles 
(aerodynamic diameter) and the mode of inspiration (flow rate, velocity 
profile) (Smyth, 2003). The optimum size range of particulates for inhalation 
therapy has been shown to be between 2.5 and 6 pm (Pritchard, 2001).
Asthma, together with Chronic Obstructive Airways Diseases is associated 
with approximately one-third of the common causes of death in the European 
Union (International Pharmaceutical Aerosol Consortium (IPAC), 1997). 
Clearly, the requirement for an effective treatment of such respiratory 
diseases remains in continuous demand.
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1.2 CURRENT RESPIRATORY DELIVERY MECHANISMS
Current mechanisms of drug delivery to the respiratory tract can be classified 
via three approaches: dry powder inhalers (DPIs), nebulisers and pressurised 
metered dose inhalers.
Dry powder inhalers are the most recent development in the delivery of drug 
therapy to the lung. They rely on the energy supplied by the forced inhalation 
breath of patients to de-aggregate and deliver the active ingredient to the site 
of action. In general, the drug is in the form of micronised particles, either as 
agglomerates or in combination with a carrier substance (typically lactose). 
The main advantage of this delivery system is that it does not rely on patient 
compliance. However, the efficiency of a dry powder inhaler is often hindered 
by the energy required to overcome de-aggregation of the small drug 
particles (Ganderton and Jones, 1987) upon actuation.
Nebulisers can produce a constant stream of aerosol particles that can be 
inhaled via tidal breathing. The main advantage of such delivery systems is 
that they provide a potential means of administrating aqueous formulations. 
Furthermore, the aerosol droplets produced are smaller than DPIs and 
pMDIs, making them capable of easily penetrating the small airways (Gupta 
and Hickey, 1991). However, the system is usually cumbersome and can 
only be used at home or in a clinical setting. The most significant draw backs 
of this delivery system include: length of time needed for delivery of 
medication, the complexity of device assembly and the requirement on mains 
electrical supply for operation.
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1.2.1 Pressurised metered dose inhalers
Pressurised metered dose inhalers (Figure 2) have been marketed to the 
public as a medicament since the mid 1950’s. They were first introduced by 
Riker Laboratories in Santa Barbara, now 3M Healthcare (Clarke, 2002). 
Fundamentally, pMDIs rely on aerosol propellant technology, in which a high 
vapour pressure gas (typically a liquid propellant) is contained in a 
pressurised canister, under a super-cooled state. On release of a metered 
volume of the drug/propellant mixture, the volatile propellant rapidly expands 
through the metering stem and vaporises through an actuator orifice to 
deliver micrometer-sized drug aerosols (Dunbar et al., 1997).
In pMDI based systems, the drug can either be homogeneously suspended 
(colloidal system) or solubilised in a propellant (either with or without the 
addition of co-solvents). By metering the release of a given volume of 
propellant (typically 25 to 100 pi) within an integral metering valve, a 
reproducible dose of drug can be delivered. The high, internal energy 
produced upon evaporation of the propellant, provides the inertial driving 







Drug / Propellant 
Form ulation
Figure 2 Basic pMDI design
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Until 1995, all marketed pMDI products contained CFC as the delivery 
propellant. However, concerns over the possible detrimental ozone depleting 
effects of CFCs (Molina and Rowland, 1974) brought 150 nations to sign the 
Montreal protocol in 1987, which committed the signatory nations to cease 
CFC production by 1996 (United Nation Environment Programme, 1996). As 
a result, pharmaceutical companies have committed large resources to the 
research and development of CFC-free pMDI systems (Vervaet and Byron, 
1999).
The candidates that emerged from this research as potentially suitable CFC 
replacements were short-chain hydrofluoroalkanes (HFAs) (Dalby et al., 
1990): Specifically, 1,1,1,2,3,3,3 Heptafluoropropane (HFA-227) and 1,1,1,2 
Tetrafluoroethane (HFA-134a). However, HFA and CFC propellants posses 
quite different physical and chemical proprieties, as shown in Table 1, 





















CFC 11 1.49 0.43 23.7 -1.8 1 1
CFC 12 1.33 0.22 -29.8 67.6 1 3
CFC 114 1.47 0.36 3.6 11.9 0.7 3.9
HFA 134a 1.21 0.22 -26.5 68.4 0 0.3
HFA 227 1.41 0.26 -17.3 56.0 0 0.7
* Relative to CFC 11
Table 1 Physico-chemical properties of pMDI propellants (adapted from 
McDonald and Martin, 2000)
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As indicated in Table 1, the boiling points and vapour pressures of CFCs and 
HFAs vary significantly. Vapour pressure ultimately will relate to the speed of 
evaporation, and, consequently the aerosol droplet size and efficiency of 
deposition within the lung. A high vapour pressure propellant (as for HFA 
propellants) would produce rapid evaporation resulting in the formation of 
small droplets. Furthermore, the increased internal energy within the system 
upon evaporation of the propellant may lead to high plume velocities that 
may result in a large percentage of drug particles being impacted on the oro­
pharynx (Polli et al., 1969). Similarly, propellant boiling points may have an 
impact on the filling method of pMDI canisters. For example, CFC filling can 
be achieved at ambient temperature (using a CFC mix) while HFA filling must 
occur under pressure at low temperature via the valve.
More importantly, however, is the solvency properties of HFAs differ from that 
of CFCs (Dickinson el al., 2000). Partial solubility of a suspended drug in the 
dispersant may result in Ostwald ripening, crystal growth, poor physico­
chemical stability and out of specification performance as a function of 
storage.
Propellant driven suspension metered dose inhaler formulations consist of 
solid drug(s), typically micronised, dispersed in a propellant medium, which is 
liquefied under pressure. Given the relative poor solvency power of HFAs 
relative to CFCs propellant, suspensions containing micronised drug in 
liquefied HFA propellants have become widely used in pMDIs (Michael et al., 
2001). Such formulation approaches are unique in pharmaceutical systems, 
and are only otherwise applied to non-aqueous dispersions in, for example, 
the oil and paint industries.
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One area of concern however, in such systems, is suspension stability.
Since the drug particles being delivered to the respiratory tract are of micron 
size, the suspended particles have a tendency to agglomerate together or 
adhere to internal components of the device. The reason for such adhesion is 
due to the high surface area to mass ratio of the micronised particles and the 
interaction forces dominating particulate interactions, which are the omni 
present van der Waals force, polar and electrostatic-double layer 
interactions.
Such interactions can be described using conventional physics, with the most 
relevant approaches being discussed below.
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1.3 PARTICLE INTERACTION THEORY
Interactions between colloidal particles are usually described by the 
Derjaguin-Landau-Verwey-Overbeek (DLVO) theory (Derjaguin and Landau, 
1941; Verwey and Overbeek, 1948). The DLVO theory considers two types 
of interactions: a dispersive attractive interaction of the Lifshitz van der Waals 
(LW) type, and a predominately repulsive electrostatic (EL) interaction due to 
the interpenetration of electrical double layers.
1.3.1 DLVO theory
The Lifshitz-van der Waals force (van der Waals, 1899), which is generally 
attractive in nature, is a short range force. This force can be further divided 
into three closely connected phenomena: Debye-lnduction force (Debye, 
1920), Keesom-orientation forces (Keesom, 1912) and London dispersion 
forces (London, 1930). However, the most ubiquitous of the van der Waals 
forces are the dispersive or London forces. Dispersive forces are finite 
between all atoms and are of predominant importance between macroscopic 
bodies (Overbeek, 1952).
From the interactions on a molecular basis, two different approaches have 
been developed to predict interactions on a macroscopic level.
Hamaker developed a theory to calculate the van der Waals forces 
conducting pair-wise summation of the dispersion (van der Waals- 
London) energies theoretically, based on microscopic interactions, for 
macroscopic bodies (of flat surfaces) interacting with each other, by 
assuming additive molecular forces throughout the material. He went on to 
show that the dispersive energy between two surfaces decayed 
proportionally with the square root of the separation distance (Hamaker,
1937) and that it was actually possible for the van der Waals-London 
interactions between two different materials immersed in a liquid to be 
repulsive.
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In simple terms, for two materials 1 and 2 immersed in a medium 3, the 
combining rule is described by Equation land Equation 2.
Equation 1
A 131 -  A n  + A 33 + 2 A ,3
where A is described as the Hamaker constant and An and A33 refer to the 
Hamaker constants of the solid/solids and the medium, respectively, in 
vacuo.
Equation 2
A ,32 = A ,2 + A 3 3 - A , 3 - A 3,
It is clear that A131 is always positive or zero, however A132 can assume 
negative values, when An > A33 > A22 or An < A33 < A22.
In contrast to Hamaker’s approach, which started with single interatomic 
interactions, to arrive at the total interaction energy for macroscopic bodies 
by a process of summation, Lifshitz (Lifshitz, 1956) has constructed a more 
accurate approach through a purely macroscopic framework. The problems 
associated with the use of summation process have been completely 
eliminated in this macroscopic treatment of dispersion forces.
Lifshitz treated the interacting bodies as continuous media. The dispersion 
forces in this approach have been derived in terms of the macroscopic 
properties of interacting bodies, such as their dielectric constants or refractive 
indexes. In his macroscopic approach, Lifshitz eliminated the total additive 
molecular force in favour of a screening effect caused by the atoms present 
on the surface of the two contiguous bodies. (Israelachvili, 1992) used this 
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where / is the distance between the particles and yLW the apolar component 
of the surface free energy.
Surface free energy of a liquid or a solid is defined as half of the free energy 
charge AGLW due to the cohesion of material in vacuo according to 
Equation 4.
Equation 4
= - - & G "
2
The application of the DLVO theory to the stabilisation of drug suspensions in 
non-aqueous pMDI media has not been fully validated. The possible 
limitation of the approach, which has been successfully employed to describe 
the behaviour of aqueous suspensions, is the absence of an ionic double 
layer (Kitahara, 1974; Pugh et al., 1983). However, a quick theoretical 
calculation of the repulsive electrostatic energy of interaction between 1 pm 
solid particles as a function of inter-particulate distances in liquefied 
propellants with varying dielectric constants (reciprocal thickness of the 
diffuse double layer set at 2x106 cm'1) show that the electrostatic repulsive 
forces acting between particles are small. This is attributed to the overlap of 
very diffusive electrical double layers due to a combination of low dielectric 
constants and low ionic strengths (Wyatt and Vincent, 1989). Thus, the 
attractive Lifshitz van der Waals forces are thought to predominate at all 
separation distances. As a result, DLVO theoretical descriptions of non- 
aqueous drug suspensions such as pMDI formulations are very limited, as 
they fail to predict the stability of these formulations observed in some cases.
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1.3.2 Surface component approach
An alternative approach to the DLVO theory has been proposed by van Oss 
(van Oss, 1994). The van Oss approach decomposes the surface energetics 
(i.e. surface tension or contact angle values) into independent contributions, 
and in particular introduces a polar acid-base (AB, electron donor/electron 
acceptor) component (van Oss, 1994). These electron-acceptor (y+, Lewis 
acid type), electron-donor (y\ Lewis base type) interactions are essentially 
asymmetrical. The corresponding polar free energy of interaction, which can 
be repulsive or attractive (depending on the chemical structure, suspending 
medium properties and surface potential), can control the total energy of 
interaction at small separation distances.
In general, the polar component of the free energy of a material can be 
expressed as:
Equation 5
Given that electron-acceptor and electron-donor parameters of most 
substances are not equal to each other and that material 1 will react with 
material 2 and vice versa, the acid-base free energy of adhesion can be 
described using the following relationship:
Equation 6
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So adapting for polar interactions the acid-base free energy, yi2AB, can be 
expressed as:
Equation 7
Yn = 2{ 4 r l  ~ 4 r l \ 4 r l  ~ 4 r l )
According to this surface component approach (SCA), the total surface free 
energy of a solid is determined by the Lifshitz van der Waals (yLW) dispersive 
component and the polar AB component (yAB), as given in Equation 8.
Equation 8
TOT LW ABy = y + y
The total free energy of interaction between two surfaces in a liquid medium 
is subsequently defined as the sum of the Lifshitz-van der Waals (LW) 
dispersive interactions, the polar component (AB), and electrostatic double 
layer (EL) interactions:
Equation 9
AGtot = \a Glw + A Gab) + A Gel
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In the absence of an electrostatic influence, the interaction energy between 
solid surfaces (S) immersed in a liquid (L) can be expressed by the interfacial 
free energy (A G sls), (see Equation 1 0 ). This in turn can be related to the 
solid-liquid interfacial tension.
Equation 10
The interfacial energy parameters for the LW and AB contributions between 
similar solids (1) in a liquid (3) can be obtained from the surface free energy 
and surface tensions of the solid and liquid by using the Good-Girifalco- 
Fowkes approach (Fowkes, 1963; Good and Girifalco, 1960) (Equation 11).
Equation 11
For liquids with very low polarity (y3+ = 73 ' -  0 mJ.m'2), the free energy of 
interaction can be simplified to:
Equation 12
Hence, knowledge of the surface energy of the solid (71LW, 71+ and 71 ')  and the 
surface tension of the liquid (y3LW, Y3+ and 73 ') enables the determination of 
interaction energy between particles.
= AGLW + AGab = - 2  ySLS ■2 ( r £ + r £ )
AGui -  - 2  (VYr  -  Vl,3W)2 "^(Vy^Y! +VY 3 Y3 _ VyiY3 —\/ti Y3 )
V
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Similarly, the energy of interaction between dissimilar solid surfaces (1 and 2) 
in a liquid (3) can be calculated using the following expression:
Equation 13
In an apolar medium (y3+ and 73 ' ~ 0 mJ.m'2), the energy of interaction can be 
used in the simplified form (Equation 14).
Equation 14
A G 132 = 2
L W  y  L W +
-J7777- 4r
L W  L W
2 Y 3
Y
-  4 r
L W  L W
1 Y 2 Y
LW +
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1.3.3 Interparticulate adhesion (JKR & DMT)
The force of adhesion can then be derived from the thermodynamic work of 
adhesion (WaCj = - A G sls) through the Hertz approximation for elastic bodies 
(Hertz, 1882). This takes into additional account the separation distance and 
the contact geometry of interacting surfaces. Two models can be used for 
this purpose: the Johnson, Kendall and Roberts (JKR) and the Derjaguin, 
Muller and Toporov (DMT) models (Derjaguin et al., 1975; Johnson et al.,
1971). The general form of the force of adhesion with relationship to energy 
(derived for van der Waals interactions between two spherical particles) can 
be expressed via: (Hertz, 1882).
Equation 15
Fad=m tR *W ad
Where R* is the harmonic mean of the particle radii (also called contact 
radius) and n is a pre-determined constant depending on the selected model 
(n=3/2 for JKR and n=2 for the DMT).
Both models have shown their strengths and limitations. The JKR model is 
applicable only when compliant materials of high surface energy and a large 
radius come into contact, i.e. in the regimen where elastic deformation due to 
the adhesion force is large compared to its effective range of interaction. In 
comparison, DMT theory is applicable only to relatively stiff systems with a 
low adhesion force and a small sphere radius, i.e. the regimen in which 
elastic deformation due to surface forces is small compared to the interaction 
range.
Consequently it is instructive to notice how the choice of contact mechanics 
theory can produce inaccurate values, for example, the surface energy.
Thus, the validity of contact mechanics models should be fully scrutinised 
when applied to experimentally derived force measurements.
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Over the past few years, many techniques have been developed to 
characterise particle-particle interactions. These include techniques such as 
centrifugal detachment, that characterise adhesion by measuring the 
centrifugal forces required to detach particles (Booth and Newton, 1987; 
Clarke et al., 2002; Kulvanich and Stewart, 1988; Podczeck et al., 1996; 
Staniforth, 1980) and electric field detachment, that uses electric fields to 
remove particles from a surface (Eklund et al., 1994; Zhou et al., 2003).
An alternative approach to such methods of fundamental adhesion 
measurement is the atomic force microscope (AFM) (as used in this 
investigation). Both centrifugal detachment and electrical filed detachment 
monitor the adhesion of many particles, and the output of these 
measurements are a distribution of adhesion forces. In comparison the AFM 
is capable of accurately measuring the adhesion of single micron sized 
particles with a variety of surfaces with high precision and control. In addition, 
using the AFM it is possible to look at the force of attraction/repulsion 
between the particle and the surface prior to and post particle contact with 
the surface. Thus, allowing the elucidation of the relationship between the 
interactive forces described earlier and experimentally measured adhesion 
forces (Schaefer et al., 1994; Schaefer et al., 1995).
However, comparison of calculated theoretical force of adhesion with direct 
and quantitative experimental measurements of interactive forces for “model” 
spheres (e.g. colloidal polystyrene) on atomically flat surfaces (e.g. mica) by 
AFM have shown large discrepancies (Schaefer et al., 1995). It has been 
suggested that the main source of inconsistency may be due to the 
difference in contact areas at any particular time between a particle and 
substrate.
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To further overcome such limitations of knowing the true area of contact 
between drug probes, the cohesive and adhesive force ratios may be 
analysed and compared using the recently developed cohesive/adhesive 
balance (CAB) analysis procedure developed by Begat et al. (Begat et al., 
2004). This AFM based approach provides for the first time a means of 
quantifying the adhesive and cohesive force balance within a powder 
formulation. Furthermore, the use of the CAB approach using AFM 
measurements of inter-particulate forces may be directly correlated to the 
thermodynamic work of cohesion and adhesion of interacting surfaces via 
surface energy measurements (e.g. using contact angle (CA) and inverse 
gas chromatography (IGC)).
In general, for a drug particulate interacting with two atomically flat surfaces 
(one alike and one different) the cohesive/adhesive balance between the two 
materials can be expressed by:
Equation 16
F  R *  n7tW1  coh _  cohesion r l ' <' r r coh
F  R * nnWx  adh adhesion adh
Where Fcoh and Fadh are the cohesive and adhesive forces measured by 
AFM, and Wcoh and Wadh are the thermodynamic works of cohesion and 
adhesion, respectively. Assuming that the contact mechanics of the cohesive 
and adhesive interaction follow the same theoretical model, the ratio of the 
forces for a series of colloidal probes should be directly proportional to the 
thermodynamic ratio of the works of cohesion and adhesion of the interfacial 
interactions. Furthermore, determining the balance of forces for a series of 
colloidal probes via AFM measurements overcomes the need to determine 
variations in the spring constant (k) of each individual AFM cantilever.
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1.4 IMPLICATIONS OF PHYSICAL-CHEMICAL FACTORS ON THE 
PERFORMANCE OF PMDI SUSPENSION FORMULATIONS
The culmination of physical-chemical factors that influence interparticle 
adhesion may result in quantifiable variations in pMDI aerosolisation 
performance.
Two of the major factors influencing such performance are canister adhesion 
and suspension behaviour. For example increased force of adhesion 
between drug particles and canister walls may result in a decrease in emitted 
dose (Michael et alM 2001; Young et al., 2003). When considering low dose 
medicaments (such as formoterol fumarate dihydrate: approx. 6-12 pg/dose) 
the possibility of drug loss to the canister wall becomes critical, since the 
internal surface area of the canister may approach the projected surface area 
of the total suspended drug.
When considering suspension behaviour, the interparticulate forces can be 
directly related to the adhesion, flocculation, caking and re-suspension 
behaviour of a formulation. Ideally, drug particles should form lose floccules 
when suspended in the propellant medium, allowing easy re-suspension 
upon shaking. In addition, it is essential that such lose floes separate upon 
aerosolisation to result in discrete particulates for respiratory deposition. 
Variation in forces between particulates may result in alteration of the 
suspension behaviour inducing irreversible flocculation, sedimentation and 
caking/creaming.
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Such factors become further complicated, when considering multicomponent 
systems. In the case of combination drug therapies, the variation in 
adhesive/cohesive between the formulation components may result in 
different aersolisation behaviour when compared to their single component 
therapies (Louey et al., 2003; Michael et al., 2001).
In general, many formulation strategies have been developed to overcome 
such issues. These include particle engineering (Shekunov and York, 2000; 
Steckel and Brandes, 2004; York, 1999), canister modification (Ashurst et al., 
1996; Young et al., 2003), and the addition of formulation stabilisers (Ashayer 
et al., 2003; Brambilla et al., 1999; Clarke et al., 1993). The later two will be 
investigated in this thesis.
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1.5 GENERAL DISCUSSION: AIMS AND SCOPE
As previously stated, understanding the interaction and behaviour of surfaces 
and drug particulates in pharmaceutical systems is of critical importance to 
enable us to model these systems accurately. The classical model of 
suspension stability, DLVO, has historically described these interactions. This 
model derives from an energy balance composed of attractive and repulsive 
interactions. The original model focused exclusively on attractive van der 
Waals and repulsive coloumbic interactions. In the last several years, this 
traditional model has been unable to describe correctly the behaviour of drug 
particulate in pharmaceutical environments. In 1986 van Oss introduced a 
new theory, in which he suggested the presence of other interactions that 
could play a role in suspension systems not commonly included by traditional 
particle stability models: e.g. Lewis acid/base interactions and steric 
interactions. Significant work has been focused on extending the principle of 
the traditional DLVO model to accommodate these non-DLVO forces 
(energies) for pharmaceutical suspension systems, using the SCA model 
(Traini et al, 2005).
Therefore, the purpose of this investigation was to investigate such factors in 
relation to HFA based pMDI systems using a combination of conventional 
and novel techniques.
As previously stated, there are many formulation variables in pMDI systems. 
Here, the author has focussed on three major areas; drug-canister 
interactions, drug-drug interactions in single and combination formulations 
and the influence of stabilisers. Since such systems are complex, the focus 
on discrete areas allowed in depth investigation, while keeping other possible 
variables constant.
The interactions in such systems were characterised using both theoretical 
and experimental approaches, in order to understand and predict formulation 
aersolisation performance.
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CHAPTER 2: GENERAL MATERIALS AND METHODS
In order to fully understand particle-particle and particle-substrate interactions 
in pressurised metered dose inhalers the materials were first characterised in 
terms of sample morphology, particle size, surface energy, surface area, 
density and solubility. Furthermore, the preparation of materials used 
throughout the study is described.
2.1 MATERIALS
Drugs, propellants and pressurised metered can materials used throughout 
the investigation are given in Table 1. All organic solvents used in the study 
were supplied by BDH (Poole, Dorset, UK) and were of at least analytical 
grade. Water was prepared by reverse osmosis (MilliQ, Molsheim, France).
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Material Supplier
Salbutamol sulphate AstraZeneca, R&D Charnwood, UK
Budesonide AstraZeneca, R&D Charnwood, UK
Formoterol fumarate dihydrate AstraZeneca, R&D Charnwood, UK
Polyethyleneglycol (200, 400, 600 M.W) Acros Organics, New Jersey, USA
Polyvinylpyrrolidone (Povidone K25) AstraZeneca, R&D Charnwood, UK
2H, 3H, decafluoropentane model propellant Apollo Scientific, Derbyshire, UK
HFA 134a, hydrofluoroalkane propellant (Zephex 
134a)
Inverted metering valves BK 357 (50 p i )
IneosFluor, Cheshire, UK
Bespack Europe Limited, Norfolk, 
UK
Inverted continuous valves BK 357 (cont) Bespack Europe Limited, Norfolk,
Cut edge aluminium cans (18 ml brim capacity)
UK
Presspart, Lancashire, UK
Cut edge anodised aluminium cans (18 ml brim 
capacity)
Cut edge perfluoroalkoxy cans (18 ml brim capacity)
Presspart, Lancashire, UK
Intrapacgroup, Harrisonburg, VA, 
Canada
Cut edge fluorinated ethylene propylene -  polyether Intrapacgroup, Harrisonburg, VA,
sulphone (18 ml brim capacity) Canada
Cut edge polytetrafluoroethylene
3M United Kingdom PLC-Bracknell, 
UK
Actuators ( 0.3 mm orifice diameter)
Bespack Europe Limited, Norfolk, 
UK
Glass containers Saint Gobain pic, London, UK
Table 2 Drugs, propellants, formulation components and pressurised
metered can materials used throughout the investigation
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2.1.1 Note on the drug materials used for investigation
The chemical structures of salbutamol sulphate budesonide and formoterol 


















Figure 3 Chemical structures for (a) salbutamol sulphate, (b) budesonide 
and (c) formoterol fumarate dihydrate
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Salbutamol sulphate is a P2 bronchodilators agonist prescribed for chronic 
and sever asthma.
Likewise the structure for budesonide (corticosteroid used in prophylaxis of 
asthma) is generally considered relatively normal and can be compared to 
other commonly used steroids such as beclometasone dipropionate (Florey,
1972).
The crystallographic asymmetric unit of formoterol fumarate dihydrate (potent 
P2 adrenoreceptor agonist used as long acting bronchodilator in asthma 
therapy) contains one molecule of formoterol, a half molecule of fumarate 
and one molecule of water. The crystal water and fumarate anion are both 
involved in intricate hydrogen bonding, both as donor and acceptor (Ertan et 
al., 1997).
2.1.1a Important note relating to drug names
Unless otherwise stated in the text, salbutamol sulphate shall be referred as 
salbutamol and formoterol fumarate dihydrate shall be referred to as 
formoterol.
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2.2 SCANNING ELECTRON MICROSCOPY
The morphology of the drug particle surfaces used throughout the 
investigation was investigated by scanning electron microscopy (SEM). 
Scanning electron microscopy involves generating a high-resolution image of 
a conducting sample, by collecting and analysing the secondary electrons 
(weakly bound conduction-band electrons) emitted as a result of high-energy 
electron beam collisions.
2.2.1 Materials and methods
The morphology of each micronised drug powder was investigated using a 
JOEL 6310 SEM (JEOL, Japan) at 10 KeV. All samples were mounted on 
adhesive black carbon tabs, (pre-mounted on aluminium stubs), and coated 
with gold (using a sputter coater S150B, Edwards High Vacuum, Sussex,
UK) prior to analysis.
2.2.2 Results and discussion
Representative scanning electron micrographs of the micronised salbutamol, 
budesonide and formoterol samples are shown in Figure 4, Figure 5 and 
Figure 6, respectively.
In general, representative photomicrographs of the ‘as supplied’ salbutamol 
suggest the crystals have a columnar shape. In comparison, analysis of the 
budesonide and formoterol images suggests the crystal form to have both 
columnar and irregular plate-like crystal shapes.
In addition, it is important to note, large variations in crystal size were 
observed for all three drugs. Such observations may be attributed to the 
limitations of high-energy milling processes (Buckton, 1997; Larhirib et al., 
2003).
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Figure 4 Representative scanning electron micrographs of micronised
salbutamol taken at (A) X  500, (B) X  5,000 and (C) X  10,000 magnifications
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memm
Figure 5 Representative scanning electron micrographs of micronised
budesonide taken at (A) X  500, (B) X  5,000 and (C) X  10,000 magnifications
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Figure 6 Representative scanning electron micrographs of micronised
formoterol taken at (A) X  500, (B) X 5,000 and (C) X  10,000 magnifications
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2.3 PARTICLE SIZE ANALYSIS
The particle size distribution of each drug material was investigated using 
laser light scattering. In simple terms, particle size measurement using laser 
light scattering involves measuring the intensity and pattern of scattered light 
from a laser passing through a particulate sample. However, when 
investigating particles of a diameter of less than 10 jam the optical properties 
of the material are considered (Mie theory). The final particle size distribution 
is calculated by matching the experimental diffraction pattern to theoretical 
patterns (British Standard, 1999).
2.3.1 Materials and methods
Particle sizing of each drug sample were performed using a Malvern 
Mastersizer X (Malvern Instruments Ltd, Malvern, UK). The instrument was 
equipped with a small volume circulating cell and a 100 mm lens. 
Approximately 1 mg of drug material was suspended in a 0.1% lecithin / 
cyclohexane solution dispersant. Each sample was subsequently sonicated 
for 10 minutes at 25°C prior to analysis (determined sufficient to fully de­
aggregate the powder sample) (Chawa et al., 1994; Franco et al., 2004). 
Each sample was conducted in triplicate and represented as a volume 
distribution.
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2.3.2 Results and discussion
The 10%, 50% (median) and 90% cumulative percentile volumetric diameters 
for the micronised drugs are given in Table 3, while full distributions are 
shown in Figure 7.
Micronised salbutamol was found to have a median diameter of 3.33 pm 
(with over 74% of particles below 5 pm), budesonide a median diameter of 
3.24 pm (with over 82% of particles below 5 pm) and formoterol a median 
diameter of 2.69 mm (with 93% of particles below 5 pm).
Drug Sample D0.1 pm D0.5 pm D0.9 pm
Micronised salbutamol 1.60 ±0.01 3.33 + 0.03 6.92 ± 0.06
Micronised budesonide 1.80 + 0.00 3.24 ± 0.01 5.93 ± 0.03
Micronised formoterol 1.54 + 0.01 2.69 + 0.01 4.63 ± 0.02
Table 3 Basic size distribution percentiles for the micronised drug 
materials (n=3, ±  Standard deviation)
In general, the particle sizing data agreed well with SEM observations, with 




































Figure 7 Particle size distributions for micronised (A) salbutamol, (B) 
budesonide and (C) formoterol
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2.4 X-RAY POWDER DIFFRACTION
X-ray powder diffraction (XRPD) involves the measurement of diffracted 
monochromatic X-rays as they pass through the atomic spacing that exists 
between the atoms in a crystalline material. In simple terms, the rotation of a 
crystalline sample, in relation to the X-ray beam, allows calculation of the 
three-dimensional structure from the diffracted X-rays that pass between the 
crystal planes. In comparison to single crystals, a powder sample will have a 
random orientation of crystallites. Thus, for a powder sample, a diffraction 
cone of semi apex angle 2-Theta is produced. The subsequent diffraction 
pattern will be particular to the material under investigation (Guinier, 1994).
2.4.1 Materials and methods
X-ray diffraction spectra of the micronised drugs samples were obtained 
using a Phillips X-ray powder diffraction system (Phillips X-Ray Analytical, 
Cambridge, UK) fitted with a 4-kW X-ray generator (PW 1730/00). Scanning 
was performed in steps of 2-Theta over the range of 20, 5-60° to produce 
each spectrum.
2.4.2 Results and discussion
Powder X-ray diffractograms of micronised salbutamol, budesonide and 
formoterol are shown in Figure 8 A, B and C, respectively.
Analysis of the X-ray powder diffractograms for the micronised drugs suggest 
a predominantly crystal structure. In addition, the diffractograms suggest 
good correlation with studies reported previously (Columbano et al., 2002; 
Ertan et al., 1997; Steckel et al., 2004; Ticehurst et al., 1994).
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Figure 8 XRPD diffractographs for micronised (A) salbutamol, (B) 
budesonide and (C) formoterol
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2.5 TRUE DENSITY
For pMDI suspension systems, the density of drug particulates will play an 
important role on the physical behaviour of the system. True density of 
powder samples are generally measured using helium pycnometry.
Helium pycnometry measures the true density by calculating the pressure 
change of helium in a calibrated volume in relation to an unknown mass with 
an unknown volume (Webb and Orr, 1997).
2.5.1 Materials and methods
True density measurements were determined using helium pycnometry 
(Accupyc 1330 Gas Pycnometer, Micromeritics, Norcross, GA). Samples 
were prepared by storing in open pans at 40 °C for 48 hours prior to analysis. 
The temperature was maintained at 27°C during out-gassing and analysis.
2.5.2 Results and discussion
True density measurements are given in Table 4.
Drug Sample Sample density (g.cm3)
Micronised salbutamol 1.306 ±0.001
Micronised budesonide 1.240 ±0.007
Micronised formoterol 1.295 ±0.007
Table 4 Density measurements for the micronised salbutamol, 
budesonide and formoterol. (n-10, ±  Standard deviation)
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2.6 SURFACE AREA
Specific surface areas of the three micronised drugs were determined by 
nitrogen adsorption. Briefly, the principle involves measuring the difference in 
pressure between a sample and reference blank, under isothermal 
conditions, after addition of finite quantities of adsorption gas. By applying the 
B.E.T equation (Brunauer et al., 1938), describing monolayer-multilayer 
surface adsorption it is possible to calculate the point of monolayer coverage 
and thus surface area (Webb and Orr 1997). The linear form of the B.E.T 
equation is given by:
Equation 17
P
K (P o ~ P ) VmC VmC P0
1 + ( C - l ) P
Where P is the partial pressure of adsorbate, Va is the volume of gas 
adsorbed at the specific pressure, Vm is the volume of adsorbed gas in a 
monolayer, P0 is the saturation point of the adsorbate and C is the B.E.T 
constant. Subsequently, by plotting the transform of the equation the 
monolayer coverage can be calculated from the slope and intercept.
Equation 18
VJP, -P ) vs P0
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2.6.1 Materials and methods
Specific surface area was measured by 5-point B.E.T nitrogen adsorption 
(Gemini 2360, Micromeritics, Dunstable, UK) at 77 K in triplicate. Samples 
were accurately weighed into standard glass bulbs and dried under nitrogen 
at 40°C for 24 hours prior to analysis (FlowPrep 060 Micromeritics, 
Dunstable, UK).
2.6.2 Results and discussion
Specific surface areas for salbutamol, budesonide and formoterol are given 
in Table 5.
Drug sample Surface area (m2g'1)
Micronised salbutamol 3.11 ±0.01
Micronised budesonide 5.90 ± 0.06
Micronised formoterol 5.63 ± 0.04
Table 5 Specific surface areas of the micronised drug samples 
measured by multipoint B.E.T nitrogen adsorption. (n=3, ±  Standard 
deviation)
It is interesting to note that while budesonide and formoterol have 
comparable surface area, the surface area of salbutamol is relatively smaller. 
This is in agreement with particle size values for the same drugs where 
salbutamol had the largest mean values and consequently smaller surface 
area.
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2.7 DIFFERENTIAL SCANNING CALORIMETRY
The influence of heating on the thermal properties of the micronised drugs 
was investigated using differential scanning calorimetery (DSC). In principle, 
DSC operates by measuring the heat flow associated with chemical changes 
in a material (i.e. crystallisation or melting) in relation to change in 
temperature. This is achieved by measuring the current required to maintain 
an equal heat flow to both a sample and reference during heating or cooling 
(Charsley and Warrington, 1992).
2.7.1 Materials and methods
Thermal properties of the micronised drugs were investigated using a 
differential scanning calorimeter (DSC 2920, TA instruments, Surrey, UK). 
Approximately 5-10 mg of micronised drug was accurately weighed into a 
DSC sample pan and crimped with a lid to form a hermetic seal. The sample 
and reference (empty hermetically sealed pan) were heated using a 
10°C.min'1 ramp rate. Calibration of the DSC was checked by measurement 
of an indium standard (melting point, 156.6°C).
2.7.2 Results and discussion
Representative thermograms of salbutamol, budesonide and formoterol are 



















Figure 9 Differential scanning calorimeter thermographs o f (A) 
salbutamol, (B) budesonide and (C) formoterol
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The DSC thermograph for salbutamol (Figure 9 A) suggested an isothermal 
response with respect to heat flow, until an endothermic response was 
observed with a peak at approximately 202°C (suggesting a melt with 
decomposition). In general, such observations were in good correlation with 
previously published data (Ticehurst et al., 1994; Ward and Schultz, 1995).
Analysis of the DSC thermographs for budesonide (Figure 9 B) suggested an 
isothermal response with respect to heat flow until an endothermic response 
was observed with a peak at approximately 261 °C (suggesting a melt with 
decomposition) (Martin et al., 2002).
In contrast, the thermal response for formoterol (Figure 9 C) produced a wide 
endothermic response from approximately 100°C to 160°C, indicative of 
water loss and melting of a hydrated organic material which demonstrated 
formoterol to undergo a complex phase transition when heated.
53
2.8 KARL FISHER WATER DETERMINATION
The water content of the micronised salbutamol budesonide, and formoterol, 
were determined by coulometric Karl Fisher water titration.
In the Karl Fisher moisture content measurement, water reacts with iodine 
and sulphur dioxide in the presence of an alcohol and base.
S0 2 + CH2OH +RN <-► CH3S03‘ + RNH'
CH3SO3- + H20  + l2 + 2RN <-> CH3SO4 + 2RNH+ +21'
In a coulometric Karl Fisher titration, the iodine is electronically generated 
from the anolyte and monitored by a platinum electrode.
As long as water is present in the reaction cell, a proportional current will be 
generated to produce iodine. This iodine is detected by the platinum 
electrode and the iodine production is stopped when the water has been 
converted. The reaction between one mole of water and iodine is equivalent 
to a charge of 10.72 C.mg'1, therefore allowing total water content to be 
measured as a function of electrical input (Connors, 1988).
2.8.1 Material and methods
Each drug was accurately weighted (~ 10 mg for all three drugs) and placed 
directly into the titration cell before being analysed for total water content 
(n=3) by coulometric Karl Fischer Titration (MKC-510E, Kyoto Electronics, 
Tokyo)
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2.8.2 Results and discussion
The ubiquitous presence of water in the atmosphere enables it to be readily 
sorbed by solid pharmaceutical materials during processing and storage. The 
amount of water that is sorbed is dependent on the chemical identity and 
polarity of the compound, as well as the relative humidity and temperature 
(Dalton and Hancock, 1997). The water content for the drugs is showed in
Table 6.
Drug sample % Moisture Content
Micronised Salbutamol 0.2 ±0.01
Micronised Budesonide 0.6 ± 0.03
Micronised Formoterol 4.9 ± 0.20
* Analysis performed in triplicate at 21 °C and 55% RH
Table 6 Karl Fisher water contents for the micronised drugs. (n=3, ±  
Standard deviation)
In accordance with other investigations (Young, 2002; Ticehurst et al., 1994) 
salbutamol indicated low water content along with the steroid budesonide 
(although the previous study used a similar steroid, triacinolone acetonide). 
In comparison formoterol, being a dihydrate, showed the highest water 
content.
Unfortunately, Karl Fisher water determination revealed little information 
about the water sorption capacity of the micronised drugs, since 
measurements were conducted from an ambient environment.
Thus, to further understand such relationships, dynamic vapour sorption was 
applied.
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2.9 DYNAMIC VAPOUR SORPTION
The influence of humidity on water sorption and de-sorption for salbutamol, 
budesonide and formoterol was investigated gravimetrically using dynamic 
vapour sorption (DVS). A schematic representation of the DVS is presented 
in Figure 10.






Figure 10 Schematic representation o f a DVS
In simple terms the DVS is an ultra-sensitive microbalance with a resolution 
of 1 part in 10 million (Cahn microbalance). The main instrument is housed in 
a temperature controlled chamber (5-85°C) and required humidities are 
generated by mixing dry and saturated vapour gases using a mass flow 
controller before passing over the sample and reference holders (Buckton 
and Darcy, 1995).
2.9.1 Materials and methods
Moisture sorption for salbutamol, budesonide and formoterol, were 
determined using a DVS (DVS-1, Surface Measurement Systems Ld, London 
UK). Approximately 10 mg of sample was weighted into the sample cell and 
subjected to two 0-90% RH cycles, over 10% RH increments. Equilibration 
moisture content at each humidity was determined by a change in mass to 
time ratio of 0.002 dm/dt (%).
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2.9.2 Results and discussion
Graphical representation of time versus equilibrium moisture content and 
DVS moisture sorption isotherms (calculated as a percentage of dry mass) 
for salbutamol, budesonide and formoterol, are shown in Figure 11, Figure 12 
and Figure 13, respectively.
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Figure 13 Moisture sorption profile (A) and moisture sorption isotherms for 
formoterol
Analysis of water sorption isotherms for salbutamol indicated an “L -3 type 
curve”, typically representative of multilayer water molecules absorbing flat 
on the surface, or, sometimes, vertically oriented with particularly strong 
intermolecular interaction (Giles et al., 1960).
In comparison, analysis of the moisture sorption curves for budesonie 
suggested a “C, constant partition” isotherm. In general, “C-1 curves” result 
when the availability of sites for solute molecules remains constant at all 
concentrations up to saturation (Giles et al., 1960). Such curves are 
commonly observed in materials that have high affinity for the adsorbate or 
are porous. Previous investigations, studying the steroid, triacinolone 
acetonide (Young, 2002) suggested similar isothermic curves.
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Water sorption isotherms for formoterol is indicative of a “C -2 type curve”, 
characterised by the constant partition of solute between solution and 
substrate, right up to the maximum possible adsorption, where an abrupt 
change to a horizontal plateau occurs. Fundamentally, the linearity shows 
that the number of sites of adsorption remains constant; such situations could 
arise where the solute has a higher attraction for the substrate molecules 
than the solvent itself has (Giles et al., 1960).
In addition analysis of the formoterol data, suggested a linear relationship 
between humidity and mass, after the initial 0-10% RH increment. It is 
suggested that the relatively large increase in mass between 0% and 10%
RH is due to interconversion between an anhydrous/partial hydrate to 
dehydrate form. The relative percent moisture sorption for formoterol was 
approximately double than that of salbutamol. Since the surface areas were 
of similar order of magnitude (3.11 and 5.63 m2.g‘1 for salbutamol and 
formoterol, respectively) these data suggested that formoterol had a higher 
affinity for water.
In general, moisture sorption of powders in pMDI systems may result in 
variation of drug solubility and stability. However, in the case of the three 
drugs under investigation, moisture sorption values were relatively low (when 
compared to pMDI drug formulations such as disodium cromoglycate, which 
has the potential of adsorbing 9 molecules of water per unit cell (Young, 
2002).
More importantly, is the relevant sorption and solubility properties of the 




The in situ determination of drug solubility in suspension or solution-based 
pMDI systems is clearly of importance. For example, the potential 
solubilisation of suspended drug particles may result in chemical degradation 
of the dissolved molecules. Furthermore, the potential for dissolution of 
smaller particulates (through the Kelvin effect) and potential crystal growth of 
large particulates (Oswald ripening) may result in particles outside the size 
range for inhalation therapy. (Johnson, 1996)
Previously, Dalby et al. (1991) described an apparatus for the determination 
of salicylic acid solubility in mixtures chlorofluorocarbons, and demonstrated 
how a limited solubility of the drug can result in Oswald ripening. More 
recently, Williams et al. (1999) modified the apparatus for the measurement 
of steroid solubility in hydrofluorocarbon based systems. A schematic of the 
original apparatus described by Dalby et al. (1991) is shown in Figure 14.
Figure 14 Solubiiity filter as described by Dalby el al., 1991
Although the technique described was a powerful tool for determining 
solubility in pMDI systems, limitations in the experimental apparatus existed. 
For example the seal between the two connecting pMDI canisters and filter 
needed to be firmly secure. In addition, the experimental apparatus required 
crimp assembly and disassembly (through can cutting) for each solubility 
study.
Therefore, for this study, a re-usable pMDI solubility apparatus that contained 
an integral filter holder was developed. The device was designed to be used 
in conjunction with a pressurised, reusable, reciprocal continuous/metering 
valve (similar to the method described previously (Dalby et al., 1991;
Williams et al., 1999)) and/or in conjunction with a dose uniformity or 
impinger apparatus (as conducted here). Furthermore a high performance 
liquid chromatography (HPLC) assay was used. In previous investigations, 
using ultraviolet light detector (UV) to determine solubility, experiments 
suggested pMDI valve component extractables influenced the measured 
drug absorbance (Dalby et al., 1991).
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2.10.1 Materials and methods
A schematic diagram of the solubility apparatus is shown in Figure 15. The 
apparatus consists of a primary and secondary stainless steel casing that 
sandwiched a steel frit and stainless steel filter (0.1 pm) between two slit O- 
rings. Micronised drugs: salbutamol, budesonide and formoterol, were 
investigated. Excess drug was accurately weighed into the secondary casing 
which was then assembled as shown in Figure 15 B.
A standard continuous pMDI valve was crimped to the primary casing and 
the apparatus accurately filled with approximately 7 g of HFA134a using a 
manual fill Pamasol device (Pamasol Willi Mader AG, Pfaffikon,
Switzerland). Samples were agitated in a gyratory water bath shaker 
(Gallenkemp BKS-350, Loughborough, UK) at 25°C for 48 hours prior to 
analysis. Drug solubility was determined using the twin stage impinger (TSI) 
sampling apparatus (Copley Instruments Ltd, Nottingham, UK). The TSI was 
used as a simple dose collection device and contained 7 ml of mobile phase 
in stage one and 30 ml of mobile phase in stage two. The equilibrated 
solubility apparatus was connected to a standard actuator (fitted with a 0.30 
mm diameter orifice), which was fired to exhaustion in the TSI apparatus at 
60 L.min"1. Mass of the solubility apparatus was recorded prior to and post 
firing.
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Figure 15 (A) Solubility apparatus components. Where 1, standard pMDI
continuous valve; 2, primary casing for solubilised drug; 3, o-ring supports; 4, 
filter; 5, secondary casing (drug under investigation is weighed into this 
compartment). (B) Assembled solubility apparatus
The TSI components, actuator and upper/lower casings of the solubility 
device were rinsed into separate volumetries with appropriate mobile phase 
and made to volume. Methods for HPLC drug analysis are given in 
Table 7 using HPLC apparatus described in more detail in Chapter 8. 
Samples were sequentially diluted as to fit within the linearity region of the 
HPLC analysis (0.5 fig.ml'1 -  10 pg.ml'1).
Solubility of each drug in HFA134a was determined by dividing the total drug 
mass recovery from the upper casing and all TSI-actuator components by the 
initial HFA 134a mass added. In addition the total recovered drug was 
compared to the initial weighed drug for mass balance. Each solubility study 
was conducted in triplicate.
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Sphereclone™ ODS, 5 pm 
packing, 25 cm x 0.32 mm id.




223 nm ~ 8  mins
Budesonide
Supercosil™ LC-SI, 5 pm 




248 nm ~ 6  mins
Formoterol Supercosil™ LC-SI, 5 pm 
packing, 5 cm x 4.6 mm id.




218 nm ~ 8  mins
Table 7 HPLC conditions for the drug materials under analysis. Where column temperature = 25°C and injection 
volume = 100 pi
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2.10.2 Results and discussion
Solubility values for the micronised salbutamol, budesonide and formoterol 
are shown in Table 8.
Drug sample




Micronised salbutamol 0.000 ± 0.000 99 % ± 2.3
Micronised budesonide 23.136 ±2.951 101 % ±1.7
Micronised formoterol 7.761 ± 1.023 95 % ± 2.0
Table 8 Summary table of solubility values for salbutamol, budesonide 
and formoterol with relative mass balance (n-3, ±  Standard deviation)
Significant differences (ANOVA p<0.05) in the solubility of each drug was 
observed, however the processing method did not effect the solubility in HFA 
134a. In general the solubility of budesonide (23 ug.g'1) using the new 
apparatus suggested similar values to previous studies using steroids 
(Williams et al., 1999, from graphical data: approximated as 20-45 ug.g'1). 
Furthermore solubility of salbutamol (0.00 pg.g"1) using the new apparatus 
suggested similar values to previous studies of P2 agonists (Dickinson et al., 
2000, described as < 0.004 mg.g"1).
Recovery efficiency was greater than 95 %, for all drugs examined. 
Furthermore, it is interesting to note that multiple peaks were observed 
during HPLC analysis which did not correlate to the drug standard peak. It is 
speculated that such peaks are related to valve extractables and without 
resolution would clearly contribute to the measurement errors observed by 
Dalby et al., (1991).
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2.11 SOLUBILITY IN MHFA
The molecular parameters affecting the solubility of a compound in a variety 
of solvents have been well documented (Barton, 1974; Barton, 1983; James, 
1986). The predictive nature of this characteristic, however, tends to be 
dependent on the system (i.e. solvent) (Ruoff, et al., 1994)
Due to the fact that “real” propellants are not liquid at atmospheric 
pressure/temperature and taking into consideration that a great part of this 
study was undertaken using model propellant conditions (liquid at room 
temperature and atmospheric pressure), accurate solubility values for 
salbutamol, budesonide and formoterol were determined in order to 
understand the affinity and interactions of the drugs in a model propellant 
(mHFA, 2H, 3H-decafluoropentane).
2.11.1 Materials and methods
To insure the absence of any water residue or impurity in the system, mHFA 
was stored with molecular sieves (3A, 3.2 mm pellets, Aldrich Chemical 
Company, Inc., USA) purified with acid and basic alumina (aluminium oxide, 
type 5016 A basic and 504 C acidic, Fluka, GmbH) and filtered trough a 0.1 
pm PTFE filter before use (according method devised by Goebel and 
Lunkenheimeir, 1997). A supersaturated solution of drug in mHFA was 
prepared by addition of approximatly 25 mg of drug in 50 ml of mHFA. 
Samples were agitated in a gyratory water bath shaker (Gallenkemp BKS- 
350, Loughborough, UK) at 25°C for 48 hours prior to analysis. Each sample 
was filtered through a 0.1 pm pore size PTFE filter (13 mm diameter, 
Whatman USA). The recovered solution was weighed and dried in an oven at 
50°C for 24 hours. The recovered dry mass was then reweighed and 
solubility calculated by HPLC (as described previously). Samples were 
analysed in triplicate.
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2.11.2 Results and discussion
Solubility for the three drugs in mHFA is given in Table 9.
Drug sample
Solubility of drug in model 
propellant (ug.ml*1)
Micronised salbutamol 0.000 ± 0.000
Micronised budesonide 81.970 ± 1.185
Micronised formoterol 0.553 ± 0.048
Table 9 Solubility values for salbutamol, budesonide and formoterol in 
mHFA at 25 °C (n = 3, ± Standard deviation)
Significant differences (ANOVA p<0.05) in the solubility of each drug was 
observed.
Previous data by Dickson et al., 2000, shown salbutamol to have a solubility 
of < 0.007 mg.g'1 in perfluorohexane and 0.12 ± 0.02 mg.g'1 in 1H- 
fluorohexane. As expected, the introduction of a hydrogen substitute in the 
model propellant produced an increase of the solubility of the solute in the 
solvent. Conversely, the mHFA propellant (2H-3H decafluoropentane), used 
in this investigation, has two hydrogen atoms that substitute the fluorine 
atoms (increasing the polarity and solubility of the solutes), a longer carbon 
chain, and different dielectric constant. Consequently a direct comparison 
with previous findings can not be established.
However, as expected a similar rank order in solubility between HFA134a 
and mHFA was observed. Clearly such issues should be considered when 
developing an experimental protocol for AFM based measurements. These 
factors are investigated further in Chapters 4-7.
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2.12 GENERAL DISCUSSION
From preliminary investigations into the physical properties of micronised 
salbutamol, budesonide and formoterol, it becomes apparent that all three 
drugs differ, for instance, in particle size, morphology, water sorption and 
solubility.
As such materials are chemically and physically very dissimilar, such 
differences were expected. This will have a significant effect on the specific 
physical -chemical and mechanical characteristics, influencing all aspects of 
formulation development, performance and storage.
For instance, characteristics such as surface area, density and particle size 
will directly influence inter-particulate adhesion forces (Hinds, 1999). 
Additionally, solubility and differential vapour sorption calculations indicate 
that the three materials have varing degrees of water affinity, suggesting a 
potential for Ostwald ripening, crystal growth, surface dissolution, crystal 
bridging and potentially poor physico-chemical stability.
Consequently, a series of investigations were undertaken to examine the 
cohesive and adhesive interactions of individual drug particles with 
neighbouring drug particles and model surfaces in the present of a model 
hydrofluoroalkane propellant, with the final aim of characterising pressurised 
metered dose inhaler performance.
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CHAPTER 3: SURFACE ENERGY MEASUREMENTS
3.1 GENERAL INTRODUCTION
The majority of pharmaceutical processes require interfacial contact between 
particulates. It is not surprising, therefore, that surface energetics play an 
important role in determining the outcome of all particulate interactions.
For a pressurised metered dose inhaler system, the interfacial energy may 
relate to drug-drug interactions (cohesion/adhesion), drug-carrier or drug- 
device interactions (adhesion) and de-aggregation phenomena during use.
Since all adhesive and cohesive interactions are interfacial phenomena, it is 
logical to accept that the basis of interactions within pressurised metered 
dose inhalers is via interfacial forces. As previously discussed (Chapter 1), 
these can be divided into apolar (Lifshitz-van der Waals), polar (electron 
donor-electron acceptor) and electrostatic (electrostatic double layer) 
components.
Consequently, changes in the nature of any surface within the product (the 
drug, the carrier or the container) can be expected to result in changes in the 
relative surface interactions. Hence, measurement of these surfaces 
energetic becomes of paramount importance.
Given the importance of surface energy terms as a means of predicting the 
interactions between different formulation components, it is desirable to gain 
clear insights into the relative merits of different surface energy measurement 
techniques. In this study, a comparison is made between contact angle (CA), 
inverse gas chromatography (IGC), organic differential vapour sorption (DVS) 
and capillary intrusion (Cl) techniques.
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While the contact angle method, even with its limitations (Buckton, 1995), is 
an established technique, the use of IGC, organic DVS and Cl have only 
relatively recently been applied to pharmaceutical systems (Ahfat et al.,
2000; Buckton and Darcy, 1995; Dove et al., 1996; Feeley et al., 1998; 
Kiesvaara et al., 1993; Prestidge and Tsatouhas, 2000; Sunkersetta et al., 
2001; Ticehurst et al., 1994). Clearly, it would be interesting to compare the 
data yielded from such different approaches when applied to pMDI based 
systems.
Here, each technique is described in detail and investigated for its potential in 
examining interactions in pMDI based formulations.
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3.2 CONTACT ANGLE MEASUREMENT
3.2.1 Introduction
Measuring the contact angle (0) of powders is a useful indicator of wettability, 
giving information on surface energetics.
Interfacial tension is a phenomenon between two immiscible phases due to 
molecular attractions. In simple terms, molecules at the interfacial region 
between two contiguous bodies are subject to attractive forces from 
neighbouring molecules in both phases.
In a paper presented at the Royal Society in 1804, Thomas Young correlated 
the work of adhesion between the surface tension of a solid (ys) and a liquid 
(yi), the interfacial tension between the solid and the liquid (yis) and the 
contact angle 0 made by a drop of liquid (L), deposited on a horizontal flat 
solid surface (S). Dupre (1869) developed the equation that is now 
universally used and that express the relationship between work of adhesion 
between solid and liquid (Young-Dupre: Equation 19).
Equation 19
- A G "  - A G "  ^ ( l  + costf)
where A G sllw and A G slab are the dispersive and acide/base surface free 
enenergy contribution for the solid and the liquid, respectively. The negative 
sign is made imperative by the thermodynamic convention that a negative 
sign for AG signifies an attraction.
Since the free energy of adhesion is contributed by a number of more or less 
independent forces, Fowkes (1962) proposed that the surface tension can 
also be broken down into separate components. Van Oss (van Oss et al., 
1988a) developed such theory further to suggest that electron-acceptor- 
electron-donor interactions are essentially asymmetrical and additive.
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According to Fowkes (1962, 1963) and van Oss et al., (1988a) (and their 
theory that most solids have Lewis acid and basic sites on their surfaces that 
are capable of forming complexes with a second phase), the total surface 
energy (calculated from the interaction between a liquid with known physical 
properties and solid surface) can be defined from the following equation:
Equation 20
w ~  -  r r ( i  +  c o s (> )  =  +  J r y ;
The parameters in question, namely, ysLW, Ys+ and yf, can be evaluated by a 
three liquid method. In this method, an apolar and two polar liquids of know 
surface energy parameters are used. Solving Equation 20 using an apolar 
liquid Equation 21 can be derived, since ys+ and yf are zero, and ysLW can be 
evaluated.
Equation 21
K  = 24Kr>(i+cos0)r?
Because two unknown remain (ys+, yf), Equation 20 is with two known polar 
liquids which can be solved simultaneously. From this discussion it is evident 
that to be able to compute the interfacial free energy of a given solid-liquid 





SU BSTR ATE SU BSTR ATE
Poor surface wettability Good surface wettability 
Low surface energy High surface energy
Contact angle > 90’  Contact afigte < 60°
Figure 16 Diagram indicating the measurement o f contact angle (6)
between a liquid and solid surface
Unfortunately, data for liquids are still scarce but they may be obtained from 
contact angle measurements in appropriate liquid/solid systems or from 
interfacial tension measurements. Moreover, the values of the surface 
tension components are relative to the reference value assumed for water as 
y+ = y = 25.5 mJ.m'2
3.2.2 Materials and methods
Contact angle measurements were obtained using the sessile drop method 
on model compacts of the micronised drug. Compacts were prepared by 
direct compression using a servo hydraulic press (Model 25010, Specac Ltd., 
Kent, UK). Approximately 250 mg of the micronised material was weighed 
into a 10 mm stainless steel die, spread evenly in the die and compacted with 
a compression force of 10 kN. Compacts were stored in sealed containers in 
a controlled environment (44 %RH, 25 °C) for at least 24 hours prior to use.
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The contact angle of the powder compact surfaces were measured using the 
sessile drop method (Good, 1992; Good and Girifalco, 1960; van Oss, 1994; 
van Oss et al., 1988b) with a NRL goniometer (Rame-Hart, Inc., New Jersey, 
USA) equipped with a 2.3x objective lens and an 10x Ramsden type 
eyepiece. A liquid drop was introduced onto the substrate surface via a 
microsyringe. The advancing contact angles (i.e. the angle the drop makes 
when it has ceased advancing) were measured for three different liquids 
(water, diiodomethane and ethylene glycol) at room temperature (20°C). A 
summary of the surface tension components of the liquids used in the direct 
contact angle determination (van Oss, 1994) is presented in Table 10.
Surface tension components and parameters (mJ.nT2)
yLW +Y y y* b
Diiodomethane 50.8 -0 0 0
Water 21.8 25.5 25.5 51.0
Ethylene glycol 29.0 1.92 47.0 19.0
Table 10 Surface tension components and parameters of liquids used in 
CA measurements at 20 °C (van Oss, 1994)
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3.2.3 Results and discussion
The surface energy components obtained by CA measurements are 
presented in Table 11.
Surface energy components from CA (mJ.m'2)
yLW +Y y C
D
Salbutamol 46.5 ± 0.7 8.3 ±1.5 18.5 ± 1.2 24.6 ± 2.5
Budesonide 49.1 ±0.4 0.34 ± 0.43 22.5 ± 3.8 4.6 ±2.9
Formoterol 48.5 ± 0.4 0.11 ±0.15 35.0 ± 3.2 3.2 ± 3.0
Table 11 Surface free energy components obtained using CA 
measurement (n=3, ± Standard deviation)
The highest dispersive value was measured for budesonide followed by 
formoterol and salbutamol, respectively.
Interestingly, there are clear statistical differences in the electron donor and 
electron acceptor components of the surface free energies. These variations 
are most likely due to the chemical nature of the drug and the surface 
functional groups on the faces of the micronised crystalline (Chapter 2) 
material. However, since such these materials are micronised, it becomes 
difficult to associate each component with specific surface chemistry.
The contribution of the polar and dispersive components is however 
discussed in more detail in subsequent Chapters.
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3.3 INVERSE GAS CHROMATOGRAPHY
3.3.1 In troduction
Inverse gas chromatography (!GC) is an extension of conventional gas 
chromatography (GC) in which the non-volatile material to be investigated is 
packed as the stationary phase within a GC column. Inverse gas 
chromatography is able to generate adsorption isotherms of known analytes 
with the packed “unknown” stationary phase. Thus allowing evaluation of 
dispersive and acid/base interactions for specified adsorbate-adsorbent 
pairs.
IGC has become a widely used technique to characterise the surface 
properties of organic and inorganic materials. More specifically, the physical 
properties of pharmaceutical solids have been investigated (Planinsek et al., 
2001; Planinsek and Buckton, 2003; Ticerhurst et al., 1994). In simple terms, 
the technique consists of measuring the chromatographic retention times of 
vapour-phase probes of known properties on a column packed with the 
material of interest (Figure 17). Acid-base probes are used to measure the 
acid-base characteristics of the solid surface, and saturated n-alkenes are 
used to measure the dispersive components of the surface energy of 
interaction.
Single probe gas pu&so Packed sarr-pte column (particulate or libra) «on t im e  Sq)
Figure 17 Inverse gas chromatography (Modified from Surface 
Measuremet Systems website: www.smsuk.co.uk)
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In the present study, retention times of saturated n-alkanes and acid-base 
probes, injected at infinite dilution, were used to calculate the dispersive 
component (yLW) of the surface energy, the free energy of adsorption (AGab), 
and the enthalpy of desorption (AHab) corresponding to acid-base surface 
interactions.
Papirer's approach (Gutmann, 1978; Lavielle and Schultz, 1991; Papireret 
al., 1999) as described by Schultz and colleagues may be used to estimate 
the acceptor (Ka) and donor (Kd) parameters of the test substrate.
The fundamental parameter in the IGC measurements is the specific 
retention volume, VN, defined as the volume of carrier gas required to elute a 
probe from a column containing the test substrate material.
The interaction of neutral probes, such as saturated n-alkanes, with the 
substrate material is predominated by the van der Waals dispersive forces of 
interaction. Furthermore, it has been shown that under conditions of infinite 
probe dilution, the dispersive component yLWsof the total surface energy of 
the substrate is related to VN by:
Equation 22
r t  invN = 2  N(r!;w)0'5a ( r iw)0'5 + c
Where R is the gas constant, T the temperature, N Avogadro’s number, a the 
projected surface area of the sample probe, yiLW the dispersive component of 
the probe and Vu the net volume of carrier gas required to elute the probe 
molecules from the column (corrected for column dead time and compression 
factors). A plot of RT In Vn versus a(ytw)0'5 should provide a linear profile 
and the slope = (ysLW)0'5.
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The interaction of polar probes with the substrate involves both dispersive 
and acid-base interactions. The free energy of resorption, AGab, 
corresponding to acid-base surface interactions, may be related to Vg by:
Equation 23
RT= ln(Vn/VN ref) = AGab
where Vn is the specific retention volume of a polar probe and Vn ref is the 
specific retention volume of a corresponding reference n -alkane. The 
equation suggests that values of RT In Vg plotted versus a(ytw)0b for polar 
probes should fall above the straight line obtained by plotting RT In V versus 
a(yiLW)0 5 for the reference n-alkane probes. The difference in the ordinates 
between the point corresponding to the specific polar probe and the 
reference line gives an estimate of the value of the free energy of resorption 
corresponding to the specific acid-base interactions. The free energy of 
adsorption corresponding to the specific acid-base interactions may be 
related to the enthalpy of resorption, AHab by:
Equation 24
AGab= AH^b- TAS*b
where AGab is the entropy of resorption corresponding to the specific acid- 
base interactions.
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A plot of AGab/T versus 1/T should yield a straight line with slope, AHab. The 
enthalpy of resorption corresponding to the specific acid base interaction is 




Where DN and AN are the donor and acceptor numbers, respectively, of the 
acid-base probe as defined by Gutmann (Gutmann, 1978). Riddle and 
Fowkes (1990) determined that part of the electron acceptor value, AN, was 
due to dispersive forces; therefore, AN* was developed, being solely due to 
polar interaction forces. A plot of AHab/AA/ versus DN/AN should yield a 
straight line with slope KA and intercept Kq.
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3.3.2 Materials and methods
The surface free energy components of micronised salbutamol, budesonide 
and formoterol were determined using a commercially available IGC (SMS 
IGC 2000, Surface Measurement Systems Ltd, London, UK). Approximately 
1 g of drug powder was weighed into standard glass IGC columns and 
plugged with glass wool. Each column was tapped for five minutes, using the 
minimum setting on a jolting voltameter (Surface Measurement Systems Ltd, 
London, UK) to a produce 'uniform' powder bed. Each column was 
equilibrated in the IGC at 0% RH, at 318.05 K, under dry nitrogen for 3 hours 
prior to analysis. The retention time of a series of n-alkanes (hexane to 
decane) and polar probes (ethanol, ethyl acetate, acetone and chloroform) 
were analysed at infinite dilution by flame emission detector. Column settings 
and run times for all three drugs were optimised at 318.05 K. Three columns 
for each drug were analysed.
3.3.3 Results and discussion
Micronised salbutamol, budesonide and formoterol were analysed by IGC 
using both apolar and polar probes. An example of the apolar linear response 
and polar probe retention times for micronised salbutamol is shown in Figure 
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Figure 19 Micronised salbutamol acid-base component plot. Where R2 =
0.976
The specific surface free energy components (calculated from the probe 
retention time) are shown in Table 12. Corrected donor DN numbers 
(Gutmann, 1978) and acceptor numbers AN* (Riddle and Fowkes, 1990), 
used for the estimation of the acidic and basic components of the surface
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free energy, were as follows (AN*:DN, in Kcal/mol) ethanol 10.3:20, acetone 
2.5:17, ethyl acetate 1.5:17.1, chloroform 5.4:0.
Surface energy components from IGC
yLW (mJ.nT2) Ka Kd
Salbutamol 39.1 ± 1.3 0.085 ± 0.002 0.029 ± 0.001
Budesonide 62.9 ± 1.7 0.113 ±0.002 0.013 ±0.001
Formoterol 51.2 ±0.7 0.093 ± 0.002 0.026 ± 0.001
Table 12 Surface free energy components obtained using IGC 
measurement (n=3, ± Standard deviation)
The higher dispersive value was measured for budesonide, followed by 
formoterol and salbutamol, respectively. The surface energy components 
obtained by CA and IGC measurements follow a similar trend. The highest 
dispersive values were measured for budesonide by both techniques, 
followed by formoterol and then salbutamol. These observations are in 
general agreement with related studies of the ranking of the dispersive 
parameters of pharmaceutical powders (Ahfat et al., 1997; Ahfat et al., 2000; 
Planinsek et al., 2001).
A direct comparison of the data between the two techniques is difficult due to 
the variations in experimental and theoretical approaches (Ticehurst et al., 
1994). The acid and basic components of the powder samples from IGC 
measurements are not consistent with the results obtained from CA 
measurements. This is because determination of the polar components from 
IGC would require specific knowledge of the surface contact area of the 
solvent probes with the solid. This limitation currently precludes the use of 
the surface component approach (SCA) in determining the polar free energy 




Organic DVS is a relatively novel method for determining the surface energy 
of powders by measuring the adsorption isotherm of organic vapours using 
an automated gravimetric vapour sorption analyser. In general, the organic 
DVS works using the same principle as standard water moisture sorption 
described in Chapter 2.9.
Using organic probes with known physical properties, and assuming 
Langmuirtype adsorption (B.E.T type adsorption described in Chapter 2.6), it 
is possible to calculate the monolayer coverage for each probe, and thus 
relative spreading pressure. From this specific surface energy components 
may be calculated (Levoguer and Williams, 1999)
3.4.2 Materials and methods
All vapour sorption experiments were carried out on a modified DVS-1 
automated gravimetric vapour sorption analyser (Surface Measurement 
Systems Ltd., London) according to the method previously described in 
Chapter 2. The humidity probes in the instrument were removed and 
replaced with sealing blanks to protect them from irreversible damage due to 
the organic vapours, and the vapour outlet was exhausted to a fume 
extractor due to safety considerations. The substrate was initially dried by 
flowing under dry nitrogen, and the relative partial pressures of an organic 
liquid probe were generated by mixing dry and saturated vapour gas flows in 
a similar manner to the water vapour sorption experiments described in 
Chapter 2.
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Isotherms were measured on micronised samples of salbutamol, budesonide 
and formoterol in the partial pressure P/Po range 0-1.0 using both analytical 
grade n-octane and isopropyl alcohol (IPA) vapours at 25.0°C. Typical 
powder sample sizes were approximately 50 mg, with baseline instrument 
performances better than 2 pg drift per day during instrument operation.
Table 13 includes data recently obtained for the components of the surface 
energy of IPA and octane. Data is based on Wilhelmy wetting experiments 
performed using a PTFE substrate of known surface energy (Booth and 
Williams, 1998). This data is necessary so that a full analysis of the surface 








Octane 21.8 0 21.8
IPA 19.3 2.4 21.7
Table 13 Literature values for y tw, yPB and yiTot for octane and isopropyl 
alcohol
In the case of a non polar wetting agent (i.e. octane), the work of adhesion 
Wadh is a function of the dispersive interactions only, whereas for polar 
wetting agents (i.e. isopropanol), it may be expressed as the sum of 
dispersive and polar components of the wetting interaction. Therefore, 
measuring Wsi for both non polar and polar interactions, allows the polar and 
dispersive components of the surface energy to be calculated for a particular 
unknown material using an extension of the Fowkes equation (Equation 26).
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Equation 26
K = U r f r f+ U r f r f
Where Wsi is the work of adhesion between the solid and the liquid surfaces, 
ysLW and yiLW are the dispersive component of the surface energy of the solid 
and liquid, respectively; and ysAB and yAB are the polar component of the 
surface energy of the solid and liquid, respectively.
3.4.3 Results and discussion
As an example, Figure 20 shows typical gravimetric data for two complete 























•  Adsorption (run 1)
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Figure 20 Moisture sorption profile (A) and moisture sorption isotherms 
(B) of octane vapour for salbutamol
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Table 14 summarises the surface energy values obtained by the above 
methodology for samples of micronised salbutamol, budesonide and 
formoterol.



















Salbutamol 54.69 41.50 96.20
Budesonide 59.37 20.80 80.17
Formoterol 47.00 38.73 85.73
Table 15 Experimental values for ysLW y?AB and ysTot for salbutamol, 
budesonide and formoterol via organic DVS measurements
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The ysLW values for both salbutamol and budesonide calculated by organic 
DVS, although in the same order of magnitude, are slightly higher than that 
obtained by IGC and CA. In comparison, formoterol ysLW values calculated by 
organic DVS were slightly lower than that obtained by IGC and CA. 
Budesonde appeared to have the higher dispersive surface energy value in 
all three surface energy applied techniques. All the y / 8 values calculated by 
organic DVS are higher than via the other surface energy technique.
These observations are consistent with the notion that IGC experiments are 
conducted at infinite probe dilution involve probing only higher energy surface 
sites at less than 0.1% surface coverage. The vapour adsorption method 
obtains average information based on complete surface coverage. Thus, the 
vapour adsorption method is similar to traditional wetting experiments in 
which the solid surface is covered completely by either vapour or liquid 
species.
Unfortunately, as for the IGC method employed in the Chapter 3.3, the 
organic DVS technique does not allow, at the present, the calculation of the 
specific polar contributions of the acid and basic components of the surface 
energy. Although empirical information may be obtained from both IGC and 
organic DVS (relating to polar components), the use of these techniques with 
the use of the surface component approach (Chapter 1) is presently not 
possible. Such limitations will be discussed in more detail when applied to 
fundamental measurements later in Chapter 4-7.
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In summary, the gravimetric flow gas techniques have been shown to be a 
highly sensitive method for obtaining adsorption/desorption isotherms for 
organic vapours on particulate pharmaceutical materials. These adsorption 
isotherms may be analysed to obtain the equilibrium spreading pressure and 
this has been successfully undertaken for octane and isopropanol on all three 
micronised drug samples. From this data the dispersive, polar and surface 
energies of these powders have been accurately estimated using the 
classical semi-empirical model of Fowkes. This recently developed technique 
does not suffer from any of the problems often associated with liquid wetting 
based approaches and has the significant benefit of being able to monitor 
some aspects of the morphological stability of the powder during the 
experiment.
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3.5 CAPILLARY INTRUSION TECHNIQUE
3.5.1 Introduction
An alternative practical technique to obtain the solid surface tension of rough 
and porous solids is capillary intrusion (Cl). In this system a powder column 
is analogous to a packet column of capillaries (Buckton, 1993). The 
spontaneous filling of a void by a liquid is due to the capillary force and 
consequently, in a powder sample, contact angle may be determined via the 
liquid rate uptake through capillary action.
Washburn (Washburn, 1921) introduced the basic theory for determining the 
contact angle of a solid-liquid particle system by liquid intrusion method. 
Grundke (Grundke et al., 1996) modified the Washburn equation and 
proposed an alternative method to obtain the surface energy of rough and 
porous solid by capillary intrusion technique. The modified Washburn 
equation was used to relate the measurements of liquid uptake rate to 
contact angle for the spontaneous uptake of liquid due to capillary action 
(Equation 27).
Equation 27
t  =  A'm2
Where t is time, m is the mass of adsorbed liquid and A’ is a constant 
determining the cross-sectional area of capillary (Equation 28).
Equation 28
c p 2ycosO
Where r| is the viscosity of the liquid, c is the material constant, p is the 
density of the liquid, y is the surface tension and 0 is the contact angle.
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The material constant is dependent on the porosity of the sample. The two 




Consequently, if m2/t is monitored experimentally, the contact angle can be 
measured. The c value still remain an unknown but may be determined for a 
reproducible sample using a liquid with a 0° contact angle (cos0 =1).
For many materials, such as the micronised drugs in this study, n-hexane 
may be used to determine the value of c (Roulison, 1996). Careful attention 
must be taken to obtain a uniform and homogeneous powder packed column. 
This may be achieved by control tapping providing the initial powder loading 
is carried out in a reproducible manner (Desai et al., 2001).
3.5.2 Materials and methods
All drug materials were used as supplied. Diiodomethane, glycerol, n-hexane 
and ethanol where supplied by Aldrich (Gillingham, UK), were of analytical 
grade, and used as supplied. The rate of uptake of liquid by the powder 
column was determined gravimetrically. Experiments were performed at 25 
°C in an air-conditioned room. Custom built borosilicate capillary tubes, fitted 
with a porous frit, where reproducibly filled with 1000 ± 10 mg of powder. 
Tubes were tapped 50 times using a jolting voltameter (J. Engelslsmann, 
Ludwigshaven, Germany). The tube was then suspended under a modified 
analytical balance and over a large 10 cm diameter bath containing the 
solvent in use. Using such a large bath is preferred because the liquid level
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will not be significantly affected by the liquid uptake of the powder column. 
The bath was then raised manually toward the hanging borosilicate tube until 
just in contact with the liquid surface and the capillary rise could be seen to 
have begun, affecting the reading in the balance. Mass vs. time data were 
collected automatically at a rate of one point per second over no more than 
400 seconds of the intrusion. The n-hexane was initially run as a blank (n =
3) using 3 intrusion tubes in order to determine the contribution of the solvent 
adsorbed in the frit. This value, which should remain constant throughout the 
experiment, was subtracted from the raw data prior to plotting the m2 against 
the time curve. A schematic of the capillary intrusion apparatus is presented 
in Figure 21.
Physical data and surface tension parameters for the four liquids used for the 
capillary intrusion analysis are listed in Table 16.
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Figure 21 Capillary Intrusion Apparatus A) Balance, B) borosilicate tube, 
C) solvent bath, D) laboratory jack
Each micronised drug sample was analysed to determine the “c” constant. 
Least square linear regression analysis was used to obtain the slope over the 
straight part of the m2 against time curve. It was noted that slight variations in 
the diameter of the tubes were shown to affect the “c” value, consequently 



















n-hexane 659 0.31 18.1 18.4 0 0 0
glycerol 1261 945 64.0 34.0 3.92 57.4 30
diiodomethane 3325 2.6 50.8 50.8 0 0 0
MillQ water 1000 1.00 72.3 21.8 25.5 25.5 51.0
ethanol 789 1.20 21.4 18.8 0.019 68 2.6
Table 16 Summary of physical and surface tension parameters for the five liquids at 20°C. (van Oss, 1994.). Due to the 
solubility o f salbutamol in water, ethanol was used as a substitute for the correspondent analysis
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3.5.3 Results and discussion
The main factors affecting capillary intrusion are both the properties of the 
wetting liquid and the drug particulate characteristics. Of this, particle size is 
of great importance. Samples analysed in this case had particle size 
distributions smaller than powder samples reported in the literature 
(Prestidge and Tsatouhas, 2000) with consequent larger surface areas and 
greater heterogeneity. Clearly, such conditions are undesirable due to the 
negative effect relating to the variation in the effective capillary radii of the 
particle bed (Diggings et al., 1990).
The material “c” constant and its relative standard deviation was calculated 





Micronised salbutamol 1.9656 ± 1.1852
Micronised budesonide 6.2330 ± 3.7871
Micronised formoterol 22.7467 ± 1.3663
Table 17 Material constant determination for micronised salbutamol, 
budesonide and formoterol (n = 3, ± Standard deviation)
Using the relative c values, the contact angle data for the three micronised 
drug samples via Cl measurements were calculated and summarised in 
Table 18.
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Diodomethane Glycerol Water Ethanol
Drug
Angle (°) Std Angle (°) Std Angle (°) Std Angle (°) Std
Salbutamol 70.19 1.43 * * N/A N/A 54.50 14.51
Budesonide 80.19 8.58 * * 84.52 6.39 N/A N/A
Formoterol 89.84 0.05 * * 89.98 0.01 N/A N/A
Table 18 Contact angle (6°) data for the three micronised drug samples investigated using Cl method. * Glycerol 
produced a values for cos 6 bigger then one, consequently no angle value could be extrapolated. N/A is due to solubility of 
the drug in the respective solvent
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As previously discussed, the determination of contact angle using the Cl 
method is dependent on a reproducible determination of the material 
constant “c”.
As results of small particle size for the three drug samples, the experiments 
produced very poor reproducibility of the material constant with consequent 
inconsistent final results. This is in agreement with previously published data 
(Kiesvaara et al., 1993; Kiesvaara and Yliruusi, 1993), where particle size 
has an effect on the liquid penetration. In addition, due to differences in 
solubility for the three drug samples, one of the solvents could not be used 
throughout all the experiments. Further, the use of glycerol as polar liquid 
produced inconsistent results in all cases. In conclusion, without one set of 
the results obtained using this polar liquid, calculation of the surface energy 
was limited in all cases.
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3.6 GENERAL DISCUSSION
The techniques investigated in Chapter 3, for determining surface properties 
are based on essentially different theoretical approaches. Clearly such 
different approaches make comparing results a difficult task.
Indeed, others have reported such difficulty when attempting the 
measurement of particulate surface energies (Buckton, 1993).
Contact angle methods are not well suited to powdered samples and the 
presence of liquid probes may result in a potential change in the physical 
form (e.g. dissolution and/or crystallisation of amorphous regions). 
Furthermore, to obtain contact angle of a pharmaceutical powder it is 
necessary to first compress the particle to obtain a flat surface. This 
compression may cause changes in surface properties, and the rough micro­
surface produced often leads to contact angle hysteresis, reducing the 
accuracy of the results (Buckton and Newton, 1986).
One possible method of overcoming such issues in CA is capillary intrusion. 
In the case of Cl, powder compaction is not required, since analysis relies on 
capillary intrusion through a powder bed. However, again, Cl has potential 
drawbacks due to powder column repeatability, possible phisco-chemical 
change in presence of probes and relative solubilities of different powders in 
the organic probes.
Recently it has been argued that vapour sorption methods are the preferred 
approach to the study of powder surface energetics. Vapour sorption 
methods include gravimetry (Buckton and Darcy, 1995), isothermal 
microcalorimetry (Buckton and Darcy, 1995) and inverse gas 
chromatography.
The merits of each of the techniques investigated in Chapter 3 are discussed 
below, and related to the proposed fundamental adhesion measurements in 
Chapter 4-7. For completion, direct comparison of the results obtained from 
the four techniques is presented in Table 19.
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Surface energy components Surface energy components Surface energy components
from CA (mJ.m"2) from IGC (mJ.m‘2) from organic DVS (mJ.m'2)
















































*Note: no values from Cl are given due to experimental limitations discussed previously
Table 19 Surface free energy components obtained using CA, IGC and organic DVS measurement. (n=3 ± Standard 
deviation)
In general, CA, IGC and organic DVS values follow a similar trend. The highest 
dispersive values were measured for budesonide for all three techniques. These 
observations are in general agreement with related studies of the ranking of the 
dispersive parameters of pharmaceutical powders (Ahfat et al., 1997; Planinsek 
et al., 2001). Dispersive values of formoterol and salbutamol follow the same 
ranking for both CA and IGC techniques (with formoterol higher then 
salbutamol), but the order changes when the same drugs are analysed by 
organic DVS (salbutamol higher then formoterol). Furthermore, the same 
ranking pattern is present if the total polar component is considered only 
between CA and organic DVS. Unfortunately in this respect IGC data cannot be 
included since Ka and Kb are dimensionless numbers.
As previously stated, similar correlations using Cl could not be made due to 
logistics of the experimental analysis.
In summary, direct comparison of the data between the three techniques is 
difficult due to the variations in the experimental and theoretical approaches 
(Ticehurst etal., 1994).
Furthermore, since individual polar components of the surface free energy are 
not obtainable using either organic DVS, IGC or Cl, it therefore remains, that 
direct CA measurement may be the most useful technique when considering the 
SCA model for predicting particle interactions.
Therefore, CA measurements were specifically utilised for comparison when 
conducting fundamental particle interaction measurements in Chapter 4-7.
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CHAPTER 4: INTERPARTICULATE INTERACTIONS MEASURED BY AFM -
GENERAL METHODOLOGY
4.1 GENERAL INTRODUCTION
As previously stated, a common approach to formulating pMDI is to prepare 
suspensions (Chapter 1). However, few works have been published addressing 
the nature and range of the particle interactions involved in such a system 
(Michael et al., 2000; Young et al., 2003).
High resolution topographical analysis of material surfaces has been 
revolutionised with the invention of the Atomic Force Microscopy (AFM) in 1986 
(Binnig et al., 1986). The nature of the technique allowed rapid development of 
other AFM based techniques including the capability for measurement of 
interactive forces acting between a tip and substrate under specific media 
(Ducker et al., 1992). With the capability of measuring a range of physical 
and/or chemical properties on the sub-nanometer scale coupled with high- 
resolution imaging and versatility, the AFM briskly found application across a 
vast range of scientific disciplines (Wickramasinghe, 2000). More recently the 
AFM has also been applied to a number of pharmaceutical problems (Ibrahim et 
al., 2000; Louey et al., 2001; Sindel and Zimmermann 2001; Young et al., 2003). 
The AFM has been particularly useful for characterising the surface morphology 
of materials at very high resolution and measuring fundamental interactive 
forces between contiguous surfaces. For pharmaceutical analysis, the AFM 
colloid probe approach has successfully been developed to allow the 
measurement of micronised particle interactions specific to inhalation technology 
(Eve et at., 2002; Young et al., 2003) under controlled environmental conditions.
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The AFM operates by measuring the deflection of a microfabricated 
cantilever (usually by laser reflection) as it interacts with a surface. In simple 
terms, the AFM consists of four major components: (1) a micro-fabricated 
cantilever probe, (2) a detection system, (3) a piezoelectric scanner and (4) a 
computer controlled feedback system. These components are discussed in 
more detail below and shown graphically in Figure 22.
(1) Cantilever probe.
Cantilevers are critical components of an atomic force microscope system 
since they determine the force applied to the sample and directly relate to the 
ultimate lateral resolution of the AFM system. The cantilever consists of a 
spring-like probe generally with an integrated tip. Cantilever assemblies are 
fabricated from silicon or silicon nitride using photolithographic techniques. 
For topographical imaging, sharp proximal tips are produced with high aspect 
ratio probes. However, tipless cantilevers can also be utilised for allowing the 
preparation of colloidal drug probes for measurement of particle interactions. 
Atomic force microscope cantilevers are produced with spring constants 
lower than the effective spring constant between atoms in a solid, which are 
of the order of 10 N.rrf1. The spring constant of the cantilever depends on its 
shape, dimension (particularly the thickness), and the material from which it 
is fabricated. Since the cantilever obeys Hooke's Law (Equation 30), for small 
displacements the interaction force between a probe and an interacting 
surface sample can be measured:
Equation 30
F - -k.AD
Where F is the Force (N), k is the cantilever spring constant (N.m"1) and AD 
is the recorded deflection.
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(2) Photodiode detector.
A quadrant photodiode detector is used to measure the position of a laser 
that is reflected from the tip of the cantilever probe. As the cantilever flexes, 
the light from the laser is reflected onto the split photo-diode. By measuring 
the difference between the two photodiode signals, the angular deflection of 
the cantilever can be calculated.
(3) Piezoelectric scanner.
The movement of the sample (or tip depending on AFM system) is performed 
by an extremely precise positioning device made from a piezoelectric 
ceramic (typically constructed of lead zirconium titanate, with various 
dopants). The scanner is capable of sub-Angstrom resolution through x, y 
and z dimensions. The z-axis is conventionally perpendicular to the sample. 
Four electrodes cover the outer surface of the tube, while a single electrode 
covers the inner surface. Application of voltage to one or more of the 
electrodes causes the tube to bend or stretch through the chosen axis. The 
maximum scan size that can be achieved with a particular piezoelectric 
scanner depends upon the length of the scanner tube, the diameter of the 
tube, its wall thickness and the strain coefficients of the particular 
piezoelectric ceramic from which it is fabricated (typically this ranges laterally 
from tens of Angstroms to over 100 microns and vertically from the sub- 
Angstrom range to about 10 microns).
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(4) Feedback loop controller.
Maintaining the optimal pre-set parameters (cantilever deflection, amplitude 
etc) a digital feedback loop adjusts the tip-sample separation via the 
displacement of the piezo in maintaining a constant amplitude or constant 
force between the tip and the sample.
4
Figure 22 Schematic representation of the AFM components, where (1) 
cantilever probe, (2) photodiode detector, (3) piezoelectric scanner and (4 
feedback loop controller
During this investigation, the AFM was used in two distinct modes of 
operation: its conventional topographical imaging mode and in the force 
measurement mode. Each method of operation is described in more detail 
below.
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4.1.1 High resolution topographical imaging using AFM
The atomic force microscope was originally developed as an imaging tool for 
conducting materials (Binning and Quate, 1986). The rapid development of 
this technique has allowed the routine imaging of a variety of non-conducting 
materials in various media and between various surfaces (Atkins and 
Pashley, 1993; Li et al., 1993; Weisenhorn et al., 1992)
Imaging modes can be classified as "contact" or "tapping" depending on the 
net forces between the probe and sample.
In simple terms the contact mode operates by maintaining a pre-defined 
deflection (constant force) between the tip-cantilever assembly and sample 
surface (via a feedback loop), as the probe is rastered across a surface.
The degree to which the sample is moved through the z axis to maintain 
constant force between the tip and sample surface is recorded and when 
combined with the x, y raster scan data produces a 3 dimensional 
topographic image of the surface.
Contact mode is the most common method of operation for imaging in 
liquids. However, since the tip is ‘dragged’ across the surface, for very soft 
samples, there is the potential for sample damage due to frictional forces.
In air, tapping mode AFM imaging is often employed. Tapping mode imaging 
is similar to contact mode, however the image is produced by oscillating a 
“stiff’ cantilever at a specific resonant frequency. As the tip is brought close 
to the sample it encounters a dampening force, reducing the oscillation 
amplitude. A constant amplitude (set point) is maintained by moving the 
sample z axis, as the tip is rastered across the surface. The feed back 
controlled movement is recorded and used to produce a 3 dimensional 
topographic image of the surface. By maintaining a low set point, tapping 
mode is capable of imaging delicate samples, or regions containing low yield 
stress without causing sample damage (Hoper et al., 1995; Price and Young, 
2004).
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A schematic of both (A) contact mode and (B) tapping mode imaging 
methods are shown in Figure 23.
feedback system adjusts scanner 





As deflection of cantilever changes





Force measurements are recorded as an AFM probe is brought into 
(approach curve) and out of contact (retraction curve) with a sample surface. 
The raw output data obtained by cycling a probe towards, in-contact and 
away from a sample is referred to as a force-distance curve. A force-distance 
curve provides a large amount of information to be extracted about the 
interactive and adhesive forces acting between two surfaces. As previously 
discussed, by mounting an individual drug particle to the apex of a tipless 
cantilever, it becomes possible to investigate drug-sample interactions.
A typical force-distance curve with schematic of particle-substrate interaction 
during the approach and retraction cycle is shown in Figure 24.
a. b. c. d e. f
V  i t i i  i
♦
scanner movement
Figure 24 Typical schematic particle-substrate interaction (top) and the 
corresponding force-distance curves (bottom)
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A detailed explanation of the measurement of a force-distance curve is 
described below:
The cantilever starts far above the surface at point a where no distance 
dependent forces act on the probe. This leads to no deflection of the 
cantilever. When the piezo has moved the sample to position b an attractive 
force deflects the cantilever-probe assembly downwards. When the gradient 
of the tip-sample force becomes larger than the elastic constant of the 
cantilever, equilibrium can no longer be maintained and the cantilever jumps 
into contact with the surface at point c. The contact region cd  is called the 
constant compliance region and reflects the combined deformation of probe, 
cantilever and sample. Continued vertical movement of the surface is met by 
a linear response in cantilever deflection as a predetermined cantilever load 
is applied and removed; lack of linearity within this region indicates tip and/or 
surface deformation. The piezo motion is reversed at d  and the retraction 
continues back to the starting position to complete the cycle. At point e the 
force acting on the cantilever becomes greater than the adhesive force and 
the cantilever jumps to point f. The distance e-f will always be larger than the 
jump-in to contact due to the presence of the adhesion forces (i.e. van der 
Waals). Utilising Hooke’s law, relating cantilever deflection and the spring 
constant of the cantilever to interactive forces, the adhesive/cohesive force 
can be determined. Furthermore, by integrating the area under the adhesion 
part of the curve the energy of separation may be measured.
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4.1.3 Force volume imaging
The measurement of individual force curves between an individual drug 
probe and given substrate can yield limited data, since the contact geometry 
(and thus adhesion) may vary with lateral resolution. To overcome such 
issues, force-distance measurements can be conducted using force volume 
imaging. Force volume imaging mode conducts multiple (up to 4096) 
individual force curves over a specific area. The result is: (1) a large quantity 
of data points that can be statistically analysed, (2) a low resolution height 
imaged produced from the constant compliance value and (3) a map of the 
forces across the area under investigation. Since the data collection rate for 
force volume imaging is high, an in-house computer program was developed 
to analyses the data.
4.1.4 In situ atomic force microscopy
One of the key advantageous of the AFM technique is the relative ease of 
sample preparation. For example, samples can be investigated in their native 
environments, such as air or liquid with little more than simple mounting on a 
substrate. Although, some basic sample topography (tapping mode) in this 
study was conducted in air, the majority of measurements were conducted in 
an in situ cell containing model propellant. The in situ cell allows sample 
measurements to be conducted in liquids under static or constant flow 
regimens. Furthermore, when investigating soluble excipients, samples could 
be changed without disturbing the probe/substrate set-up. A schematic of the 





Figure 25 Schematic of the AFM in situ liquid cell
During the course of these investigations, only mHFA propellant was used 
since, to date, AFM measurements cannot be performed under pressure. 
Future innovations, including the development of a pressurised AFM cell, 
may allow a better insight into the interactions of such a complex system.
The aim of this investigation was to utilise the in situ AFM colloid probe 
technique as a tool to quantitatively measure the influence of adhesive and 
cohesive interactions between three drugs (salbutamol, budesonide and 
formoterol) within combination formulations and with ternary excipients and 
pMDI can materials.
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4.2 PREPARATION AND ANALYSIS OF CRYSTAL SUBSTRATES
In order to investigate the influence of the adhesive and cohesive properties 
of micronised drugs using the colloid probe technique, the preparation of 
single crystal drug substrates was required. One of the limitations of the 
colloidal probe AFM approach has been associated with dramatic inter and 
intra variations in cohesion and adhesion measurements related to 
differences in contact geometry between interacting surfaces. In this study, 
direct comparisons of the force of interaction between specific colloid probes 
and an array of substrate materials was possible by crystallising molecularly 
smooth single crystals directly from solution.
4.2.1 Materials and methods
4.2.1a Crystallisation of drug substrates
Single crystals of salbutamol, budesonide and formoterol were 
heterogeneously nucleated and grown on borosilicate glass substrates using 
a sitting drop technique (Rhodes, 1993). Briefly, a saturated solution (25°C) 
of each drug was produced using an appropriate solvent: an aqueous 
solution of salbutamol, ethanol for budesonide and methanol for formoterol.
Each saturated solution was filtrated through a 0.1 pm PTFE filter and 
deposited as a droplet onto a 15 mm circular borosilicate microscope cover- 
slip. The subsequent saturated solutions were crystallised via primary 
nucleation, using an appropriate anti-solvent (ethanol for salbutamol, water 
for budesonide and acetone/methanol (50:50 % v/v) for formoterol). 
Crystallisation was achieved over a period of 48 hours in an enclosed 
chamber surrounded by the respective anti-solvent vapour. A schematic of 
the sitting drop crystallising technique is presented in Figure 26.
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S aturated  drug in solvent 
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C ontro lled  crystal growth
Figure 26 Schematic representation of the sitting drop crystallising 
technique
This process produced crystals with large areas (> 100 pm diameter). All 
crystal samples were subsequently stored in hermetically sealed containers 
prior to analysis.
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4.2.1b General analysis of drug crystal morphology
The general morphology of the drug crystals was investigated using optical 
microscopy, AFM tapping mode (air) and computationally via the use of a 
crystal shape prediction software.
Optical photographs of each crystal were taken using a 200x long working 
distance microscope (Digital Instruments, Cambridge, UK) connected to CCD 
camera and associated software. The scale was determined by overlaying 
the image with a calibration grid (Digital Instruments, Cambridge, UK).
Predictive crystal morphology was conducted by inputting the crystal 
structure data for salbutamol (Crystal system: monoclinic; Space group: Cc; 
Z=8: a=28.069 (5), b=6.183 (1), c=16.914 (2) A), budesonide (Crystal 
system: orthorhombic; Space group: P2i2i2i; Z=4: a=8.550 (1), b=9.406 (1), 
c=28.401 (3) A) and formoterol (Crystal system: triclinic; Space group: P\; 
Z=2: a=6.737(1), b=10.384 (1), c=16.571(1) A), (obtained by Albertsson et 
al., 1978; Ertan et al., 1997; and Leger et al., 1978, respectively) into SHAPE 
V 7.0 crystal computational software (Kingsport, USA ).
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Topographical data was produced using Tapping Mode™ with a high-aspect- 
ratio silicon probe (OTESP, Digital Instruments, UK), at a scan rate of 0.7 Hz. 
All AFM studies were performed using a commercially available Multi Mode 
AFM with a Nanoscope Ili controller (Digital Instruments, Cambridge, UK). 
The root mean squared surface roughness ( R r m s )  of each sample was 
calculated from the AFM height data over a 5 pm x 5 pm area as follows 
(Equation 31).
Equation 31
Where n is the number of points in topography profile and yt is the distance of 
asperities (i) from the centre line.
To investigate the stability of active particles in a model pMDI system, in situ 
contact mode imaging of the surface topography of the dominant crystal 
growth faces of salbutamol, budesonide and formoterol were recorded in 
model propellant.
In situ AFM Imaging of the bespoke crystals was performed in contact mode 
with standard SiN4 contact mode probes, (Digital Instruments, UK) over 50 
pm x 50 pm areas at a scan rate of 0.7 Hz. To further investigate potential 
dissolution of the crystal substrates during AFM investigation, experiments 
were conducted in both pure mHFA and saturated mHFA solutions of the 
respective drug. Saturated solutions were prepared as described in Chapter 
2. Measurements were conducted at 30 minute time intervals for both 
saturated and unsaturated mHFA on all three drug crystals.
rms
4.2.1c In situ analysis of drug crystal morphology
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4.2.2 Results and discussion
As previously discussed, with the aim of significantly reducing the influence 
of substrate roughness on drug probe interactions, a series of 
‘mesoscopically smooth’ surfaces were produced by controlled crystallisation 
using the sitting drop technique.
4.2.2a General analysis of drug crystal morphology
The dominant crystal face predicted for each of the three drugs was used 
throughout this investigation. The Miller indicies of these faces were the {111} 
for salbutamol, {002} for budesonide and the {100} for formoterol.
Representative SEM micrographs of the re-crystallised salbutamol, 
budesonide and formoterol and predicted crystal morphology derived from 
SHAPE V 7.0 crystal computational software (Kingsport, USA) are shown in 
Figure 27 (A, B and C, respectively).
In general, good correlation between the SEM micrographs and predicted 
crystal morphology was observed for all drug materials.
Specific analysis of the topographical data produced by tapping mode AFM is 
discussed later in the text, since fresh batches of drug crystals were prepared 
for each colloidal probe study. However, for the purpose of this section 
analysis of topographical data indicated R rms values of 1.33 nm ± 0.04 nm for 
salbutamol, 0.68 nm ± 0.01 nm for budesonide and 1.52 nm ± 0.01 nm for 
formoterol (n = 25).
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Figure 27 Salbutamol, budesonide and formoterol crystals SEM 
microphotographs and respective crystal morphology predictions.
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4.2.2b In situ surface stability of crystal surfaces
The stability of the surface topography of individual salbutamol, budesonide 
and formoterol crystal faces in unsaturated model propellants are shown in 
Figure 28, Figure 29 and Figure 30, respectively.
In the presence of pure mHFA, real-time changes in the surface topography 
of budesonide crystal faces were observed over 30 minute periods. In 
comparison, no etching of the salbutamol or formoterol crystals was 
observed over the same time scale. Such observations were in good 
correlation with the solubility measurements conducted in Chapter 2, which 
indicated that budesonide was substantially more soluble than formoterol and 
salbutamol in mHFA.
It is interesting to note, budesonide crystals etched inward forming a pit 
starting from previous structural defects present on the dominant crystal 
plane, which formed larger and concomitantly rougher etch pits. Although not 
in the scope of this research, these preliminary observations suggest that 
surface dissolution may have a major implication on the stability issues and 
formulation properties of suspension based budesonide particles. Predicting 
how and at what rate a solid dissolves under certain conditions is paramount 
to the long term stability of a suspension based pMDI formulation and may 
limit the effects of Ostwald ripening on particle size characteristics (Blondino 
and Byron, 1998).
Studies using the saturated solutions of drug in mHFA (not shown here) 
suggested no change in crystal morphology for all drugs (images were 
conducted over a 6 hour period).
Consequently, unless otherwise stated, all particle interaction AFM 
investigations were conducted using saturated mHFA solutions of the 




Figure 28 AFM in situ visualisation of salbutamol exposed to unsaturated
solution of mHFA. A, t =  0 and B, t =  30 minutes
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Figure 29 AFM in situ visualisation of budesonide exposed to unsaturated
solution of mhiFA. A, t =  0 and B, t = 30 minutes
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---------------
Figure 30 AFM in situ visualisation of formoterol exposed to unsaturated
solution of m FI FA. A, t = 0 and B, t =  30 minutes
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4.3 MICROMANIPULATION OF DRUG PARTICLES ONTO TIPLESS 
CANTILEVERS
4.3.1 Materials and methods
Micron sized particles where attached to tipless AFM cantilevers using multi­
stage micromanipulation. This technique has been adapted from the method 
described by Preuss and Butt (1998).
A glass cover slip, previously cleaned with methanol, was attached to a 
custom build microscope slide holder. At the centre of the glass cover slip, a 
micro droplet of epoxy resin (Ducker et al., 1991) was placed. This assembly 
was then fixed to a 160 X bifocal transmission microscope lens (Ziess, 
Germany) and focus adjusted on the glue.
A tippless ‘v-shaped’ cantilever (DNP20 Digital Instruments, Cambridge, UK), 
with a nominal 0.38 N.m'1 spring constant, was mounted onto a custom built 




x, y, z transition stage
Figure 31 Graphical representation of the micromanipulation apparatus
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The tip was placed in the holder at a 4° angle to allow just the end protrusion 
of the tip to touch the glue. The tip was then moved and placed at the edge of 
the glue droplet and adjusted to remove a small quantity of the glue from the 
protrusion (Figure 32 A).
After lowering the tip assembly, the glue coated cover slip was removed and 
replaced with another glass cover slip assembly. The second cover slip was 
sprinkled with a sample of the micronised drug particles under investigation. 
After re-lifting the tipless cantilever (now equipped with a micronsized drop of 
glue) close to the glass slide sample holder, the tip was adjusted to remove a 
representative single micron size particle from the glass slide surface (Figure 
32 B).
Figure 32 Graphical representation o f the micromanipulation technique
A CCD video, reflection microscope (Digital Instruments, Cambridge, UK) 
with a 500 X long working distance lens was used throughout the 
micromanipulation process to evaluate tip quality, quantity of glue, and tip 
particle integrity prior to and post curing. Prepared drug probe tips were 
stored in tightly sealed containers for 24 hours prior to use.
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Furthermore, at the end of each study the colloid probes were investigated 
using scanning electron microscopy, using the method described in Chapter 
2. Samples were analysed at the end of each study (i.e. on completion of the 
required measurements), since the gold sputtering process would effectively 
render the tip redundant. If there was an issue with tip integrity, upon post 
observation by SEM, the colloid probe data would be discarded.
A sample tip with micronised budesonide particle mounted is presented in 
Figure 33.
Figure 33 A scanning electronmicrograph o f a micronised budesonide 
particle attached to a tipless AFM cantilever
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4.4 COLLOID PROBE MEASUREMENTS
As previously mentioned, the interactions between individual particles and 
their respective surfaces were carried out in saturated drug solutions of 
mHFA with an in situ liquid AFM cell (Ashayer et al., 2003; Young et al., 
2003). It is important to note that conventional AFM systems are currently 
limited to studies in air and/or low vapour pressure liquid environments. Thus, 
mHFA was chosen for its similarities to the physico-chemical properties of 
HFA227, used in pMDIs (Rogueda, 2003).
4.4.1 Materials and methods
Multiple force distance curves (n = 512) were determined between each drug 
probe and substrate over 5 pm x 5 pm areas with the following settings: 
approach-retraction cycle 0.5 pm, cycle rate 4.07 Hz, and a loading force of 
20 nN. All studies were performed with a minimum of three probes of each 
drug.
To avoid significant variations in contact area between an individual probe 
and the respective substrate surfaces, a great deal of care and attention 
were taken to maintain the integrity of the colloid probe throughout the study.
After considering the complexity of pMDI systems, three key areas were 
chosen for investigation by AFM:
Chapter 5 Drugs-canister surface energy interactions;
Chapter 6 Drug-drug interactions;
Chapter 7 Effects of surfactant and stabilisers on drug-drug 
interactions;
Where possible, AFM measurements obtained for each of the systems was 
discussed in relation to the physico-chemical properties, morphology and 
surface energy.
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CHAPTER 5: DRUG-CANISTER SURFACE ENERGY INTERACTIONS VIA
ATOMIC FORCE MICROSCOPY
5.1 INTRODUCTION
As previously stated, many pMDI formulations rely on the suspension of 
micronised drug particulates in propellant with or without stabilising 
excipients. Historically, the materials used within the device construction 
have sometimes been found to cause suboptimal performance of the 
formulation. Reasons for reduction in formulation performance include: 
elastomer swelling, extraction of low molecular weight polymers into the 
propellant, poor lubrication and adsorption of the formulation to canister walls 
(Tiwari et al., 1998).
During upright storage and use, the drug particulates will come into contact 
with the can wall resulting in a potential for non-reversible adhesion. This can 
be exemplified in a recent patent (Ashurst et al., 1996 - US Pat.No: 
6,143,277) that describes coating the inside of aerosol containers with 
fluorocarbon and non fluorocarbon polymers to specifically reduce particle 
adhesion.
As previously stated, in any such system there is the potential for the 
adhesion of suspended micronised drug particulates to the pMDI canister 
walls (resulting in a deviation from delivered dose label claim). However, 
such interactions become particularly important for higher potency, low-dose 
formulations, as the total drug surface area will be less than that of the 
canister wall (Young et al., 2003).
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Few works published to date have focused on the nature and range of the 
interactions (present in aqueous and non-aqueous systems), between drug 
particles in suspension and canister walls. Furthermore, such observations 
have generally been empirical and have studied the subject in a semi- 
quantitative manner (Chibowski et al., 1992; Parson et al., 1992; Podczeck et 
al., 1996; Young eta!., 2003; Young and Buckton, 1990). Consequently, a 
more rational approach into the understanding of these interactions would be 
beneficial when considering the formulation of pMDI suspensions.
The primary objective for investigating such phenomena in this study was to 
quantitatively investigate the influence of canister wall material on the 
adhesion of micronised drug particulates, and to correlate the adhesion to the 
various surface free energy components and theoretical thermodynamic work 
of adhesion.
More specifically, the study involved an attempt to correlate the interfacial 
free energy of interaction (thermodynamic work of adhesion), modelled using 
the van Oss theory for interfacial forces in non-aqueous media (as described 
in Chapter 1), and the surface energy of different polymer coated and non­
coated aluminium canister walls (measured using conventional contact angle 
methods) with direct adhesion measurements of micronised drug probes on 
respective surfaces (using AFM).
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5.2 MATERIALS AND METHODS
Aluminium (ALU), anodised aluminium (AN-ALU) and polymer coated pMDIs: 
(perfluoroalkoxy (PFA), fluorinated ethylene propylene -  polyether sulphone 
(FEP-PES) and polytetrafluoroethylene (PTFE)) were used for the study. For 
AFM and surface energy measurements, the materials were cut using metal 
snips, to produce ~1 cm2 substrates suitable for analysis. The canister 
materials were washed with methanol and dried using filtered nitrogen prior 
to study.
5.2.1 Surface morphology of the canister materials
The morphology of each canister material was studied using both SEM and 
conventional tapping mode AFM. The methods for preparation and analysis 
follow those described in Chapter 2 and 4, respectively.
5.2.2 Surface free energy measurement of drug and can materials
The surface free energy of the canister and drug materials were investigated 
using the sessile drop method (CA) as described in Chapter 3 (Buckton,
1995; Good, 1992; Good and Girifalco, 1960; Good and Stromberg, 1979; 
van Oss et al., 1988b). As previously stated small 1 cm2 areas of the canister 
materials were used, while the drug materials were formed into model 
compacts using the method described in Chapter 3.
5.2.3 In vitro AFM measurements of micronised drug probes on 
respective canister surfaces
The interaction of drug particles with canister surfaces, in a mHFA system 
(Rogueda, 2003) filled with saturated mHFA solution of the respective drugs 
under investigation was conducted using the atomic force microscope 
equipped with an in situ cell (Chapter 4). Force volume settings were as 
follows: scan size 10 pm x 10 pm, approach retraction cycle 500 nm, cycle 
rate 4.07 Hz and a constant compliance of 60 nm.
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A drawback in the use of the colloid probe technique in adhesion studies is 
the fact that the actual size and geometry of the AFM probe is unknown and, 
therefore cannot be normalised. Consequently, variability in probe contact 
radius geometry was expected. Accordingly, to avoid significant variations in 
contact area between each probe and the model canister material surface, 
the same drug probes (3 for each drug) were used for all the measurements.
Data was processed to produce separation energy values between each 
drug probe and canister surface. The adhesion between each canister 
material and drug was repeated in triplicate (3 drug probes) for each material 
and micronised drug.
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5.3 RESULTS AND DISCUSSION
5.3.1 Surface morphology of the canister materials
Previous investigations have suggested that canister morphology will 
significantly influence the drug-surface adhesion (Young et al., 2003). 
Therefore, to fully understand the relationship between surface fee energy, 
total work of adhesion and drug surface interactions in a mHFA system the 
canister surfaces were first investigated using tapping mode AFM and SEM. 
Tapping mode height images and SEM microphotographs of ALU, AN-ALU, 
PFA, FEP-PES and PTFE canister surfaces are represented in Figure 34.
In general, SEM inspection of the canisters surface morphology suggested 
ALU and AN-ALU to have relatively planar surfaces containing linear 
striations similar to that reported previously (Young et al., 2003). PTFE 
appeared to have the smoother surface, while both PFA and FEP-PES 
presented creased, crumpled surfaces, probably due to the non uniformity of 
the coating materials during manufacture. In addition, the height data 
obtained by AFM was processed to produce root mean squared roughness 
values. Analysis of the R rms values over multiple 5 pm x 5 pm areas of each 
surface suggested statistical differences (ANOVA p<0.05) (n=25). Results 
are shown in Table 1. Roughness rank order for the canister materials under 
investigation was found to be PFA>PTFE>ALU>AN-ALU>FEP-PES, 
respectively.
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Figure 34 Taping mode height images (left) and SEM microphotographs 
(right) o f ALU, AN-ALU, PFA, FEP-PES and PTFE canister surfaces
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Materials Rrms (nm) 5 |jm x 5 |jm
ALU 37.36 ± 8.66
AN-ALU 20.93 ± 4.43
PFA 53.01 ± 16.23
FEP-PES 20.48 ± 7.24
PTFE 44.93 ± 16.05
Table 20 Analysis of root mean squared surface roughness values 
(Rrms) of the canister surface materials investigated (n =25 ± Standard 
deviation)
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5.3.2 Surface free energy measurement of drug and can materials
The surface energy components (Lifshitz-van der Waals, electron 
donator/acceptor) and total surface free energy of the canister materials and 
drugs were determined using the contact angle method, and are shown in 
Table 21. Although the surface energy values for the micronised drugs have 
been reported previously, in Chapter 3, they are repeated in this section for 
convenience.
When comparing the canister materials, significant differences in the 
dispersive yLW surface energy was observed. Analysis of the data indicated a 
rank order for dispersive yLW surface energy parameter of AN- 
ALU>ALU>FEP-PES>PTFE>PFA, respectively. In addition, ALU and AN- 
ALU had yLW values approximately double that for the polymer coated 
canisters. A reasonable explanation for such difference in surface energy 
values may be related to the chemical nature of the coating material used. It 
is generally agreed that material surface free energy decreases with 
increased fluorine content (Zisman, 1963).
Analysis of the polar components of the surface free energy indicated a 
difference in rank order for y+ PTFE>ALU>AN-ALU>PFA>FEP-PES and y 
AN-ALU> ALU>PFA>FEP-PES>PTFE, respectively.
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Surface energy by CA (mJ.nrf2)
AN-ALU 43.36 ± 0.76 0.54 ± 0.24
ALU 40.44 ± 0.24 0.79 ± 0.24
PFA 17.33 ±0.78 0.42 ±0.11
FEP-PES 24.19 ±0.87 0.02 ± 0.02
PTFE 18.88 ±0.80 3.14 ±0.57
SS 46.49 ± 0.69 8.25 ± 1.46
BUD 49.07 ± 0.39 0.34 ± 0.43
FFD 48.51 ± 0.40 0.11 ±0.15
Table 21 Surface energy values for canister surface 
Standard deviation)
Y" / 8 ytot
24.68 ± 2.23 7.14 ± 1.32 50.51 ± 0.52
16.05 ± 1.72 7.03 ± 1.23 47.67 ± 1.23
10.36 ±0.91 4.17 ±0.69 21.49 ±0.16
6.64 ± 0.23 0.49 ± 0.49 24.68 ± 0.47
2.04 ± 0.27 5.01 ± 0.22 23.9 ± 0.59
18.48 ± 1.16 24.64 ± 2.50 71.12 ±2.97
22.47 ± 3.78 4.59 ± 2.85 53.66 ± 2.75
35.04 ±3.18 3.18 ±3.02 51.69 ±3.24
ial and drug calculated by contact angle (mJ.m'2) (n = 3, ±
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5.3.3 Determination of the theoretical work of adhesion of different
polymer coated and non-coated aluminium canister walls
The energy of interaction between salbutamol, budesonide and formoterol 
surfaces, were modelled against ALU, AN-ALU, PFA, FEP-PES and PTFE, 
respectively, using the surface component approach for interfacial forces in 
non aqueous media (SCA model described in Chapter 1). The dispersive 
component of the surface energy of the three drug particulates against the 
respective canister surfaces together with the acid/base, total and adhesive 
ratios are presented in Table 22.
Comparison of the LW and AB work of adhesion, for each drug with canister 
materials, suggested adhesive forces are controlled by the combination of 
dispersive and polar interactions. This is exemplified when comparing the 
rank order in predicted adhesion using dispersive or polar and dispersive 
calculations. For example, calculation of the work of adhesion for salbutamol 
with can materials shows a rank order of:
AN-ALU>ALU>FEP-ES>PTFE>PFA when considering dispersive forces 
only.
However, with the introduction of the acid-base component, the rank order 
alters with: AN-ALU> ALU>PTFE>PFA>FEP-PES.
Clearly, such a change in interaction if influential will directly affect particle 
adhesion and subsequent formulation performance.
Analysis of budesonide and formoterol theoretical work of adhesion, 
suggested a similar change in rank order, when combining dispersive and 
polar components.
With the aim of quantifying the contribution of the various surface free energy 
components (of the materials and drugs), to the thermodynamic work of 
adhesion, the theoretical values were compared with direct force 
measurements using AFM.
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Theoretical thermodynamic work of adhesion (mJ.m'2)
Material Salbutamol Budesonide Formoterol
£_i
Z 8 ytot y L W y*b ytot yLW
CD
ytot
AN-ALU 18.16 34.85 53.00 19.24 12.78 32.02 19.01 11.94 30.95
ALU 16.74 30.66 47.40 17.74 13.13 30.87 17.52 13.06 30.68
PFA 2.98 24.08 27.06 3.16 9.94 13.10 3.12 9.79 12.92
FEP-
PES
7.72 15.88 23.59 8.18 4.22 12.38 8.08 3.18 11.26
PTFE 4.14 23.42 27.55 4.38 18.46 22.84 4.32 21.89 26.22
Table 22 Theoretical thermodynamic work of adhesion between the drug materials and canister surfaces calculated 
using SCA model (mJ.m2)
136
5.3.4 In situ atomic force adhesion measurements of polymer coated
and non-coated aluminium canister walls
Measurement of adhesive forces between individual particles and substrate 
surfaces by in situ AFM have been reported previously (Ashayer et al., 2003; 
Hooton et al., 2004; Young et al., 2003; Young et al., 2004;). However, a 
direct link between the macroscopic measurements of surface energy, 
theoretical predictions of the thermodynamic interfacial interactions and 
particle adhesion have not been undertaken.
The integrity of all three drug probes were investigated prior to and post 
measurement using a high-magnification 500 X long-working-distance 
reflective microscope. Drug probes appeared visibly proud of the cantilever 
surface, with no observable differences between the start and end of the 
experimental procedure (indicating no macroscopic change in drug probe 
morphology). As expected, comparison between drug probes (1-3) on the 
correspondent canister material indicated large variation in the adhesive 
force. A possible explanation is due to the difference in particle size and 
differences in contact area due to the irregularity of the drug-probes.
Although attempts have been made to calculate the true contact area 
(Hooton et al., 2004), until now inter-probe variations cannot be quantified 
with accuracy. However by using one probe on a series of substrates, trends 
may be ranked (Appendix A1).
An obvious issue to consider when comparing the adhesion of a drug particle 
on a series of can substrates is the variation in roughness. Previous studies, 
have suggested similar roughness values to produce wide log-normal 
adhesion distributions when compared to measurements on atomically flat 
substrates (Young et al., 2004; Price et al., 2002). In such cases, a useful 
approach is to represent the data via its median (50th percentile) value. Such 
an approach reduces the positive skew in mean values induced by the log­
normal distribution, and also takes into account the elastic responses of the 
materials under investigation (Appendix A2).
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Liner regression anaiysis for the separation energy between drugs and 
canister surface materials indicated a iog-normai distribution for ail 
substrates. Median separation energy values (eo.5) were calculated for each 
individual specific distribution with 95% confidence limits. A summary table of 
median values for salbutamol, budesonide and formoterol (with respective 
high and low confidence intervals) are presented in Table 23, Table 24 and 
Table 25, respectively.
The AFM data for salbutamol drug probes suggested that the force of 
adhesion followed the following decreasing rank order of AN- 
ALU>ALU>PTFE>FEP-PES>PFA for all three probes. For the budesonide 
drug probe, rank order was AN-ALU>ALU>PTFE> PFA> FEP-PES.

























AN-ALU 86.40 82.84 90.12 43.17 41.46 44.94 80.07 77.30 82.93
ALU 79.14 76.57 81.80 28.60 27.55 29.69 52.75 51.02 54.55
PFA 2.84 2.74 2.94 9.11 8.70 9.54 6.41 6.09 6.75
FEP-PES 1.63 1.59 1.67 7.46 7.06 7.88 5.38 5.12 5.65
PTFE 4.15 3.96 4.34 13.11 12.52 13.73 12.80 12.11 13.54
























AN-ALU 253.81 225.01 257.12 284.70 273.12 296.70 56.11 21.78 23.30
ALU 139.32 137.51 141.16 52.82 51.07 54.63 22.53 5.37 5.87
PFA 11.84 11.10 12.63 7.58 7.25 7.92 2.77 2.63 2.91
FEP-PES 4.60 4.41 4.79 5.85 5.56 6.16 0.58 0.56 0.60
PTFE 13.86 13.16 14.59 13.84 12.89 14.87 4.53 4.29 4.80























AN-ALU 39.70 37.30 42.30 26.10 25.10 27.10 48.00 46.10 50.00
ALU 1.66 1.45 1.90 12.00 11.30 12.80 18.00 17.00 19.00
PFA 0.76 0.70 0.83 10.30 9.86 10.70 3.58 3.41 3.77
FEP-PES 0.59 0.57 0.61 7.29 6.88 7.73 1.93 1.79 2.08
PTFE 2.07 1.91 2.24 22.80 21.60 24.00 31.60 30.80 32.60
Table 25 AFM median separation energy values with relative confidence intervals for formoterol drug probes
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5.3.5 Comparisons between thermodynamic work of adhesion and 
AFM measurements
From the equations discussed in Chapter 1, it is intuitive to derive that the 
thermodynamic work of adhesion is directly proportional to the force of 
adhesion. Thus by plotting the measured force of adhesion against the 
theoretical surface energy/work of adhesion, it may become possible to 
correlate theoretical and experimental measurements.
For comparison, the relationship between the surface free energy calculated 
by CA (LW-CA), the SCA theoretical work of adhesion (using the dispersive 
surface free energy only) and the total SCA theoretical work of adhesion with 
respect to the AFM separation energy measurements were plotted. Plots for 
salbutamol, budesonide and formoterol are shown in Figure 35, Figure 36 
and Figure 37, respectively.
Comparison of the AFM adhesion measurements with theoretical values for 
salbutamol, indicated a direct relationship with surface free energy measured 
using the CA method (mean R2 = 0.7952). However, when considering the 
theoretical work of adhesion dispersive components (calculated using the 
SCA method), data resulted in a less significant relationship (R2= 0.7020). In 
comparison, when assessing the relationship between adhesion 
measurement and the total theoretical adhesion values a more positive 
relationship was observed (R2= 0.9260). Such observations suggest the SCA 
results in an improved relationship when considering interactions between 
drug particles and different canister materials.
Similar observations were also observed when considering budesonide and 
formoterol interactions with canister materials. In general, an increase in the 
linear relationship between theoretical and measured adhesion was observed 
when comparing theoretical surface free energy and total SCA values. In 
general, an increase in R2 from 0.6947 to 0.7133 for budesonide and 0.6768 
to 0.8012 for formoterol was observed when comparing AFM measurements 
with CA and SCA values, respectively).
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Again, clearly, such measurements indicate the need to assess the polar 
contributions present in non aqueous media of model systems. Furthermore, 
the importance of incorporating these measurements is required when 
investigating particle-device component interactions using such theoretical 
approaches.
It is interesting to note, however, that the relative increase in R2 when 
comparing the fundamental surface energy values with the SCA, was 
relatively small in comparison to results obtained in Chapter 5. This is most 
likely due to both the large differences in surface energy values between the 
polymer and aluminium substrates and variations in surface roughness.
One of the advantages of using the SCA model instead of direct surface 
energies, derived by CA, can be observed when comparing energetically 
similar polymers. For example, the surface energy rank order for the 
polymers is PFA<PTFE<FEP-PES. It would be therefore logical to conclude 
that, PFA would result in the lowest adhesion force when considering drug- 
substrate interactions. However, direct adhesion measurements between the 
drug particles and polymer substrates suggested a different rank order, 
where FEP-PES<PFA<PTFE. Subsequently, when comparing these results 
with the total theoretical SCA work of adhesion (in mHFA), a similar rank 
order to that of AFM was observed. Such observations highlight the 
importance of including the dispersive and AB components of the drug 
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Figure 35 Plot of salbutamol AFM separation energy measurements
against CA-surface energy and W-Dispersive and W-Total for the 5 canister
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Figure 36 Plot of budesonide AFM separation energy measurements
against CA-surface energy and W-Dispersive and W-Totai for the 5 canister
materiais. (n=3 drug probes)
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Figure 37 Plot of formoterol AFM separation energy measurements
against CA-surface energy and W-Dispersive and W-Total for the 5 canister
materials. (n=3 drug probes)
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5.4 GENERAL DISCUSSION
As previously discussed, the primary objective of this quantitative study of 
drug particulate adhesion to pMDI canister materials in situ was to assess the 
contribution of all the relative forces of interactions using theoretical values 
and AFM force measurements. Furthermore, a correlation has been 
suggested.
In general, analysis of experimental adhesion data in combination with the 
thermodynamic work of adhesion, calculated using the SCA, provides 
evidence for the existence of non-DLVO type interactions in pMDI 
suspension based colloidal systems. Whilst classical DLVO theory could not 
satisfactorily illustrate the above phenomena, inclusion of Lewis AB type 
forces, in an extended DLVO (SCA) approach correlated well with the 
observed behaviour of the experimental measurements of particle adhesion 
on different substrates (shown by a relative increase in R2 values).
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CHAPTER 6: SURFACE ENERGY AND AFM MEASUREMENTS TO 
INVESTIGATE DRUG-DRUG INTERACTIONS
6.1 INTRODUCTION
The primary aim of this work was to combine direct force measurement, 
(obtained using the AFM colloid probe technique) with conventional surface 
energy measurements to gain a greater understanding of the thermodynamic 
and surface properties which control particle-particle interactions in pMDI 
model systems.
This quantitative study of adhesion/cohesion interactions in a model pMDI 
was carried out by colloid probe AFM, while the surface thermodynamic 
properties of the active ingredients were measured using contact angle 
measurements. As in the previous study, the relationship between AFM 
measurements and the interfacial behaviour of the colloid particles was 
modelled using a surface component theory derived from Fowkes, Good- 
Girifalco and van Oss (Good and Girifalco, 1960; Fowkes, 1962; van Oss, 
1994).
6.2 MATERIALS AND METHODS
6.2.1 Preparation and characterisation of drug crystals
As previously discussed, one of the limitations of the colloidal probe 
technique has been associated with dramatic inter and intra variations in 
cohesion and adhesion measurements related to slight differences in contact 
geometry between interacting surfaces. In this study, direct comparisons of 
the force of interaction between specific colloid probes and an array of 
substrate materials was possible by crystallising molecularly smooth crystals 
directly from solution. Single crystals of salbutamol, budesonide and 
formoterol were heterogeneously nucleated and grown on a borosilicate 
glass substrate using the sitting drop technique described in earlier in
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Chapter 4. This process produced planar crystals with large areas of sub­
nanometre smooth surfaces.
Prior to force measurement the topography of the specific crystals used in 
each experiment was investigated using tapping mode AFM (in air) as 
described earlier in Chapter 4.
6.2.2 Surface energy measurements of the drug materials
Surface energy values, used to calculate the theoretical work of adhesion 
were calculated according to the methodology and results presented in 
Chapter 3.
6.2.3 AFM colloid probe measurements of specific drug crystals
Each study was performed with three probes of each drug. Data was 
processed to produce force of cohesion or adhesion values. To further 
overcome the limitation of not knowing the true area of contact between drug 
probes, the cohesive and adhesive forces ratios were analysed and 
compared using the recently developed cohesive/adhesive balance (CAB) 
analysis procedure as described in Chapter 1.
The AFM settings were as follows: Force volume scan size 5 pm x 5 pm, 
approach retraction cycle 500 nm, cycle rate 4.07 Hz and constant 
compliance region 60 nm.
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6.3 RESULTS AND DISSCUSSION
6.3.1 Characterisation of the drug crystals
Prior to adhesion studies, the surface roughness on the dominant crystal face 
of each drug substrate was investigated. Root mean squared surface 
roughness ( R rm s )  analysis was conducted over 5 pm x 5 pm areas of each 
substrate (n = 25). Data were processed to produce R rm s values for each 
substrate and are presented in Table 26.
Drug crystal
Rrms (nm)
5 pm x 5 pm
Salbutamol 1.33 ± 0.04
Budesonide 0.68 ± 0.01
Formoterol 1.52 ±0.01
Table 26 Rrms analysis of the drug crystal substrates used in AFM force 
measurements (n = 25, ± Standard deviation)
The data suggested that the surfaces of the crystals were extremely smooth, 
with all surfaces exhibiting a root-mean-squared roughness well below 2 nm 
over 5 pm x 5 pm areas. Although different degrees of roughness did exist 
between drugs (most likely related to differing crystal growth processes and 
kinetics during crystallisation), the uniform and smooth topography made 
them highly suitable for quantitative AFM analysis with micron sized drug 
probes. The critical size of rugosity is still an issue of debate, and it is 
probably dependent on both the material and the shape of the surface 
asperities, but the figure of 100 nm, proposed by Neumann et al., 1971, is 
still widely accepted to be a reasonable indication of the size below which 
roughness will not have a significant influence (Buckton, 1995). Only the 
dominant crystal faces of each crystal were studied in this investigation.
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6.3.2 Surface energy components and potential interactions
In the previous AFM study (Chapter 5) the canisters surface energy values, 
used to compare with AFM based measurements, were obtained from 
contact angle measurements (since the logistics of conducting IGC, Cl or 
DVS on the canisters samples was not feasible).
When investigating drug-drug interactions, it becomes possible to use the 
values obtained from the other surface energy measurements. However, for 
the purpose of this study, only contact angle and IGC values were utilised 
(since DVS is an adsorption based technique similar to IGC and use of 
capillary intrusion was not possible due to reasons discussed in Chapter 3). 
Although the surface free energy data is discussed in Chapter 3, it is 
presented here, in Table 27, for ease of comparison.
As previously discussed, both the CA and IGC values followed a similar trend 
with the highest dispersive values being measured for budesonide by both 
techniques, followed by formoterol and then salbutamol.
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Surface energy components from CA (mJ.m"2)
yLW +y Y" Z 8
Salbutamol 46.5 ± 0.7 8.3 ± 1.5 18.5 ± 1.2 24.6 ± 2.5
Budesonide 49.1 ±0.4 0.34 ± 0.43 22.5 ± 3.8 4.6 ± 2.9
Formoterol 48.5 ± 0.4 0.11 ±0.15 32.0 ± 3.0 3.2 ± 3.2
Surface energy components from IGC (mJ.nrf2)
yLW K a K b
Salbutamol 39.1 ± 1.3 0.085 ± 0.002 0.029 ± 0.001
Budesonide 62.9 ± 1.7 0.113 ±0.002 0.013 ±0.001
Formoterol 51.2 ±0.7 0.093 ± 0.002 0.026 ± 0.001
Table 27 Surface free energy components obtained using CA measurement and IGC. (n = 3, ± Standard deviation)
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Using the dispersive and polar components of the surface free energy, the 
work of cohesion and adhesion for all drug particulate combinations were 
calculated using the surface component approach (Chapter 1).
Specific values for the W lw , W ab and W tot were calculated for each drug 
combination and are given in Table 28.
However, it is important to note, that at present it is not possible to calculate 
the polar components (and therefore total contribution) of the thermodynamic 
work of adhesion for IGC (as for DVS), since specific knowledge of the 
projected contact area of the solvent probes with the solid is required. 
Furthermore, current theoretical calculation of AN and DN from IGC results 
yield dimensionless numbers and not surface energetic measurements.
In general, comparison of the LW and AB works of cohesion/adhesion for 
salbutamol suggests that both the cohesive and adhesive interactions are 
dominated by polar interactions. When considering the dispersive 
components (salbutamol interactions), the theoretical interaction is greatest 
for the salbutamol-budesonide combination, and smallest for salbutamol- 
salbutamol. This is true for both CA and IGC measurements.
However, when considering the total energy of interaction for salbutamol 
based systems (i.e. when both LW and AB components are taken into 
consideration), the cohesion energies are greater followed by the adhesion 
energies of salbutamol-formoterol and salbutamol-budesonide.
For budesonide, the LW components dominate the AB interactions for 
cohesive and adhesive (budesonide-formoterol) energies. However, the polar 
contributions are higher for the budesonide-salbutamol adhesive energy. 
Interestingly the total theoretical energy of interaction is greater for 
budesonide-salbutamol, with a strong polar component.
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For formoterol, the dispersive energy component is greater for the 
budesonide-formoterol adhesion. The polar energy component is greater for 
the formoterol-salbutamol adhesion, and the total energy is greatest for this 
system (thus, highlighting yet again the importance of polar energetic 
components).
In summary, this brief theoretical treatment of particle interactions derived 
from surface energetic components highlights the possibility of significant 
variations between interfacial interactions depending on whether they are 
calculated from dispersive components only or a combination of polar and 
dispersive contributions. The fact that polar components of the solids should 













Salbutamol -Salbutamol 13.15 19.62 49.40 69.00
Formoterol-Formoterol 24.08 21.50 7.74 29.24
Budesonide-Budesonide 36.04 22.04 11.12 33.14
Adhesive energies (mJ.rrf2)
Salbutamol-Formoterol 17.79 20.54 36.82 57.34
Salbutamol-Budesonide 21.77 20.80 32.26 53.06
Budesonide-Formoterol 29.46 21.76 10.04 31.8
Table 28 Theoretical values drug-drug interaction energies in mHFA calculated with Equation 14
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6.3.3 Direct adhesion/cohesion measurements by AFM
The in situ AFM probe technique allowed direct measurements of the 
cohesion and adhesion between single drug particulates and the dominant 
crystal faces of each drug material. As in the previous study, the integrity of 
all drug probes was investigated prior to and post measurement using a high- 
magnification 500x long-working distance optical microscope. In all cases, 
the drug probes appeared proud of the cantilever surface, with no visible 
differences between the start and end of the experimental procedure 
(indicating no macro/microscopic change in drug probe morphology).
In comparison to Chapter 5, the number distribution of each data set 
indicated a normal distribution with low variability. This is to be expected 
since the substrate surfaces were smooth and planar. Subsequently, the 
specific mean values and standard deviations for the interaction for each 
drug probe and drug substrate were calculated and are given in Table 29.
As expected, comparisons between probes of the same drug (probes 1-3) 
indicate large variations in adhesion force. This may be explained by the 
difference in particle size and variations in contact geometry due to the 
irregular probe shape. The interaction between a probe and the respective 
substrates were compared using one-way ANOVA. The results were found to 
be significantly different based upon 95% probability values (p < 0.05).
Trends can be discerned for each drug probe and forces of interactions 




Substrate Tip 1 Tip 2 Tip 3 Tip 1 Tip 2 Tip 3 Tip 1 Tip 2 Tip 3
Salbutamol 29.5 ± 1.5 41.5 ±1.7 63.9 ± 2.3 10.9± 1.1 48.2 ± 2.9 71.9 ±2.2 58.2 ± 2.1 15.3 ±1.9 11.2 ±2.4
Budesonide 12.5 ± 0.9 14.8 ± 1.0 25.8 ± 1.3 0.9 ± 0.2 5.0 ± 2.2 7.9 ±4.0 13.7 ±0.3 6.7 ± 1.9 3.7 ±0.2
Formoterol 18.4 ± 1.9 32. 1 ± 0.8 45. 0 ± 3.7 1.2 ±1.1 3.7 ± 0.7 6.7 ±1.4 13.1 ±0.7 6.2 ± 0.9 4.1 ± 1.3
Table 29 AFM separation force measurements for micronised salbutamol, budesonide and formoterol (n = 3 probes, ± 
Standard deviation). All forces in nN
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Statistical analysis of each drug probe with different drug substrates 
suggested the cohesive force between salbutamol-salbutamol to be stronger 
than the adhesion between salbutamol-formoterol, which in turn was higher 
than salbutamol-budesonide. The AFM data suggested that the salbutamol- 
formoterol interaction was approximately twice that of the salbutamol- 
budesonide adhesion.
For the budesonide probes, the rank order was budesonide-salbutamol, 
budesonide-budesonide and budesonide-formoterol. The quantitative AFM 
data suggests that the adhesive (budesonide-salbutamol) interaction is 9 
times greater than the cohesive one.
Finally, for formoterol the order is formoterol-salbutamol, formoterol- 
formoterol and formoterol-budesonide. AFM data suggested that the 
formoterol-salbutamol interaction was approximately five times greater than 
the force of cohesion.
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6.3.4 Comparisons between thermodynamic work of adhesion
and AFM measurements
As previously discussed, the thermodynamic work of adhesion is directly 
proportional to the force of adhesion. To highlight this relationship and the 
specific role of the dispersive (LW) and total (LW + AB) interactions, 
representative plots of the theoretical work of adhesion of the Lifshitz- van 
der Waals ( W a d L W )  interactions and the influence of acid-base interactions 
( W a d To t =  W a d L W  +  W a d A B )  versus the force measurements are shown in Figure 
38 (for the case of salbutamol drug probe). It is anticipated that the work of 
adhesion/cohesion should increase with an increasing force of 
adhesion/cohesion.
In general, the plots suggested no direct relationship between the separation 
force measurements and the dispersive component of the work of adhesion 
( W a d L W )  calculated from either IGC or CA measurements (Figure 38). 
However, a positive relationship is observed between the force 
measurements and the total work of adhesion ( W a dT o t)  when taking into 
account both the non-polar and polar contributions.
Similarly, analysis of the budesonide and formoterol interactions indicate no 
correlation between the LW work of adhesion (from IGC and CA) and AFM 
measurements, while the total theoretical works correlate well with 
experimental AFM data. Such observations suggested that polar interactions 
between contiguous surfaces play a significant role in particle 





^40 O *g 40 ^ SS-BUD.2 m O
I20 • o
•  oJ-------- ---------- .------ .--------- ------- -----
















Figure 38 Plot of the theoretical thermodynamic work of adhesion vs.
AFM force measurements for salbutamol drug probes (n=3 probes, •  = 1; o = 
2; ▼ = 3). Energies were calculated from IGC and CA measurements. Top 2 
graphs take into account the dispersive contribution only. Bottom graph 
includes the polar as well as dispersive contributions. Key to the 
abbreviations: salbutamol (SS), formoterol (FFD) and budesonide (BUD)
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6.3.5 Relationship between CAB plots and theoretical
cohesion/adhesion ratios
An estimation of the separation force from theoretical treatment of the 
interfacial interactions via surface energy measurements would require 
knowledge of the effective contact area of each probe, as indicated by 
Equation 15 in Chapter 1. This limitation has precluded direct correlation of 
individual AFM force measurements for each probe with theoretical 
measurements. However, the determination of the force balance for a series 
of colloid probes utilising the cohesive/adhesive balance (CAB) analysis 
procedure does allow quantification of the relationship between the 
theoretical works of cohesion and adhesion and corresponding AFM 
measurements without prior knowledge of the contact area between an 
irregular probe and model substrate surfaces.
As previously discussed, from theory, the cohesion between material 1 and 
adhesion between materials (1) and (2) in a liquid media (3) can be 
expressed Equation 16 (repeated here for convenience):
Equation 16 (from Chapter 1):
Fi3i _  n r c R i 3 i W i 3 i
F132 n 7 lR 132W132
Where F131 and F132 are the cohesive and adhesive forces, respectively. 
Assuming that the tailoring of the substrate surfaces enables equivalence of 
the contact radii R*i3 i and R*132, the relationship between the theoretical 
measurement of the thermodynamic work of cohesion and adhesion and 
experimental measurements can be discerned. From Equation 16, the slope 
of a plot of the force of cohesion versus the force of adhesion for a series of 
probes would yield an experimental measurement of the ratio of the 
thermodynamic work of cohesion over the work of adhesion. In the 
theoretical CAB graph, the measurements of the adhesive force for a number 
of colloidal probes on the respective sample surfaces of the interactive
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materials (Fadhesion) are plotted on the x axis; the correspondent force of 
cohesion of the same probes ( F COh e s io n ) is plotted on the y axes. Considering 
the contact radius of the probes involved as being equivalents, the data 
obtained from the force measurements of several probes on the specific 
sample surfaces should follow a linear fit. The bisecting line (solid) 
corresponds to the F a d h e s io n , F COhesion equilibrium ( F c o h  = F a dh , or W a dh = W c o h ) .  
The relative position of the aligned experimental plots with respect of the 
bisector line is a direct indication of the adhesive/cohesive characteristic of 
the interactive material in the binary system. This line defines two distinctive 
regions on the CAB graph: plots on the lower sector of the graph indicate an 
affinity for the probe material to present adhesive interactions ( F a dh > F Co h ) ,  
conversely, plots above the bisector denote dominant cohesive properties. 
From the relative slope of the linear regression calculations, information on 
the quantitative relative strength of the adhesive and cohesive interactions 
can be directly calculated.
The CAB plots for the salbutamol, budesonide and formoterol drug probes 
are shown in Figure 39, Figure 40 and Figure 41, respectively. The dotted 
lines represent theoretical adhesion/cohesion ratios calculated from surface 
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Figure 39 CAB plot. Relationship between AFM cohesion and adhesion 
measurements for salbutamol probes (SS, n=3). Solid line indicates line of 
cohesion/adhesion equilibrium ( F a d h e s io n  =  Fc o h e s io n ) -  Dotted lines are 
theoretical ratios calculated from surface component approach with polar and 
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Figure 40 CAB plot. Relationship between AFM cohesion and adhesion 
measurements for budesonide probes (BUD, n=3). Solid line indicates line of 
cohesion/adhesion equilibrium ( F a d h e S io n  = Fc o h e s io n ) -  Dotted lines are 
theoretical ratios calculated from surface component approach with polar and 
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Figure 41 CAB plot. Relationship between AFM cohesion and adhesion 
measurements for formoterol probes (FFD, n=3). Solid line indicates line of 
cohesion/adhesion equilibrium (Fadhesion = Fcohesion)- Dotted lines are 
theoretical ratios calculated from surface component approach with polar and 
dispersive contributions. ▲ = salbutamol (SS) substrate; •  = budesonide 
(BUD) substrate
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Analysis of the salbutamol CAB graph in Figure 39 (together with 
measurements of the relative slopes of the different probes), suggested 
salbutamol to have a stronger cohesive rather than adhesive nature. In basic 
term, when comparing salbutamol cohesion forces to salbutamol adhesion 
forces on either budesonide or formoterol, (maintaining equivalent contact 
area) the cohesion forces were always greater.
Similar analysis of CAB data for the budesonide drug probes (Figure 40) 
suggests that budesonide is more adhesive with salbutamol than cohesive 
with itself. The theoretical approach is in agreement with this tendency for an 
adhesive interaction. Similar agreement between theory and experiment is 
found for the budesonide-formoterol interactions.
The CAB and theoretical analysis of formoterol interactions (Figure 41) 
suggests that formoterol is biased towards adhesion. This again confirmed 
experimental and theoretical findings.
A linear regression analysis of the balance of the cohesive and adhesive 
forces as measured by AFM was performed to calculate the 
cohesive/adhesive force ratio. The coefficient of determination (R2) for all 
probes confirmed uniformity in contact area between crystal surfaces and the 
relationship between the adhesion and cohesion for the interactive probes. 
These ratios are summarised in Table 30, together with the theoretical ratio 
of the work of cohesion to the work of adhesion.
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Experimental ratio
F  c o h e s io n /F  adhesion
R2
F  c o h e s io n /F  adhesion
Theoretical ratio
W c o h e s io n /W  adhesion
Salbutamol-Budesonide 2.41 0.9880 1.30
Salbutamol-Formoterol 1.29 0.9875 1.20
Budesonide-Salbutamol 0.11 0.9958 0.62
Budesonide-Formoterol 1.24 0.9832 1.04
Formoterol-Salbutamol 0.21 0.9005 0.52
Formoterol-Budesonide 0.94 0.9960 0.92
Table 30 Experimental, R2 and theoretical ratio of the force and work of cohesion/adhesion
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In general, there is a good correlation between the experimental and 
theoretical ratios, although absolute values are not well correlated, albeit of 
the same order of magnitude. The two approaches suggest the same bias 
towards either adhesive or cohesive interactions.
The discrepancy between experimental and theoretical measurements, which 
is of greatest significance for interactions involving salbutamol, may relate to 
a slight polarity of the model liquid propellant that has not been taken into 
account in the equation. This for instance is known to affect liquid-liquid 
surface tension predictions (AstraZeneca R&D, private communication).
Other possible reasons could be related to the AFM measurements being 
conducted on the dominant face of each drug crystal, while the surface 
energy values were calculated from contact angles measurements derived 
from compacts of micronised drug. Thus, it is reasonable to assume that the 
less dominant faces will contribute to the interactions. The relationship 
between face specific surface free energy and work of adhesion should be 
considered for future investigation.
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6.4 GENERAL DISCUSSION
Direct measurements of the interaction forces (via AFM measurements) 
responsible for the stability of colloid particles in binary pMDI formulations 
indicate a fine balance between adhesive and cohesive tendencies. A 
relationship between the theoretical interfacial thermodynamics, derived from 
the surface component approach, and experimental force measurements 
was demonstrated. The most relevant model to correlate experiment with 
theory is one that must include polar as well as dispersive components of 
surface energetics. This is an unexpected finding for interactions in a non­
polar liquid such as mHFA. Furthermore, surface component parameters 
derived from contact angle measurements are preferred over IGC derived 
values.
Again, as with the investigations into drug canister adhesion (Chapter 5) such 
observations suggest the need to include polar acid/base interactions in the 
evaluation of suspension stability of colloid particles in non-aqueous media. 
The model developed in this work, and its correlation with direct AFM force 
measurement provides the basis for a powerful pMDI preformulation tool 
when selecting candidate drugs for inhalation.
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CHAPTER 7: THE USE OF AFM MEASUREMENTS TO INVESTIGATE 
DRUG POLYMER INTERACTIONS
7.1 INTRODUCTION
As previously discussed, the transition from CFC to HFA propellants has 
been the motivation for further evaluation of the technology and performance 
of pMDIs. It has been established that the new alternative propellants are 
delivered in a manner that does not imitate CFCs. This may be attributed to 
the physico-chemical characteristics of the propellant (Vaervaet and Byron, 
1999). In such a system, suspension based pMDIs are generally considered 
the most popular since the process of solubilisation in a relatively non-polar 
solvent is eluded. Conversely, suspension systems raise distinctive 
formulation challenges. While these new HFA liquid environments have 
comparable boiling points and vapour pressures to their CFC counterparts, 
their increased polarity make “controlled flocculation” an unresolved issue for 
many formulations (Blondino and Byron, 1998). Subsequently the use of 
secondary excipients such as surfactants and or stabilisers is of paramount 
importance to the final delivery and stabilisation of a suspension formulation. 
It is known that suspension stability can be facilitated via steric repulsive 
forces (arising from colliding particles with adsorbed layers) and/or 
electrostatic repulsive forces (that originates when the electrostatic double 
layer of interacting particles overlap) (Pugh et al., 1983). Previous reports 
have investigated the role of excipients in suspension pMDIs (Vearveat and 
Byron, 1999); however, to date, few papers have been published that 
quantitatively deal with the nature and range of interactions existing between 
drug - drug particulates and excipients in suspension (Clarke et al., 1993; 
Michael et al., 2000; Young et al., 2003). In addition, many of the 
investigations have been of empirical approach, subsequently leaving the 
subject relatively poorly understood.
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7.1.1 Stabilisation of suspension based pMDIs
The stabilisation of pharmaceutical suspensions, against flocculation and or 
coalescence, necessitates the presence of an energy barrier between the 
particles that prevent their close approach where the van der Waals 
attraction is large.
In general, two mechanisms of stabilisation can be applied: electrostatic and 
steric stabilisation.
Electrostatic stabilisation is based on charge separation and controlling the 
relative balance of charge in solution with respect to the particle electrical 
double layers (Wyatt and Vincent, 1989). Briefly, the electrostatic double 
layer is characterised by a surface charge that is compensated by unequal 
distribution of counter ions. The magnitude of repulsion depends on the 
surface (or zeta) potential, the electrolyte concentration. This forms the basis 
of the theory of the DLVO colloid stability developed independently by 
Derjaguin and Landau (1941) and Verwey and Overbeek (1948) respectively. 
However, previous work (Pugh et al., 1983) has shown that, electrostatic 
stabilisation was ineffective in non-aqueous suspensions of carbon black until 
the zeta-potential was greater than 100 mV. Such a zeta -potential is far 
greater than reported for salbutamol (Clarke et al., 1993). Such observations 
are further substantiated via Kitahara Theory (1974), which stated unless 
particles in suspension are large and posses a substantial zeta -potential, the 
electrostatic mechanism of stabilization in a low dielectric constant is 
ineffective. Moreover, Osmond and Waite (1975) described such objections 
quantitatively with the DLVO theory concluding that 50-1 OOmV potential was 
insufficient to stabilise their system. Consequently, for this study, the 
electrostatic double layer interactions can be considered of negligible 
importance.
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The second mechanism is steric stabilisation or hindrance. This system is 
based on the use of surface active polymers which adsorb very strongly to 
the surfaces of particles (Heller and Pugh, 1960). In order to achieve such 
goals, the polymers, like other surface active substances, must be able to 
interact with both the particles and the medium in a way that they are 
adsorbed on the particle substrate and yet remain freely soluble in the 
medium. Such a combination of properties is generally obtained with steric 
stabilisers. Steric stabilisers are usually a block of copolymer molecules with 
a lypophobic “head”, which attaches strongly to the particles surfaces, and a 
lyophilic “tail”, which moves freely in the dispersive medium. The lyophilic tail 
extends from the surface giving a layer thickness (d) that is several 
nanometers in thickness. When two particles approach to a distance of 
separation I (I, distance between the particles) that is smaller than 2d, the 
polymeric chains may undergo overlap and/or become compressed 
preventing their relative approach to a distance where the net van der Waals 
energy of interaction will prevent them escaping by thermal motion. When 
these chains are in good solvent conditions, such overlap is unfavourable 
and this leads to strong repulsion that increases very sharply with decrease 
of separation distance. Poly ethylene glycol (PEG) is usually the hydrophilic 
polymer chosen to provide such a hydrated steric barrier in pMDI systems.
Stabilisers are generally macro molecular (M.W > 1000, i.e. Poly vinyl 
pyrrolidone - PVP), non-ionizing compounds with a relative number of 
hydrophilic groups. Poly vinyl pyrrolidone is a commonly used water-soluble 
and physiologically inert polyamide homopolymer. With respect to high 
molecular weight PEGs, these rigid macromolecules interact with the 
disperse phase (i.e. by adsorption and bridging) and lie flat on the surface of 
the “protected” particles, reducing the “effective” van der Waals energy of 
interaction between colliding colloidal particles (Eliassaf et al., 1960), hence 
altering the settling behaviour of the dispersed phase.
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In summary, for pharmaceutical systems manufactured in non aqueous 
media, the latter mode of steric stabilisation has evidently a number of 
advantages over the electrostatic model: further of being equally effective in 
aqueous and non-aqueous media. They are effective even for suspensions 
with high solid content and reversible, since a true thermodynamic 
equilibrium is obtained. Hence the interaction forces can be reversed by 
changes in the physical state of the system.
It is well established that the success of flocculation by the use of polymers 
depends on various factors related to the surface chemistry of the particles 
as well as on the ionic nature, molecular weight, charge density and bulk 
properties of the flocculants in solution. However, it may be considered that 
the most important influence affecting the extent and mechanism of 
flocculation is dependent on the nature and conformation of polymer 
adsorption. It is also interesting to note, both theoretical calculations and 
previous experimental reports have suggested flocculation does not require 
high or complete coverage of the particle surface by the polymer (Kerkar and 
Feke, 1991; Heller and Pugh, 1960)
The aim of this work was to investigate the force of cohesion of salbutamol 
and its interactions with three different molecular weight non-ionic homo­
polymers used in pMDIs pharmaceutical formulations in a model propellant 
with a low dielectric constant with or without stabilizer.
Salbutamol was chosen as a model drug since it was the most common 
generic drug used in respiratory therapy. The use of budesonide and 
formoterol in this part of the investigation were not considered since the 
matrix of experiments would have become too large.
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7.2 MATERIALS AND METHODS
Poly ethylene glycol (M.W. 200, 400 and 600, polymers of industrial grade 
suitable for pharmaceutical applications) and Poly vinyl pyrrolidone 
(Povidone K25, M.W. 30-70, non-ionic polymer) were used as supplied. As 
previously stated only salbutamol drug-drug interactions in the presence of 
these polymers were investigated.
7.2.1 Preparation and characterisation of drug crystals
As previously discussed single crystals of salbutamol were nucleated and 
grown on a glass substrate using a sitting drop technique as described in 
Chapter 4. This process produced planar crystals with large areas of sub­
nanometre smooth surfaces. Using mesoscopically smooth and pristine 
crystals, problems related with the heterogeneity of surface materials and the 
inadequate knowledge of the contact area is eliminated. To avoid problems 
related to potential contamination (due to polymers residues in the AFM in 
situ cell, between experiments, freshly nucleated crystals were used for each 
set of experiments (12 crystals in total). The surface topography of the drug 
crystal surfaces was investigated using the AFM in a conventional ex situ 
imaging mode prior to force measurement.
7.2.2 Preparation of polymeric solutions
Increasing concentration of PEGs in mHFA, ranging from 0.05, 0.1, 0.25 and 
0.5% v/w, were prepared for PEG 200, 400 and 600. In addition, samples of 
PEG 400 and PVP in mHFA were prepared in a similar manner, where the 
concentration of PEG 400 ranged from 0.05, 0.1, 0.25 and 0.5% v/w, while 
concentration of PVP was kept constant at 0.001% w/w for all samples. All 
solutions were stored in tightly sealed containers under ambient conditions 
prior to use. For the solubility of PEGs in chlorine-free liquefied gas 
propellants the authors refer to previously published data by Blondino and 
Byron (1998).
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7.2.3 In situ AFM colloid probe measurements of salbutamol drug 
probe and salbutamol crystal substrate with three different 
molecular weight non-ionic polymers
Measurements between each salbutamol drug probe and salbutamol crystal 
substrate were conducted using the methodology described previously in 
Chapter 4, section 4.1.4. Force separation measurements were collected 
using force-volume mode to produce multiple force distance curves (n = 512) 
between each drug probe and crystal surface over a 5 pm x 5 pm area with 
the following settings: approach-retraction cycle 0.5 pm, cycle rate 4.07 Hz 
and a loading force of 20 nN. A disadvantage in the use of the colloid probe 
technique in cohesion studies is the fact that the actual size and geometry of 
the AFM probe is unknown and, therefore cannot be normalised. 
Consequently, variability in probe contact radius geometry was expected. 
Accordingly, each study was performed in triplicate (n = 3 salbutamol probes 
for each set of PEG or PEG+PVP studies), with a new drug particle attached 
on the AFM cantilever and a new crystal substrate used for each set of 
experiments so as to minimise the effects of cross contamination and that of 
the environment on the particle and substrate. Furthermore, a great deal of 
care was taken to maintain the integrity of the colloid probe throughout each 
study to a avoid inter-intra probe variation. Twenty minutes were allowed to 
elapse after the addition in the in situ cell of each different concentration of 
the drug saturated polymeric solution to allow for system stabilisation.
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7.3 RESULTS AND DISCUSSION
As previously discussed, the aim of the present study was to investigate the 
physical interactions between salbutamol in the presence of PEG stabilising 
polymers. Atomic force microscopy was used for the assessment of the 
cohesion of salbutamol with salbutamol crystals in a mHFA in the presence 
of different concentrations of these excipients. In addition, the influence of 
PVP on the force of interaction of the drug was evaluated.
7.3.1 Analysis of crystal substrates
Prior to AFM cohesion measurements, the surface roughness on the 
dominant crystal face of each drug substrate was investigated, avoiding 
problems related with face-specific crystal chemistry (Munster and Prestidge, 
2002). Roughness analysis (n = 25, ± standard deviation, 5 x 5 pm area) of 
the surface topography for each drug crystal are presented in the following 
Table 31.
Analysis of the roughness data suggested extremely smooth surface 
morphologies for all salbutamol drug crystal face used in the investigation. In 
general, all crystals exhibited a root-mean-squared ( R rSm )  below 5 nm over a 
5 x 5 pm area. It is important to note, that significant differences in roughness 
between crystals were observed (ANOVA p<0.05). However, each PEG 
concentration study was conducted with a single specific crystal thus allowing 
comparison. Furthermore, in all cases, the salbutamol crystalline substrates 
possessed an absence of micrometre scale roughness (Buckton, 1995), thus 





1 0.96 ± 0.04
2 1.20 ±0.01
3 1.68 ±0.01
4 0.80 ± 0.03
5 0.41 ± 0.04
6 1.72 ± 0.05






Table 31 Rrms analysis (n = 25, 5 x 5  pm area) of the surface topography 
for each salbutamol drug crystal dominant face (111)
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7.3.2 In situ AFM force of cohesion measurement: the stabilising effect 
of surfactants and stabilisers and its variation with 
concentrations
As previously stated, the in situ AFM probe technique allowed direct 
measurement of the cohesion between single salbutamol drug particulates 
and salbutamol crystal surfaces in the presence of surfactants and/or 
stabilisers. As with the adhesion cohesion studies conducted on atomically 
smooth crystals, analysis of the adhesion data suggested normal Gaussian 
distributions of the measured forces. Thus, data were processed to produce 
mean cohesion values and standard deviations. Adhesion data for each drug 
probe in mHFA, in the presence of different PEG polymer concentrations are 
given in Figure 42.
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Figure 42 Force of cohesion between salbutamol drug probes on 
salbutamol crystals in mHFA with varied concentrations of (A) PEG 200, (B) 
PEG 400 and (C) PEG 600
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As previously discussed, three AFM probes were utilised for each molecular 
weight polymer study (where probe 1-3 were used for PEG 200, probe 4-6 for 
PEG 400 and probe 7-9 for PEG 600). New probes and substrates were 
utilised for each set of measurements to avoid polymer contamination issues. 
Furthermore, each study was conducted using sequentially increased 
concentrated PEG solutions (i.e. lowest concentration first).
Analysis of the results suggested that strong attractive forces were present in 
the systems in the absence of any stabilising agents. In general, cohesion 
forces ranged from 11.84 nN ± 1.62 nN to 111.07 nN ± 29.79 nN in pure 
mHFA alone (n =12 probes). As previously discussed, the attractive forces 
observed in the pure mHFA most probably have their origin via the London 
dispersive component (van der Waals interactions) and surface polar 
components. It is unlikely that neither the salbutamol micronised drug particle 
nor drug crystal substrate are likely to form thick diffuse layers in a non- 
aqueous environment and will unlikely be influenced by electric double layer 
forces (Wyatt and Vincent, 1989; Romo, 1963).
A sequential increase in concentration of each of the chain length PEG 
solutions, up to a concentration of 0.5% v/w, resulted in a statistically 
significant decrease in cohesion (ANOVA p<0.05). In general, the decrease 
in cohesion was particularly evident at very low concentrations of PEG (0.05 - 
0.1% v/w). In comparison, relatively high concentrations of PEG (0.25-0.5 % 
v/w) resulted in little cohesion decrease. Interestingly, such data correlated 
well with previous reports (Kerkar and Feke, 1991). In their work it has been 
reported that the adsorption of polymers onto solid surfaces showed 
adsorption isotherms with a rapid adsorption rate at low concentrations 
followed by a plateau (Kerkar and Feke, 1991). For pharmaceutical 
applications the ideal maximum absorbed layer thickness should be achieved 
at a lower surfactant concentration to avoid adverse effects on propellant 
evaporation and product performance.
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Further data analysis (Fishers Pairwise p<0.05) suggested that variation in 
cohesion was dependent on concentration and PEG molecular weight. For 
example, analysis of the higher molecular weight PEG 600 data, suggested 
that no variation in cohesion was observed above concentrations of 0.25% 
w/w. In comparison, data for the PEG 200 suggested variation across the 
entire concentration range. It is envisaged that such observations may be 
due to increased steric hindrance with the higher molecular weight polymers.
In order to compare the relative decrease in cohesion with respect to polymer 
concentration and molecular weight, the mean values for each drug probe 
were normalised to the cohesion values obtained in mHFA only. The mean ± 
StDev for the normalised mean data values are shown in Figure 43.
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Figure 43 Normalised force o f cohesion between salbutamol drug probes 
on salbutamol crystals in mHFA with varied concentrations of PEG 200, 400 
and 600. Data represents mean ± STDev of the mean for 3 probes with each 
PEG
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In general, analysis of the salbutamol cohesion force curves in the presence 
of PEG solutions suggest a rank decrease in nominal mean separation force 
of the order: PEG 200 > PEG 400 > PEG 600 (n = 3 probes for each polymer 
analysed). Equally, variability of the results decreases from PEG 600 < PEG 
400 < PEG 200. Such observations may be due to both an increase in 
particulate surface coverage and increased polymer protrusion into the 
mHFA media with increase in molecular weight. As previously discussed it 
has been reported that the degree of the steric stabilisation is dependent, in 
part, on the adsorbed layer thickness (Kerkak and Feke, 1991), and 
accordingly would expect PEG 600 to be more effective at reducing cohesion 
due to a higher molecular weight and consequently longer polymeric chain.
In comparison, a different cohesion profile was observed with the addition of 
0.001% w/w PVP to different concentrations of PEG 400. In the presence of 
only PVP and mHFA, a large statistical decrease (approximately 70%) in 
force of cohesion was observed when compared to mHFA only (ANOVA, 
Fishers Pairwise p<0.05). Interestingly, any further addition of different 
concentrations of PEG 400 (0.05, 0.1, 0.25 and 0.5% w/v) to the mHFA-PVP 
system did not result in any significant reduction of the force of cohesion 
(ANOVA, Fishers Pairwise p<0.05). As with the PEG studies the data was 
normalised to allow comparison of PVP systems to PEG. Data are presented 
graphically in Figure 44.
182
0  + P V P  0 .0 5  0 .1  0 .2 5  0 .5
P E G  C o n c e n t r a t io n  (%  w /w )
Figure 44 Normalised force of cohesion between salbutamol drug probes 
on salbutamol crystals in mHFA with PEG 400 with and without 0.001% w/w 
PVP. Data represents mean ± STDev of the mean for 3 probes with each 
PEG
In general such observations are in good agreement with the proposed 
mechanism of PVP adsorption. It is proposed that once PVP is added to the 
mHFA its large planar rigid molecules spread across the surface of the drug 
particles, achieving a greater surface coverage, preventing any further 
stabilizing effect due to the added concentration of PEG.
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7.4 GENERAL DISCUSSION
The concept of steric stabilisation has been tested through direct particle 
adhesion measurements in a model propellant system. Results are believed 
to be quantitative and representative for this kind of model suspension 
system, where drug particulates have been proven to have a certain degree 
of instability in the presence and/or absence of polymers. It was found that an 
increase in chain length, of low molecular weight polymers, added to drug 
particulate suspensions in a low polarity media like mHFA, led to a decrease 
in inter-particulate cohesion. In addition, the use of stabilisers like PVP had a 
positive effect in decreasing particle-particle interactions.
There is no clear evidence of direct PVP-PEG binding: the changes in 
suspension stability are due to change in the thermodynamics of the system. 
The presence of PVP in a suspension system will dominate the suspension 
stability and further addition of a second polymer does not destabilise the 
suspension. (Griffiths et al., 2004)
With regards to the applicability of the AFM to investigate pMDI suspensions, 
it can be concluded that such techniques can allow a better insight into the 
interactions of such a complex system and it could prove invaluable during 
the early phases of formulation product development. Clearly, an 
understanding of the conformation of polymer molecules at interfaces is of 
vital importance when controlling the stability/flocculation behaviour of 
sterically stabilized suspensions.
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CHAPTER 8: IN VITRO MEASUREMENT OF THE MICRONISED DRUG 
AEROSOLISATION PERFORMANCES
8.1 INTRODUCTION
Using a combination of surface energy and AFM measurements and the use 
of theoretical models to predict particulate interactions in non-aqueous 
solutions (Chapter 3 and 6), it has become apparent, that particulate 
adhesion and cohesion properties will play an important role in suspension 
behaviour in pressurised metered dose inhaler formulations. Nonetheless, 
there is a further requirement to correlate these measurements with 
aerosolisation processes within model pMDI systems.
Few studies to date have investigated these kinds of system, with the specific 
aim of relating the physical chemical properties of particles to in vitro 
performance (Williams et al., 1999, Martini et al., 1991). For this reason, in 
vitro studies were undertaken to assess the possibility of correlating both 
theoretical and empirical measurements of adhesion/cohesion behaviour with 
in situ particle interaction and aerosolisation performance of pMDIs.
Therefore, for comparison to the main component of Chapter 3 and 4, 6, a 
series of in vitro aerosolisation measurements were conducted on pMDI 
formulations, to assess the aerosolisation efficiency of pMDIs containing 
single or combination drugs.
Aerosolisation efficiency of the pMDI formulations was measured using an 
Andersen Cascade Impactor (ACI). The eight stage impactor separates the 
drug by effective mass median aerodynamic diameters (MMAD) (where an 
MMAD of 5.8 pm is separated between stage 2 and filter at a flow rate of 
28.3 L.min'1, equivalent to the fine particle fraction). Drug recovered from 
each stage of the ACI and inhaler components was determined by high 
performance liquid chromatography (HPLC).
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8.2 QUANTIFICATION OF DRUG CONTENT BY HPLC
The drug concentrations collected from the various ACI stages and pMDI 
actuator during the in vitro studies were analysed by reverse phase HPLC.
8.2.1 Material and methods
HPLC operates by separating organic compounds by their relative affinity for 
the solid phase. Analyses were performed using a reverse phase HPLC and 
solvents used for the HPLC analysis are given in Table 32.
Material Manufacturer
Acetonitrile (HiPerSolv Far UV grade for HPLC) 
Heptane Sulphonic Acid Sodium Salt
Glacial Acetic Acid
Water (purified through Millipore Ri05 and 








Table 32 Materials used for the in vitro study and HPLC analysis
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The HPLC used throughout the investigation was produced by Jasco (Jasco 
Corporation, Tokyo, Japan) and comprised of a UV-970/975 Intelligent 
UV/VIS Detector, AS-950 Intelligent Auto-Sampler and PU-90 Intelligent 
HPLC Pump. Data were recorded and integrated using AZUR-OSIRIS 
Chromatography Software V 3.0. (Theix, France). Details of the experimental 
set-up for each of the drugs is summarised in Table 33.
Mobile phase used throughout the investigation was prepared by weighing 
1.10 g of heptane sulphonic acid sodium salt into a 1 litre volumetric flask 
which was diluted to volume with purified water and mixed well. The solution 
was adjusted to pH 3.0 using glacial acetic acid, using a calibrated pH meter 
and de-gassed prior to use.
Dilution solvent, used throughout the study to recover drug deposits from the 
impactor and to dilute samples and standards was a 50:50 % v /v  CH3CN:H20.
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Drug Substance Salbutamol Budesonide Formoterol
HPLC Column
Column oven temperature (°C) 
Column flow rate (mil.min'1) 
Sample tray temperature (°C) 
Injection volume (pi) 
Detector wavelength (nm) 
Run time (minutes)
Hypersil, 5pm packing, 







Hypersil, 5pm packing, 







Hypersil, 5pm packing, 







Thermo Electron Corporation, Runcon, Cheshire, UK
Table 33 HPLC experimental set-up and instrument settings for the micronised drug substances
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Standards for the combination of the three micronised drugs were prepared 
from duplicate stock standard solutions. Initial stock solutions were prepared 
by accurately weighing approximately 50 mg aliquots of each material into 
100 ml volumetric flasks and dissolving to volume with dilution solvent. Each 
stock solution was ultrasonicated for no more than 10 minutes to ensure 
dissolution, left to cool at room temperature and made up to the mark with 
dilution solvent.
Working standard solutions were prepared by serial dilution of the stock 
standard solution using calibrated (class A) laboratory pipettes and same 
dilution solution. A series of working standard with concentrations between 
0.1 pg.ml'1 and 10 pg.ml'1 were prepared for each of three drug substances.
Duplicate injections of each working standard were analysed by HPLC with a 
blank, containing dilution solution, being sampled before the first injection 
and after the higher standard.
8.2.2 Results and Discussion
Sample chromatographs for the combination of the three drugs (low and high 
concentration) are given in Figure 45.
Salbutamol exhibited a peak at an approximate retention time of ~ 2.42 mins. 
Budesonide exhibited a peak at an approximate retention time of ~ 2.81 
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Figure 45 (A) Chromatograph of salbutamol, budesonide and formoterol
mixed standards across 0.1-10 jug.mf1 concentration range, (B) 
Chromatograph of salbutamol, budesonide and formoterol mixed standards 
across at low 0.1 pg.mf1 concentration range with blank injection
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The relationship between concentration and absorbance for each of the 
drugs is shown in Figure 46. Linear regression analysis for all three drugs 
indicated R2 values of 1.000 for salbutamol, 0.9940 for budesonide and 
0.9997 for formoterol, respectively, inferring a direct linear response between 
peak area and concentration over the range 0.1 pg ml'1 to 10 pg ml'1. 
Relative standard deviation for all duplicate injections of all three drugs were 
less than 5% and, in addition, no interfering peaks were observed in any of 
the initial blanks, and no sample carry over was observed in blanks injected 
after the higher standards.
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Figure 46 Peak area vs. concentration HPLC calibration plots for (A) 
salbutamol, (B) budesonide and (C), formoterol
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As previously stated, two stock standard solutions were prepared from 
separate weightings, and were subsequently diluted to give standard 
concentrations either side of the expected sample concentrations. Both 
standard and sample concentrations were prepared and diluted to fit within 
validate linearity region. Comparison between each standard solution 
prepared from each stock solution indicated a coefficient of variance less 
than 1%, for all drugs in all cases.
During sample analysis, samples (SAMP) and standards (STD) were 
analysed using a bracketed method, using the entire standard range, i.e.
BLANK, STD1, STD2, STD3, STD4, STD5, SAMP1 to SAMP11, STD5, 
BLANK.
Each sample and standard was run twice and the mean peak area 
calculated.
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8.3 PREPARATION AND ANALYSIS OF SUSPENSION FORMULATIONS
8.3.1 Materials and methods
8.3.1a Preparation o f formulations
Approximately 25 mg of micronised drug materials was accurately weighted 
into aluminium canisters. For single drug formulations 25 mg of drug was 
weighed directly, while for combination formulations 12.5 mg of each drug 
was weighed. Each canister was fitted with a 50 j iL metering valve and 
crimped. Approximately 10 g of HFA134a was then pressure filled into each 
canister. All cans were sonicated for 20 minutes and left to stabilise for 24 
hours at ambient temperature prior to testing.
In addition, to visually assess the sedimentation of the combination products, 
glass containers containing 25 mg of micronised drug material (salbutamol, 
budesonide, formoterol) or containing the relative combination of micronised 
drugs (salbutamol-budesonide, salbutamol-formoterol and budesonide 
formoterol) (12.5:12.5 mg) were prepared. For such studies, containers were 
crimped with continuous valves and as with the standard formulations, filled 
with 10 g if HFA 134a. Again the glass container formulations were sonicated 
for 20 minutes and left to stand for at least 24 hours prior to analysis.
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8.3.1b Investigation of the sedimentation of combination products
To evaluate the suspension properties, the filled glass aerosol containers 
were inspected visually over a time period of at least 24 h after preparation. 
Digital photographs were taken with a CCD 3 mega pixel digital camera 
(Pentax, Slough, UK) to document any tendency of the suspension to cream, 
sediment or to detect adhesion/cohesion characteristics.
8.3.1c In vitro testing using the Andersen Cascade Impactor
The influence of adhesion/cohesion on the aerosolisation of the pMDI 
formulations was investigated using Pharmacopoeia apparatus D (see Figure 
47, the Andersen cascade impactor) (Copley Scientific, Nottingham, UK).
Figure 47 Adapted Image of the Andersen Cascade Impactor (adapted 
from Copley Scientific home page http://www.copleyscientific.co.uk)
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All experiments were conducted at ambient temperature and humidity (25°C, 
45 % RH). In general, the ACI is an eight stage cascade impactor that 
measures the fine particle dose and size of the aerosol cloud generated by a 
pMDI. The impactor is designed such that as the aerosol passes through 
each stage in an air stream, particles having a large enough inertia will 
impact upon a particular stage plate, whilst smaller particles will pass to the 
next impaction stage. Upon impaction, the aerosol may be divided into seven 
size categories according to its aerodynamic diameter. The aerodynamic 
particle size cut-off diameters for the ACI impactor at a flow rate of 28.3 
L.min'1 are presented in Table 34.
Stage number Nominal cut-off point (pm) at 28.3 L.min'1
0 9.0-10.0
1 5.8 - 9.0
2 i cn CO




7 0.4 - 0.7
Filter <0.4
Table 34 Mass median aerodynamic particle size cut-off points for the
Andersen cascade impactor at a 28.3 L.m in1 flow rate
After assembly of the impactor, the filter stage was covered with a 53 mm 
diameter GF/A filter (Whatmann Int. Ltd., Maidstone, UK). A pump (Model 
1423-101Q-Q626X, GAST, Buckinghamshire, UK) generated a flow rate 
through the ACI of 28.3 L.min"1 (+ 2 L.min'1), which was calibrated using a 
micromanometer (model FC012, Furness controls, Bexhill, UK) by 
adjustment of a needle valve flow regulator.
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Prior to each analysis, the pMDI was shaken vigorously for 5 s. In addition 5 
shots were actuated to waste, prior to experimental procedure, to ensure the 
valve stem was seated correctly and no blockage occurred. During analysis, 
the manufactured pMDIs were inserted into a specially constructed 
mouthpiece holder and actuated in a fixed position into the throat of the 
cascade impactor for ten seconds using a solenoid valve timer. A three 
second delay in activating the timer, after the pump was engaged, was 
invigilated to allow equilibrium of the pump. Ten consecutive doses (vigorous 
shaking in between) were released into the impinger for each single drug 
formulation (twenty for combination drug).
After testing of each formulation, the pMDI actuator, mouthpiece adaptor, 
throat assembly, stage zero to seven and filter stage were thoroughly rinsed 
into suitable volumetric flask with dilution solvent and made up to the mark, 
prior to analysis. Between analyses of each formulation, the actuator and ACI 
components were rinsed with distilled water followed by methanol, and dried 
at 40°C in an oven. The ACI components were left to cool, reassembled and 
re-used. No apparent degradation in component parts or actuator integrity 
was observed by conducting this procedure. All ACI investigations, for each 
formulation, were carried out in triplicate. As previously stated, all samples 
were analysed by HPLC.
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8.3.2 Results and discussion
8.3.2a Visual analysis of combination based pMDI formulations
Information about the physical stability and the adhesive/cohesive 
characteristics of the suspension pMDI formulations may be obtained by 
observing the sedimentation characteristic of the drug particulates after a 
specific settling time. Figure 48 shows the settling characteristics of the 
individual drug pMDI formulations at time zero and after 24h.
In addition, the sedimentation behaviour of the combination formulations at 
time zero and after 24h is shown in Figure 49.
Analysis of the sedimentation data suggests the cohesive and adhesive 
characteristics of the three micronised drugs are reflected moreover in the 
respective combination products. When salbutamol is present (in 
combination with budesonide or formoterol) the system suggested a lower 
sedimentation volume when compared to budesonide-formoterol 
combinations. One possible explanation for such observations may be 
related to the higher affinity of budesonide and formoterol towards 
salbutamol, as suggested by the in situ AFM measurements
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Figure 48 Sedimentation of single drug suspensions. At T =0, just after 
shaking, and after 24 hours
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Figure 49 Sedimentation of combination drug suspensions. At T =0, just 
after shaking, and after 24 hours
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It was interesting to note that, average floe size of budesonide aggregates 
were larger than that of salbutamol. This may be partially due to budesonide 
having a lower density (1.24 g/m3) compared with salbutamol (1.31 g/m3) and 
therefore occupying a larger phase volume at the same w/w concentration. 
However, the nature of the drugs may also influence aggregation behaviour 
in suspensions (Michael et al., 2001).
From the investigation in Chapter 6, it was suggested that formoterol and 
budesonide had more adhesive characteristics when related to salbutamol. 
Likewise salbutamol had and high cohesive tendency. Thus, the relative 
sedimentation volume of salbutamol-budesonide or salbutamol-formoterol 
decrease (or remain the same) with respect to budesonide or formoterol and 
increased with respect to salbutamol. This is most likely related to a 
rearrangement of the interparticulate forces within the combination based 
formulations.
In comparison, budesonie-formoterol formulations would form loose 
interparticulate bonds due to their adhesive bias, inducing higher sediment 
characteristics. Again, such observations are in good correlation when 
comparing fundamental surface energy and adhesion/cohesion 
measurement as discussed in Chapter 6.
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8.3.2 b In vitro analysis o f combination formulations
The particle size distribution of the cumulative particle undersize for various 
aerodynamic cut-off stages (from stage 1 (<9 pm) to stage 4 (< 3.3 pm)) of 
salbutamol, budesonide and formoterol delivered from the single drug pMDIs, 
were compared with particle size distributions of the combination formulation 
inhalers (salbutamol-budesonide, salbutamol-formoterol and budesonide- 
formoterol) for the same stages.
Graphical representation for deposition of single drugs is presented in Figure 
50.
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Figure 50 Graphical representation of percentage ACI deposition for
salbutamol, budesonide and formoterol in single drug formulations
The mean percentile deposition and the range of mass on each stage (n=3), 
with respect to the effective cut-off diameter of each stage, for single drug 
formulations are shown in Table 35.
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% Deposition
Size range (pm) Salbutamol Budesonide Formoterol
<9 7.58 ± 1.18 39.18 ±3.51 41.03 ±3.50
<5.8 5.06 ± 1.53 33.63 ± 3.84 37.27 ±4.14
<4.7 3.22 ± 1.56 27.48 ± 3.25 32.20 ± 3.77
<3.3 2.07 ± 1.15 14.86 ± 1.39 18.20 ±3.42
Table 35 Particle size distribution of salbutamol, budesonide and 
formoterol delivered from a 125 pg single product (n = 10 actuations). Values 
given are mean n = 3 ±  Standard deviation
Similarly, the mean percentile deposition and the range of mass on each 
stage, with respect to the effective cut-off diameter of each stage, for the 





Salbutamol-Budesonide Salbutamol- Formoterol Budesonide- Formoterol
Size range (\im) SS BUD SS FFD BUD FFD
< 9 13.17 ± 1.65 33.06 ± 3.21 16.04 ±3.14 44.20 ± 6.80 36.02 ± 2.72 40.64 ± 3.31
<5.8 6.92 ±0.60 28.43 ± 2.83 8.38 ± 2.27 41.84 ±7.05 29.85 ± 1.58 35.97 ± 2.40
<4.7 3.74 ± 1.05 24.26 ± 2.68 4.60 ± 1.10 38.99 ± 6.45 22.30 ± 1.91 28.67 ± 2.81
<3.3 1.91 ±0.90 15.11 ±2.09 2.55 ± 0.67 28.49 ± 4.83 10.13 ±3.05 12.86 ±4.45
Table 36 Particle size distribution of salbutamol -  budesonide, salbutamol -  formoterol and budesonide -formoterol 
delivered from a 125 pg combination products (n = 20 actuations). Values given are mean n = 3, ± Standard deviation
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To further analyse the behaviour of combination formulations in comparison 
to the respective drug only systems, the emitted drug deposition was 
presented as percentage of the theoretical dose formulated as both single 
drugs and combination products (Table 37).
Graphical representations of the emitted drug deposition of single drug 
formulations are shown in Figure 51, while combination formulation data for 
salbutamol-budesonide, salbutamol-formoterol and budesonide-formoterol 
are shown in Figure 52, Figure 53 and Figure 54, respectively.
In general, when delivered as a single entity, salbutamol presented very poor 
emitted dose performance, (% emitted dose /theoretical dose 37.78 % ±
11.08). In comparison, it was evident that emitted dose of salbutamol 
increased up to three times when delivered in a combination product 
(ANOVA, p<0.05). Such observations were observed with both budesonide 
(91.24 % ± 5.26) and formoterol (78.75 % ± 23.93) (Table 37). Such findings 
can be seen graphically in Figure 52 and Figure 53, for salbutamol- 
busedonide and salbutamol-formoterol drug-combination formulations, 
respectively.
The rationale behind such observation lies in the cohesive physical 
characteristic of salbutamol. As seen in Chapter 6, salbutamol particles, 
being predominantly cohesive, when delivered as homogeneous system, 
may have the tendency to aggregate due to the omnipresent van der Waals 
attractive forces. Consequently, the homogeneous floes formed by random 
collisions would be difficult to break during inhalation (aerosolisation). Since 
breakage involves the expenditure of work during actuation, rupture of such 
aggregates will only take place if sufficient ‘locally available’ kinetic energy is 
available to overcome the ‘energy barrier’ associated with binding. 
Accordingly, cohesive drugs like salbutamol will not be proficiently delivered 
to the target site but impact in the upper stages of the ACI, giving poor drug 
delivery performances.
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From a formulation perspective, the cohesive characteristic of salbutamol 
gathered from theoretical and experimental analysis performed in Chapter 6 
correlated with observations obtained from the in vitro study. In general, the 
salbutamol formulation exhibited poor delivery efficiency unless a significant 
amount of shear energy was introduced to overcome the strong cohesive 
bonds. Moreover, unless formulated in combination with adhesive drugs, the 
salbutamol suspension formulation would probably be subjected to caking 
over time due to the very strong cohesive bonds.
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% Emitted dose I Theoretical dose
Single drug Combination drugs

















Table 37 Calculated emitted dose as function of the theoretical dose (125 fim dose) of salbutamol (SS) , budesonide 
(BUD) and formoterol (FFD) as single and combination products. Values given are mean n = 3, ± Standard deviation
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Figure 51 Graphical representation of AC I percentile of emitted dose 
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Figure 52 Graphical representation of AC I percentile of emitted dose 
against theoretical dose of (A) salbutamol and (B) budesonide in single and 
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Figure 53 Graphical representation o f ACI percentile of emitted dose
against theoretical dose of (A) salbutamol and (B) formoterol in single and in 
mutual combination formulation
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When combined with adhesive drugs like budesonide and formoterol, 
salbutamol will tend to flocculate and become loosely bound, therefore 
resulting in improved aerosolisation behaviour. Analysis of the in vitro data 
presented here along with corroborating data presented in Chapter 3 and 6 
suggest such a system may exist in the salbutamol formulations.
In comparison, fundamental surface energy and adhesion measurements 
presented in 3 and 6 suggest budesonide and formoterol particle cohesion to 
be less than that of salbutamol. Furthermore, measurement of interparticulate 
adhesion between the two drugs indicated similar forces of interaction. 
Combining both fundamental values, along with the SCA and CAB data it 
would be logical to conclude little change in force would be required to re- 
disperse budesonide, formoterol or budesonide-formoterol combination 
formulation.
Analysis of both the visualisation study and the aerosolisation performance 
analysis of budesonide and formoterol as single entities or as a combination 
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Figure 54 Graphical representation of AC I percentile of emitted dose




An in vitro investigation of the three drug systems was undertaken to 
determine if the relationship between adhesive/cohesive forces, measured by 
AFM and SCA, could be correlated with in vitro performance.
The in vitro investigation suggested that the three micronised drug materials 
had significantly different aerosolisation profiles when manufactured as single 
or combination formulations. The relationship between aerosolisation 
performances of the micronised drugs can be attributed to the modification in 
the balance of forces acting between the particulates within the respective 
formulations.
In general, the greatest significant differences were observed between 
salbutamol single drug and combination systems. Analysis of the in vitro 
performance for the salbutamol-only formulation suggested that the cohesive 
nature of salbutamol (as predicted by the SCA and observed with AFM) led 
to tightly bound floes that did not fully de-aggregate upon aerosolisation. In 
comparison, the improved aerosolisation efficiency of salbutamol in 
combination with budesonide or formoterol showed the positive effect of the 
adhesive characteristics of the latter two drug particulates (also predicted by 
the SCA and observed with AFM).
In summary, when compared to fundamental theoretical calculations and 
direct measurement of the adhesion/cohesion forces (Chapter 3 and Chapter 
6), the relationship between inter-particulate interactions and aerosol 
performance indicated a good correlation.
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CHAPTER 9: CONCLUSIONS AND FURTHER WORK
9.1 GENERAL CONCLUSIONS
The extent to which particle-particle interactions dominate within colloidal 
based pharmaceutical systems will be dependent on direct assessment of all 
the possible interactions within a particular formulation preparation.
When considering pMDI systems (which target delivery of <5 mm particulates 
to the respiratory tract), the magnitude of the adhesion or cohesion 
phenomena on aerosolisation performance may form the basis for the 
necessary particle engineering optimisation requirements for the system.
Of particular interest was the nature and interactions of the various 
fundamental forces involved in non-aqueous based pharmaceutical 
suspensions. Such interactions will be critical during the aerosolisation 
process. Three micronised drugs (salbutamol, budesonide and formoterol), 
were chosen as models for investigation as they were directly applicable to 
inhalation therapy.
The primary aim of the study was to correlate AFM measurements of 
interparticulate forces with theoretical measurements of the interfacial free 
energy of particle interactions via surface free energy data. This approach 
was taken with a view to gain a greater understanding of the thermodynamic 
and surface physico-chemical properties which directly influence particle- 
particle interactions in suspension based pMDI systems.
Atomic force microscopy studies, surface energy investigations and 
theoretical measurements of the interfacial free energy of the three 
micronised drugs indicated significant differences in the adhesive/cohesive 
properties, when investigating both drug-drug and drug-canister interactions.
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In general, when investigating drug-drug interactions, results indicated that 
the measured forces of interaction between particles in model propellant 
could not be accounted for by theoretical treatment of the dispersive surface 
free energy via CA and IGC. Furthermore, a correlation between theoretical 
work of adhesion/cohesion and AFM measurements was observed upon the 
introduction of the polar interfacial interactions within the SCA model. In 
addition, the force of interaction between the micronised drugs and pMDI 
canister sample surfaces indicated similar findings (however, it is interesting 
to note, although only small, significant variances in R2 relationship were 
observed.)
In addition to drug-drug and drug-canister interactions the influence of 
polymer excipients were also investigated. This was mainly due to their 
common use as stabilising agents in current pMDI formulations (Adjei et al., 
1995; Duan et al., 1994a, b; Israelachvili, 1992; Mistry and Gibson, 1992; 
Moris et al., 1992; Johnson, 1992; Johnson, 1994; Purewal and Greenleaf, 
1989, Schultz and Quessy, 1991a, b; Somani and Booles, 1992; Steele et al., 
1992). The influence of various concentrations of PEG and PVP on 
salbutamol interparticulate adhesion (measured by AFM) was investigated. 
Clear variation in particle adhesion was observed with both PEG polymer 
concentrations and/or upon the addition of low PVP concentrations. Such 
observations were related to a series of steric influences.
Finally, to fully investigate drug-drug interactions in combination formulations, 
a series of cascade impactor in vitro studies were conducted with 
single/combination based pMDI formulations. In general, the aerosolisation 
performance of salbutamol was shown to improve when formulated in a 
combination format, while budesonide and formoterol studies did not indicate 
significant differences when compared to single component formulations. 
Again, such findings indicated direct correlation with observations reported 
using surface energy, theoretical and AFM measurements.
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Variations in the adhesive/cohesive properties of micronised drugs may be 
attributed to the balance of interparticulate forces of interaction that exist 
within the respective systems. Such a balance will be dependent upon a 
multitude of factors including, chemistry, surface free energy, crystal 
structure and surface morphology.
For pressurised metered dose inhalation systems the balance of such force 
of interactions are of essential importance in providing a quantitative 
relationship between the particle probes and the determinations of factors 
such as surface energy. Drug particulates of micron size must be aerosolised 
and delivered to the respiratory tract. Subsequently, the understanding and 
measurement of such interactions is of great interest.
Undoubtedly, combining the fundamental knowledge gained from AFM 
measurements with surface energy techniques provides a novel means of 
predicting suspension stability of pMDI formulations.
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9.2 FURTHER WORK
Although the techniques used within this study have proven valuable in 
predicting the aerosolisation behaviour of micronised drug particulates, and 
the innovative approaches utilised in this study may provide a novel means of 
predicting suspension stability of pMDI formulations, many analogous 
investigations could be the subject of further work.
It has been demonstrated that a relationship between the theoretical 
interfacial thermodynamics, derived from the surface component approach, 
and experimental AFM based force measurements is present, which may 
have a dominant effect on the behaviour of pMDIs suspension systems.
The natural progression of this methodology would be able to apply the 
fundamental principles relating to experimental force measurements with the 
development of a high pressure AFM system for volatile HFA propellants. For 
this purpose, the initial design and manufacture of a pressurised atomic force 
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Figure 55 Schematic of the pressurised pMDI cell
While its development is still in its infancy, further development of the 
pressurised system would be beneficial for understanding the nature of the 
force involved and the behaviour of commercial pMDI systems.
Furthermore, although using the recently developed cohesive-adhesive 
balance analysis procedure eliminates the requirement for determining the 
true area of contact between drug probes, a complete understanding of the 
drug probe geometry and surface chemistry would prove invaluable when 
modelling adhesive/cohesive interaction forces.
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This could be achieved by controlled crystallisation of the drug probes, or the 
application of novel characterisation techniques to existing micronised drug 
probes.
Finally it would be interesting to further develop surface energy techniques so 
that limitations that at the moment preclude the use of the surface component 
approach in determining the polar free energy of interaction via IGC and 
organic DVS measurements could be overcome, and could provide 
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Appendix 1 Representative force-displacement curves for salbutamol 
sulphate drug probe interactions with (A) anodised aluminum, (B) PTFE 
canister, and (C) FEP-PES-coated canister. O = approach data; A = 
retraction data.
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A2. REPRESENTATIVE SEPARATION ENERGY HISTOGRAM
To enable quantitative analysis, separation energy values obtained from drug 
probe-substrate interactions over 5 x 5pm  areas were compiled as 
cumulative frequencies and plotted as a function of probability. Linear 
regression analysis for the separation energies between the drug probe 
and substrates indicated a log-normal distribution for drug-aluminum/polymer 
coated canister under investigation. Such variations in separation energy 
distribution may be attributed to surface morphology. For example, recent 
investigations have indicated that roughness influences separation energy 
distribution (Price et al., 2002; Young et al., 2004). The interactions between 
a drug particle and an atomically flat drug substratehave been shown to 
produce a normal distribution (Price et al., 2002), in comparison to a log­
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Appendix 2 Representative separation energy histogram for salbutamol 
sulphate drug probe interaction with aluminium canister material.
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A bstrac t
Drug particulate interactions in pressurized metered dose inhalers (pMDI) may lead to a decrease in aerosolization efficiency and 
subsequent efficacy in patient treatment. The interactions between salbutamol sulfate (commonly used in Ventolin pMDIs) and a series 
of pMDI canister materials were investigated using the atomic force microscope (AFM) colloid probe technique. Approximately 4000 
individual force-distance curves were determined for a drug probe and three surfaces (10 x 10 pm areas) in situ, in a model propellant. The 
area under each force-distance curve was integrated to obtain separation energy values. Median separation energy values followed the rank 
order borosilicate glass >  aluminum > PTFE, suggesting PTFE to be the most suitable canister coating.
© 2003 Elsevier Science (USA). A ll rights reserved.
Keywords: pMDI; Suspensions; Separation energy; AFM; Force volume
1. Introduction
Pressurized metered dose inhalers (pM D I) have become 
ubiquitous fo r the treatment o f asthma and other bronchial 
diseases. In  simple terms, a p M D I is a co llo ida l system con­
sisting o f a drug suspended in  propellant, w ith  or w ithout 
stabilizing and/or taste masking agents. The pressurized pro­
pellant drug system is metered in  aliquots by a volumet­
ric  chamber located in  the metering stem. D uring patient 
use, depression o f the stem mechanism isolates the metering 
chamber from  the reservoir, w hile  exposing i t  to atmospheric 
pressure. Consequently, the metered propellant rap id ly  ex­
pands through the metering stem and is vaporized through 
a p M D I device orifice  to deliver micrometer-sized drug par­
ticulates.
This p M D I technology has been successfully developed 
to produce devices w ith  satisfactory performance. H ow ­
ever, the advent o f the 1999 M ontreal Protocol has forced 
the industry to develop p M D I devices that do not contain 
chlorofluorocarbons (CFC) as a propellant. Subsequently, 
pM D Is have had to be reformulated w ith  the more envi­
ronm entally friend ly  hydrofluorocarbons (HFA). A lthough 
this was in it ia lly  considered a simple task o f sw itching one
* Corresponding author.
E-mail address: prspmy@bath.ac.uk (RM. Young).
propellant fo r another, i t  qu ick ly  became clear that existing 
formulations were not compatible w ith  the new propellants. 
This resulted in  a surge o f pMDI-based research and related 
patents [1].
Formulation stability, both chemical and physical, in 
p M D I systems is paramount in  ensuring that a product meets 
the standards o f the relevant pharmaceutical governing bod­
ies. Particle-particle and particle-com ponent interactions in 
a p M D I may lead to form ulation caking, creaming, “ wall 
loss,”  or chemical degradation. This results in  nonconfor­
m ity  to dosing regulations. I t  is, therefore, im portant to have 
a fundamental understanding o f such interactions in  a pro­
pellant system in  order to determine the most appropriate 
form ulation.
In  simple terms, the interactions present in  a p M D I sys­
tem w il l  be dependent on both the van der Waals disper­
sive and electric double-layer forces. The degree to which 
such forces dominate the form ulation w ill be dependent on 
many factors, including material chemistry and component 
morphology. For example, the ubiquitous van der Waals dis­
persive force (acting between a ll molecules over short sep­
aration distances, < 1 0 0  nm) w il l  be d irectly influenced by 
the surface roughness o f the two contiguous surfaces. Thus, 
a material w ith  a roughness consisting o f many nanoscopic 
asperities, in  contact w ith  an atom ically fla t substrate, would 
result in  a decreased contact area and subsequent adhesion
0021-9797/03/$ -  see front matter © 2003 Elsevier Science (USA). All rights reserved, 
doi: 10.1016/S0021-9797(03)00032-8
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(when compared to the adhesion between two planar sur­
faces).
Furthermore, the physicochemical properties o f the mate­
rials should be considered. Both the van der Waals force and 
e lectric double-layer interactions w il l  be dependent on the 
chemical and macroscopic (e.g., crystal and/or amorphous 
structure) properties o f a material. For example, the presence 
o f po la r groups on specific faces o f a crystal may lead to an 
increased van der Waals force (due to a change in  Hamaker 
constant and thus surface free energy) or variation in  electric 
double-layer interaction (via prom otion o f charge accumula­
tion at the so lid -liq u id  interface).
The atomic force microscope (A F M ) [2] has been exten­
sively used to measure fundamental interactive forces be­
tween surfaces. In  addition, the im m obiliza tion o f co llo idal 
particulates onto A F M  cantilevers, as pioneered by Ducker 
et al. [3 ], allows the measurement o f  particulate surface in ­
teractions, which can be applied to such diverse areas as b i­
o logy [4 ], polym er science [5 ], and xerography [6].
Here we describe the use o f the A F M  co llo id  probe tech­
nique as a tool fo r determ ining drug particulate-surface in ­
teractions in model propellant systems. A  current HFA fo r­
m ulation [7] consisting o f a m icronized drug suspended 
in HFA-134a (H FA type) was chosen as an experimental 
model. The internal canister walls o f  the form ulation contain 
a polytetrafluoroethylene (PTFE) coating, claimed to lim it 
drug particu la te-w all adhesion and subsequent dose irrepro- 
ducib ility . Canister w all materials and coatings were chosen 
fo r pre lim inary investigation, as the degree o f drug-substrate 
contact w il l  be relatively high. Such interactions become 
particu larly im portant fo r higher potency, low-dose form u­
lations, as the total drug surface area w il l  be less than that o f 
the canister wall.
In  order to investigate the possible interactions between 
a form ulation and canister coatings, A F M  separation mea­
surements were conducted between a co llo ida l drug probe 
and three surfaces in  a model propellant.
2. Experimental
A  com m ercially available A F M  (Nanoscope I I I ,  D I, 
Cambridge, U K ) was utilized fo r drug particulate-surface 
interactions. A  salbutamol sulfate drug probe was prepared 
by mounting an indiv idual drug particle (approximate diam­
eter 5 pm) on a V-shaped tipless cantilever (spring constant 
0.58 N  m - 1 , DNP-020, D I, Cambridge, U K ) using a quick- 
setting epoxy resin. The m icrom anipulation technique is de­
scribed in  more detail elsewhere [8].
Three material substrates, borosilicate glass (Schott, 
M ainz, Germany), a lum inum (Presspart, Lancashire, U K ), 
and PTFE-coated alum inum (A 64411, 3M , Berkshire, U K), 
were prepared from  com m ercially available p M D I canisters. 
Each substrate was mounted on an A F M  sample stub w ith 
epoxy resin, washed w ith  isopropyl alcohol (com m only used
to clean surfaces in  the pharmaceutical industry), and dried 
w ith  nitrogen p rio r to analysis.
Salbutamol sulfate drug probe interactions were deter­
m ined fo r each o f the substrates in a sealed, in  situ liqu id  cell 
(D I, Cambridge, U K ) containing the model hydrofluorocar- 
bon (m HFA) 2H, 3H-decafluoropentane (A po llo  Scientific, 
Derbyshire, U K ). Force-distance measurements were col­
lected using fo rce-vo lum e mode to produce 4096 ind iv id ­
ual force curves over a 10 x  10-pm area on each substrate 
surface. Settings were as fo llows; approach-retraction cy­
cle 500 nm, cycle rate 8.14 Hz, constant compliance region 
60 nm. The area under each o f the force-distance curves was 
integrated using a custom -built program to produce separa­
tion energy values.
In  addition, detailed topographical in form ation on the 
three material substrates was investigated using A F M . Im ag­
ing was conducted in  air, using Tapping M ode w ith  a 
high-aspect-ratio silicon probe (OTESP, D ig ita l Instruments, 
U K ), at a scan rate o f 0.7 Hz.
3. Results and discussion
Representative A F M  topographical images o f the borosil­
icate glass, aluminum , and PTFE substrates are shown in 
Figs. 1A, IB , and 1C, respectively. The images o f the sur­
face o f borosilicate glass suggest the presence o f a un ifo rm  
flat surface w ith  low  root-mean-square roughness (0.94 dh
0.08 nm, n =  3, 10 x  10-pm areas). Representative A F M  
images o f the alum inum (Fig. IB )  and PTFE-coated ma­
terial (Fig. 1C) suggested irregular surface morphologies 
w ith  higher root-mean-square roughness (32.22 ±  1.81 nm 
and 27.87 ±  0.84 nm fo r alum inum and PTFE, respectively; 
n =  3 ,1 0  x  10-pm areas).
Furthermore, apparent linear striations were observed on 
both the alum inum  and PTFE-coated substrates. This is 
most like ly  due to the canister manufacture process, which 
involves draw ing the canisters out from  a single sheet o f 
aluminum.
Drug probe integrity was investigated by imaging the 
tip  w ith  a h igh-m agnification 500 x  long-working-distance 
reflective microscope. The drug probe appeared to have a 
columnar morphology approximately 5 pm in length and 
was clearly proud o f the cantilever surface. Comparison 
o f the drug probe at the start and end o f the experimental 
procedures indicated no macroscopic change in drug probe 
morphology.
Representative force-displacement curves fo r the interac­
tion between a salbutamol drug probe on borosilicate glass, 
alum inum , and PTFE samples are shown in Figs. 2A , 2B, 
and 2C, respectively. Analysis o f  the force-distance curves 
suggest a rank decrease in  both force and separation energy 
o f the order glass >  alum inum  >  PTFE.
To enable quantitative analysis, separation energy val­
ues obtained from  drug probe-substrate interactions over 
10 x  10-pm areas were com piled as cumulative frequencies
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Fig. 1. Representative topographical AFM images of (A) borosilicate glass, 
(B) aluminum canister sample, and (C) PTFE-coated aluminum canister 
sample.
and plotted as a function o f probability. Linear regression 
analysis fo r the separation energies between the drug probe 
and substrates indicated a normal distribution fo r d rug- 
glass interactions (Fig. 3A) and log-normal distribution fo r 
both drug-alum inum  (Fig. 3B) and drug-PTFE interactions 
(where r 2 ^  0.99). Such variations in separation energy dis­
tribution may be attributed to surface morphology. For ex­
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Fig. 2. Representative force-displacement curves for salbutamol sulfate 
drug probe interactions with (A) borosilicate glass canister, (B) aluminum 
canister, and (C) PTFE-coated aluminum canister. O =  approach data; A = 
retraction data.
influences separation energy distribution [8,9]. The interac­
tions between a drug particle and an atomically flat drug sub­
strate have been shown to produce a normal distribution [9], 
in comparison to a log-normal distribution for irregular drug 
compacts [9].
Median separation energy values (eo.s) were calculated 
from the specific distributions and are shown in Fig. 3C 
w ith 95% confidence intervals. Median eo.5 values fo r drug 
probe interactions w ith borosilicate glass were 824, 68, 
and 3.7 nJ, respectively, suggesting that the adhesion o f
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Fig. 3. Representative separation energy histograms for salbutamol sulfate 
drug probe interactions with (A) borosilicate glass and (B) aluminum 
canister materials. (C) Median separation energies for salbutamol drug 
probe interactions with glass, aluminum, and PTFE-coated pMDI canisters 
under model propellant (n =  4096); error bars indicate 95% confidence 
intervals.
salbutamol in a propellant system would be in the rank order 
glass >  aluminum >  PTFE. Again, the reason for this rank 
order may be a combination o f factors including material 
morphology and surface free energies.
For example, the micronized salbutamol sulfate particles 
used fo r the investigation were approximately 5 pm in d i­
ameter and suggested a columnar morphology. When the in ­
teraction o f such particulates w ith a planar surface (such as 
glass) is considered, the contact area and thus adhesion w ill 
be relatively high. However, small variations in the substrate 
morphology (as observed w ith the aluminum and PTFE sub­
strates) could result in a significant decrease in contact area 
(and thus adhesion). No long-range attractive or repulsive 
forces were observed in the A FM  force-distance curves, for 
any o f the substrates, suggesting that electric double-layer 
forces did not play a dominating role (in this case).
In addition, it is important to consider the surface energy 
o f the materials. Such factors could explain, fo r example, 
the low £o.5 for PTFE-drug interactions when compared to 
aluminum (which have sim ilar surface roughness parameters 
but contrasting surface energy values). It is clear that such 
particle-substrate interactions are complex and require fur­
ther investigation. The influences o f roughness and intrinsic 
surface energies on particulate-substrate interactions need to 
be investigated further.
In a p M D I system, other components should be consid­
ered for future investigation. These include valve stems, me­
tering chambers, actuator orifices, and addition o f cosolvents 
and/or surfactants. In addition, the study o f particle-particle 
interactions may supply fundamental inform ation relating to 
drug cohesion, flocculation, and caking mechanisms.
Furthermore, the selection o f an mHFA is an important 
factor. In this case, 2H, 3H-decafluoropentane was chosen 
as a mHFA due to its chemical and physical sim ilarities to 
HFA-134a, used in the example product [10]. W hilst these 
investigations were conducted in situ, particle adhesion may 
occur at the liquid-gas interface (in a real propellant system). 
This should also be considered fo r future investigation.
4. Summary
The use o f the A FM  collo id probe technique as a method 
fo r investigating interactions in model propellant systems 
opens the possibility o f rapidly and safely screening mate­
rials during preformulation. The use o f force-volum e imag­
ing to determine separation energy values allows quantitative 
analysis o f particulate-substrate interactions as a function o f 
surface topography.
A  rank decrease in salbutamol-substrate median sepa­
ration energies in the order borosilicate glass >  aluminum 
>  PTFE was observed. This correlated well w ith the route 
adopted in the example product [7], where the use o f low- 
surface-energy material coatings (e.g., PTFE), in place o f 
aluminum canisters, has the potential for decreasing parti­
cle wall adhesion and thus improving the formulation e ffi­
ciency. In simple terms, the A F M  presents itse lf as a possi­
ble preformulation tool for rapid characterization o f particle 
interactions, allow ing the collection o f fundamental data that 
may facilitate the development o f pMDIs.
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Purpose. To compare experimental measurements of particle cohesion and adhesion forces in a model 
propellant with theoretical measurements of the interfacial free energy of particulate interactions; with 
the aim of characterizing suspension stability of pressurized metered dose inhalers (pMDIs).
Methods. Interparticulate forces of salbutamol sulfate, budesonide, and formoterol fumarate dihydrate 
were investigated by in situ atomic force microscopy (AFM) in a model propellant 2H,3H perfluoro- 
pentane. The surface thermodynamic properties were determined by contact angle (CA) and inverse gas 
chromatography (IGC). Experimental data were compared with theoretical work of adhesion/cohesion 
using a surface component approach (SCA), taking into account both dispersive and polar contributions 
of the surface free energy.
Results. Results indicated that the measured forces of interaction between particles in model propellant 
could not be accounted for by theoretical treatment of the dispersive surface free energies via CA and 
IGC. A correlation between theoretical work of adhesion/cohesion and AFM measurements was ob­
served upon the introduction of the polar interfacial interactions within the SCA model.
Conclusions. It is suggested that the polar contributions of the surface free energy measurements of 
particles may play a crucial role in particle interaction within propellant-based systems. Together with 
the application of a SCA model, this approach may be capable of predicting suspension stability of 
pMDI formulations.
KEY WORDS: AFM; pMDI; surface energy; suspension.
INTRODUCTION
The delivery o f drug particulates to the respiratory tract 
has become an essential and effective means o f treating a 
variety o f pulmonary disorders, including asthma, chronic ob­
structive pulmonary disease, bronchitis, and cystic fibrosis 
(1,2). Such popularity can be related to the relative small dose 
required for effective and often rapid onset o f the therapeutic 
effect while reducing systemic exposure and minimizing drug- 
related side effects. The pressurized metered dose inhaler 
(pM D I) remains the most commonly prescribed device for 
therapeutic aerosol delivery (3). Currently, this dosage form 
may contain hydrofluoroalkane (H FA) propellants alongside 
the drug substance, surfactant, and cosolvents. The formula­
tion of a pM D I can generally be subdivided into two catego­
ries: solution- and suspension-based systems. Suspension- 
based pMDIs are generally the most popular because drugs 
are generally insoluble in the propellant system and thus solu­
b ilization in a nonpolar solvent and/or the potential for 
chemical degradation are obviated (4).
Non-aqueous suspensions raise particular formulation 
challenges. Their preparation requires careful consideration
1 Pharmaceutical Technology Research Group, Department of Phar­
macy, University of Bath, Bath, United Kingdom.
2 AstraZeneca R&D Charnwood, Loughborough, United Kingdom.
3 To whom correspondence should be addressed, (e-mail: r.price@ 
bath.ac.uk)
of the interaction between drug particulates in liquefied pro­
pellant, and various components of the pM D I device (3,4). 
Previous approaches have investigated the behavior o f pM D I 
system mainly through empirical measurements o f the floc­
culation behavior of particulates, and analytical measurement 
o f the loss of drug within the device (4,5). Techniques such as 
zetametry, sedimentation, and particle size analysis (6), mi­
croscopy and spectroscopy (7,8) are routinely used to mea­
sure pM D I formulation stability. However, indirect and direct 
measurement of the various interactions, which govern their 
behavior, have seldom been performed. The use o f surface 
energetic measurements, via contact angle (CA) and inverse 
gas chromatography (IGC) measurements, together with the 
use o f particle interactions theories have enabled indirect 
evaluation of the particulate interactions (9-12). Moreover, 
the advent of the atomic force microscope colloid probe ap­
proach (13) provides an approach to directly quantify inter­
actions between drug particles and formulation components 
in model pM D I systems (14,15).
The primary aim o f the study was to correlate atomic 
force microscopy (AFM ) measurements o f interparticulate 
forces with theoretical measurements of the interfacial free 
energy of particle interactions via surface free energy data 
and to gain a greater understanding o f the thermodynamic 
and surface physicochemical properties that directly influence 
particle-particle interactions in suspension-based pM D I sys­
tems. The quantitative study o f adhesion/cohesion interac­
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tions in a model pM D I was carried out by in situ colloid probe 
AFM . The surface thermodynamic properties of the active 
ingredients were measured using contact angle (CA) and in­
verse gas chromatography (IGC). The relationship between 
AFM  measurements and the interfacial behavior of the col­
loid particles was modeled using a surface component ap­
proach (SCA) derived from Fowkes, Good-Girifalco, and van 
Oss models (9,16,17).
Particle Interaction Theory
Interactions between collo idal particles are usually 
described by the D erjaguin-Landau-Verwey-O verbeek 
(D LV O ) theory (18,19). The D LV O  theory considers two 
types of interactions: a dispersive attractive interaction of the 
Lifshitz van der Waals (LW ) type and a predominately repul­
sive electrostatic interaction due to the interpenetration of 
electrical double layers. The application o f the D LV O  theory 
for the stabilization of drug suspensions in non-aqueous pM D I 
media has not been fu lly validated (20). The possible lim ita­
tion o f the approach, which has been successfully used to 
describe the behavior of aqueous suspensions, is the absence 
o f an ionic double layer (21,22). A  quick theoretical calcula­
tion o f the repulsive electrostatic energy of interaction be­
tween 1-p.m solid particles as a function o f interparticulate 
distances in liquefied propellants with varying dielectric con­
stants (reciprocal thickness of the diffuse double layer set at 2 
x 106 cm-1) show that the electrostatic repulsive forces acting 
between particles are small. This may be attributed to the 
overlap o f very diffusive electrical double layers due to a 
com bination o f low d ie lectric constants and low ionic 
strengths (23). Thus, the attractive LW  forces are thought to 
predominate at all separation distances. As a result, theoret­
ical descriptions o f non-aqueous drug suspensions via a 
D LV O  approach are very limited, as they fail to adequately 
predict the stability of these formulations (4,20).
An alternative approach to the D LVO  theory has been 
proposed by van Oss (9,24,25). The approach decomposes the 
surface energetics (i.e., surface tension or contact angle val­
ues) into independent contributions and in particular in tro­
duces a polar acid-base (A B ) (electron donor/electron accep­
tor) component (9). The corresponding polar free energy of 
interaction (AB ), which can be repulsive or attractive (de­
pending on the chemical structure, suspending medium prop­
erties and surface potential) can control the total energy of 
interaction at small separation distances. According to this 
surface contribution approach (SCA), the total surface free 
energy o f a solid is determined by the LW  dispersive compo­
nent (yLW) and the polar AB  component (,yAB) as given in 
Eq. (1):
TO T  _  LW  , AB y = y + y (1)
The total free energy of interaction between two surfaces 
in a liquid medium is subsequently defined as the sum of LW  
dispersive interactions, the polar component (AB), and elec­
trostatic double layer (EL) interactions [Eq. (2)]:
A GTOT = {AGLW + AGab} + AG1 (2)
In  the absence of an electrostatic influence, the interac­
tion energy between solid surfaces (S) immersed in a liquid 
(L ) can be expressed by the interfacial free energy (AGSLS),
see Eq. (3). This in turn can be related to the solid-liquid 
interfacial tension via:
AGsls = AGLW + AGab  = -2 7sls = - 2 ( - S  + (3)
The interfacial energy parameters for the LW  and A B  
contributions between similar solids (1) in a liquid (3) can be 
obtained from the surface free energy and surface tensions of 
the solid and liquid by using the Good-Girifalco-Fowkes ap­
proach (16,17) [Eq. (4)]:
a g 13i= - 2 [ ( - -  v - £ w ) 2+ z ( v T h i + 
- V "vLvi-V tTtD]
7373
(4)
For liquids with very low polarity (y3+ = y3 -0  mJ/m 2), 
the free energy of interaction can be simplified to [Eq. (5)]:
A G ^ - a t V ^ - V ^ ) 2- (5)
Hence, knowledge o f the surface energy of the solid 
(y i ^ ,  7 i +, and y3~) and the surface tension of the liquid 
(y3LW, -y3+ and y3~) enables the determination of interaction 
energy between particles within the media.
Similarly, the energy of interaction between dissimilar 
solid surfaces (1 and 2) in a liquid (3) can be calculated using 
the following expression (6):
AG, tJ-w'yS-w- 6 w7 i  73
+ + V 7 i-  V tD + V t^ V tT
+V ^ - V ^ ) - V ^ - V ^ ]  (6)
In an apolar medium (y3+ and y3~ ~0 mJ m-2), the energy 
of interaction can be used in the simplified form (7):
AG132 - 2[\Z" LW  LW LW  LW2 73 - W LW  LW72 73LW
(7)
The influence o f the van der Waals interactions on the 
force of adhesion can be related to the thermodynamic work 
o f adhesion (Wad = -A Gsls  =  -A G 132) through the Hertz 
approximation for elastic bodies (26), which takes into ac­
count the separation distance and the contact geometry of 
interacting surfaces. Two models can be used for this purpose, 
the Johnson, Kendall, and Roberts (JKR) and the Derjaguin, 
Muller, and Toporov (D M T) models (27,28). Their validity 
have been found to depend on the interacting materials and 
their geometries. The D M T theory is typically valid for small 
particles, low surface energies and high elastic moduli, whilst 
the converse is true for the JKR model.
The general form of the relationship of the force of ad­
hesion with the energy (derived for LW  interactions between 
two spherical particles) can be expressed as in Eq. (8) (27):
Fad = mrR*Wad (8)
where R* is the harmonic mean of the particle radii (also 
called contact radius) and n is a predetermined constant de­
pending on the selected model (n =  3/2 for JKR and n =  2 
for the D M T model).
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M ATERIALS A N D  METHODS 
Materials
Micronized salbutamol sulfate, budesonide, and formo- 
terol fumarate dihydrate were supplied by AstraZeneca 
(Loughborough, Leicestershire, U K) and were used as re­
ceived. The model propellant HPFP (2H, 3H perfluoropen- 
tane) was supplied by Apollo  Scientific (Stockport, Der­
byshire, U K). The purity o f HPFP was in excess of 99.9%, 
with a moisture content less than 9 ppm. Further purification 
of the HPFP was achieved by filtering and purifying with 
chromatographic grade acidic and basic alumina (Fluka, G ill­
ingham, U K). This treatment was necessary to remove impu­
rities in the organic liquid that may otherwise directly in flu­
ence particle adhesion measurements. A ll organic solvents 
(diiodomethane and ethylene glycol) used in the study 
were supplied by B D H  (Poole, Dorset, U K ) and were of 
analytical grade. Purified water was prepared by reverse os­
mosis (M illiQ , Molsheim, France).
Scanning Electron Microscopy
Scanning electron microscopy (SEM) was used to char­
acterize the morphology o f the micronized drugs. Powder 
samples were deposited on adhesive carbon black tabs, which 
were premounted on aluminum stubs. Particles were coated 
with a thin gold film  using a sputter coater (model S150B, 
Edwards High Vacuum, Sussex, U K). Samples were imaged 
using a JEOL 6310 SEM (Jeol, Tokyo, Japan) at lOKeV.
Particle Sizing
Particle sizing of the micronized drug samples were per­
formed using a Mastersizer X  (Malvern Instruments Ltd, 
Malvern, U K). The instrument was equipped with a small 
volume cell (with a capacity of approximately 20 ml) and a 
100 mm lens, allowing particle detection in the size range of 
0.5-120 pm. Approximately 1 mg o f drug material was sus­
pended in a 0.1% w/v lecithin/cyclohexane solution and soni­
cated for 10 min at 25°C prior to analysis. The particle size 
distribution was characterized by the 10th, 50th, and 90th 
percentile o f the cumulative particle undersize frequency dis­
tribution. A ll samples were run as triplicates.
Preparation and Characterization o f  Drug Crystals
One of the limitations of the colloidal probe AFM  ap­
proach to date has been associated with dramatic inter- and 
intra-variations in cohesion and adhesion measurements re­
lated to slight differences in contact geometry between inter­
acting surfaces. In this study, direct comparisons o f the force 
of interaction between specific colloid probes and an array of 
substrate materials was made possible by crystallizing mo- 
lecularly smooth crystals from solution. Single crystals of sal­
butamol, budesonide, and formoterol were heterogeneously 
nucleated and grown on a borosilicate glass substrate using a 
sitting drop technique, described elsewhere (29). This process 
produced planar crystals with large areas of sub-nanometre 
smooth surfaces.
AFM Topographical Measurements
The surface topography of the drug crystal surfaces was 
investigated using the A FM  in its conventional imaging mode. 
Imaging was conducted in Tapping Mode operation with a 
high-aspect-ratio silicon probe (OTESP, D igital Instruments, 
U K), at a scan rate of 0.7 Hz. A ll A FM  studies were per­
formed using a commercially available M ulti Mode A FM  with 
a Nanoscope ITI controller [Digital Instruments (D I), Cam­
bridge, U K ]. The root mean squared surface roughness 
(Rmis) ° f  deviations from the average height was calcu­
lated from the AFM  height data over a 5 pm x 5 pm area via:
R rms (9 )
where n is the number of points in topography profile and 
is the heights o f the surface asperities (i).
Model Drugs Compact Preparation
Contact angle measurements were obtained using the 
sessile drop method on model compacts o f the micronized 
drug. Compacts were prepared by direct compression using a 
servo hydraulic press (model 25010, Specac Ltd., Kent, U K). 
Approxim ately 250 mg o f the micronized material was 
weighed into a 10-mm stainless steel die, spread evenly in the 
die, and compacted with a compression force of 10 kN. Com­
pacts were stored in sealed containers in a controlled envi­
ronment (25°C, 44% RH) for at least 24 h prior to use.
AFM Colloid Probe Measurements
Colloid probes were prepared by mounting an individual 
micronized drug particle (approximate diameter 5 pm) onto a 
V-shaped tipless cantilever (spring constant k = 0.32 N/m, 
DNP-020, D I, Cambridge, U K) using a quick-setting epoxy 
resin (30). Extreme care was taken during drug probe prepa­
ration to lim it the amount of drug-glue contact. The micro­
manipulation technique is described in detail elsewhere (31). 
The measurement of the forces o f adhesion and cohesion 
between individual particles and their respective crystal sur­
faces were carried out in HPFP with an in situ liquid A FM  cell 
(7,8). I t  is important to note that conventional A FM  systems 
are currently limited to studies in air and/or low vapor pres­
sure liquid environments. Thus, HPFP was chosen for its simi­
larities to the physicochemical properties of HFA227, used in 
pMDIs (32). The use of HPFP as a model system for studying 
the behavior of pMDIs, when characterization methods can­
not be adapted to the pressure regime, has been extensively 
studied by Rogueda (32).
Force-distance profiles were recorded by measuring the 
deflection o f the cantilever as the substrate surface was 
ramped into and out o f contact with the cantilever in a step­
wise fashion (30,33,34). By applying Hooke’s law, F  = kx 
(where x  is the deflection of the cantilever and k  the spring 
constant), a quantitative measurement of the force o f adhe­
sion can be obtained. Multiple force distance curves (n = 
512) were determined between each drug probe and crystal 
surface over a 5 pm x 5 pm area with the following settings: 
approach-retraction cycle 0.5 pm, cycle rate 4.07 Hz, and a 
loading force of 20 nN. Each study was performed with three 
probes of each drug. To avoid significant variations in contact
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area between an individual probe and the respective substrate 
surfaces, a great deal of care and attention were taken to 
maintain the integrity of the colloid probe throughout the 
study.
To further overcome the limitation of not knowing the 
true area o f contact between drug probes, the cohesive and 
adhesive forces ratios were analyzed and compared using the 
recently developed cohesive-adhesive balance (CAB) analy­
sis procedure (35). This approach provides a quantitative 
measurement of the adhesive and cohesive balance of the 
interactive forces within a formulation. The CAB analysis 
procedure allows AFM  measurements of inter-particulate 
forces to be directly correlated to the thermodynamic work of 
cohesion and adhesion o f interacting surfaces via surface en­
ergy measurements. For a particulate interacting with two 
surfaces (one alike and one different) the cohesive-adhesive 
balance between the two materials can be expressed by:
R*
•^adh ^adhesion ^ ^ ^ a d h
(10)
where Fcoh and Fadh are the cohesive and adhesive forces 
measured by AFM , and Wcoh and VFadh are the thermody­
namic work of cohesion and adhesion, respectively. Assuming 
the contact mechanics of the cohesive and adhesive interac­
tion follow the same theoretical model, the ratio of the van 
der Waals forces for a series of colloidal probes should be 
constant and directly proportional to the thermodynamic ra­
tio o f the work of cohesion and adhesion of the interfacial 
interactions calculated via the surface free energy measure­
ments of the interacting particles. Furthermore, determining 
the balance of van der Waals forces for a series of colloidal 
probes via AFM  measurements overcomes the need to deter­
mine variations in the spring constant (k ) of each individual 
A FM  cantilever.
Contact Angle Measurements
The contact angle o f the powder compact surfaces were 
measured using the sessile drop method (10,16,36-38) with a 
N R L goniometer (Rame-Hart, Inc., Mountain Lakes, NJ, 
USA) equipped with a 2.3x objective lens, and a lOx Rams- 
den type eyepiece. A  liquid drop was introduced onto the 
substrate surface via a microsyringe. Advancing contact 
angles were measured for three different liquids (water, diio- 
domethane, and ethylene glycol) at room temperature (20°C). 
A  summary of the surface tension components of the liquids 
used in the direct contact angle determination (9) are pre­
sented in Table I. The surface energy parameters o f the com­
pact surfaces were determined using the Young-Dupre equa­
tion, which requires the contact angle (0) measurements for a
Table I. Surface Tension Components and Parameters of Liquids 
Used in CA Measurements at 20°C (van Oss, 1994) (14)
Surface tension components 
and parameters (mJ • m-2)
7lw 7+ 7
Diiodomethane 50.8 -0 0 0
Water 21.8 25.5 25.5 51.0
Ethylene glycol 29.0 1.92 47.0 19.0
minimum of three liquids (one apolar and two polar) via the 
following relationship:
7l (1 + cos0) = 2 ( V 7 sW7lW + -  V tS D  (H )
where ys and yL are the surface free energies of the solid and 
the liquid, respectively.
Inverse Gas Chromatography
Inverse gas chromatography (IGC) provides a means of 
determining both the dispersive and polar components of sur­
face free energy for micronized drugs (11,12), without poten­
tial modification of the surface properties of the particles 
upon compaction (39). The surface free energy characteristics 
of the micronized powders were determined using a commer­
cially available IGC (IG C  2000, Surface Measurement Sys­
tems Ltd, London, U K). The dispersive component of the 
solid surface free energy (ya) can be calculated by measuring 
the retention time (volume) of a series of alkanes of known y f 
injected at an infinite dilution using the following relationship 
(40):
RT  In UN = 2 A T \ /y ^ f l\ /y f  + C (12)
where R is the gas constant, T  the temperature, N  is 
Avogadro’s number, a is the projected surface area o f the 
sample probe, y f the dispersive component o f the probe, and 
the net volume of carrier gas required to elute the probe 
molecules from the column (corrected for column dead time 
and compression factors). This procedure is based on the de­
termination o f a linear relationship between the retention 
volume (F L ln t^ ,) of the nonpolar probe against ^ (y f)0'5. The 
dispersive component o f the surface free energy o f the solid 
can be calculated from the slope.
The electron donor and electron acceptor properties of 
the micronized powders were determined by IG C using polar 
liquids in the vapor phase. The specific (polar) interactions 
AGsp can be related to the acidic or electron accepting pa­
rameter (K a) and the basic or electron donor parameter (K b) 
by the following equation:
AGSP /  D N \
^ - { an*)k>+k>A N * \A N , (13)
where D N  is an electron donor or base number characterized 
according to Gutmann (41) and A N *  is an electron acceptor 
or acid number (42). The values of K a and K b o f the powder 
samples were determined from the gradient and the intercept 
o f the line obtained plotting AGsp/AN * vs. DN/AN *.
Approximately 1.0 g o f the micronized powder was 
weighed into standard glass IG C columns and plugged with 
glass wool. Each column was tapped for 5 min, using the 
minimum setting on a jo lting voltameter (Surface Measure­
ment Systems Ltd, London, U K) to a produce “ homoge­
neous”  powder bed. Each column was purged in the IG C  at 
0% RH, at 318.05 K  with dry nitrogen for 3 h prior to analysis 
to remove surface moisture. The retention time of a series of 
n-alkanes (hexane to decane) and polar (ethanol, chloroform, 
dioxane, ethyl acetate, and acetone) probes were detected at 
infinite dilution with a flame emission detector. Column set­
tings and run times for all three drugs were optimized at 
318.05 K. Each column was analyzed twice.
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Statistical Analysis
The statistical analysis of forces of interaction between 
individual colloid probes and respective substrates were com­
pared using one-way ANOVA. The results were found to be 
significantly different based upon 95% probability values (p < 
0.05).
RESULTS A N D  DISCUSSION
Physical Characterization
The morphology and size of the micronized drugs were 
fully characterized by SEM and laser light diffraction.
Scanning Electron Microscopy
Representative scanning electron micrographs of the mi­
cronized drugs are shown in Fig. 1. In general, all three drugs 
exhibited irregular crystal morphology with clear variations in 
crystal size, which correlated well with particle size measure­
ments.
Particle Size
Micronized budesonide was found to have a median 
equivalent volume diam eter of 3.24 p-m, with over 82% of 
particles below 5 p.m. By comparison, formoterol was found 
to have a median equivalent volume diam eter of 2.69 |xm, 
with 93% of particles below 5 p.m. Salbutamol was found to 
have the largest median equivalent volume diam eter of 6.61 
ixm, with 46% of particles below 5 |xm. In general, the particle 
sizing data agreed well with SEM observations, with drug 
samples falling within the required size range for pulmonary 
delivery.
Determination o f Contact Angle and Relative Surface 
Energy Values for Powder Compacts
The surface energy components obtained by CA (9,10) 
and IG C  measurements are presented in Table II. Both CA 
and IG C  values follow a similar trend. The highest dispersive 
(LW ) values were measured for budesonide by both tech­
niques, followed by formoterol and then salbutamol. These 
observations are in general agreem ent with related studies of 
the ranking of the dispersive param eters of pharmaceutical 
powders (43,44). A direct comparison of the data between the 
two techniques is rather difficult due to the variations in the 
experimental and theoretical approaches (11). The acidic and 
basic components of the powder samples from IG C measure­
ments are not consistent with the results obtained from CA 
m easurem ents. A quantitative determ ination of the polar 
com ponents from IGC would require specific knowledge of 
the surface contact area of the polar component of the solvent 
probes with the solid. This limitation currently precludes the 
use of the surface component approach in determining the 
polar free energy of interaction via IGC measurements.
Determination o f the Theoretical Work of Adhesion/ 
Cohesion
The dispersive and polar components of the work of co­
hesion and adhesion of the drug particles were calculated 
from the surface energy m easurem ents derived from the CA
Fig. 1. Scanning electron micrographs of micronized salbutamol sul­
fate (A), budesonide (B), and formoterol fumarate dihydrate (C).
studies and the surface tension value of HPFP. The dispersive 
LW work of cohesion and adhesion was obtained using the 
Good-Girifalco-Fowkes combining rule from the IG C  m ea­
surements [Eq. (4)]. The thermodynam ic work of adhesion 
and cohesion were calculated for the various particle-particle 
combinations in HPFP, and are shown in Table III.
C om parison of the LW and AB work of cohesion/ 
adhesion for salbutam ol suggests that both the cohesive and 
adhesive interactions are dom inated by polar interactions. 
The dispersive part of the interactions is greatest for the sal- 
butam ol-budesonide combination and smallest for salbuta-
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Table II. Surface Free Energy Components Obtained via CA and IGC Measurements
Surface energy components from CA (mJ • m 2) Surface energy components from IGC (mJ • m 2)
„,LW AB7 7 7 7 7LW Ka Kb
Salbutamol sulphate 46.5 ± 0.7 8.3 ± 1.5 18.5 ±1.2 24.6 ± 2.5 39.1 ± 1.3 0.085 ± 0.002 0.029 ± 0.001
Budesonide 49.1 ±0.4 0.3 ± 0.4 22.5 ± 3.8 4.6 ± 2.9 62.9 ±1.7 0.113 ±0.002 0.013 ± 0.001
Formoterol 48.5 ± 0.4 0.1 ± 0.2 35.0 ± 3.0 3.2 ± 3.0 51.2 ± 0.7 0.93 ± 0.002 0.026 ± 0.001
Values are mean ± SD, n = 3.
mol-salbutamol. This is true for both CA and IG C  measure­
ments. The total energy, that is, when both LW  and AB  
components are taken into consideration, is greater for 
the cohesive salbutamol interactions, followed by the adhe­
sion energies o f salbutamol-formoterol and salbutamol- 
budesonide.
For budesonide, the LW  components dominate the AB 
in te ractions fo r cohesive and adhesive (budesonide- 
formoterol) energies. However, the polar contributions are 
higher for the budesonide-salbutamol adhesive energy. Inter­
estingly, the total theoretical work o f interaction is greater for 
budesonide-salbutamol, with a strong polar component.
For form oterol, the dispersive energy component is 
greater for the budesonide-formoterol adhesion. The polar 
energy component is greater for the formoterol-salbutamol 
adhesion, and the total energy is greatest for this system. 
Thus, further highlighting the importance of polar energetic 
components in particle interactions.
This brief theoretical treatment o f particle interactions 
derived from surface energetic components highlights the 
possibility of significant variations between interfacial inter­
actions depending on whether they are calculated from dis­
persive components or a combination of polar and dispersive 
contributions. The fact that polar components of the solids 
should be taken into account in non-polar liquids is counter­
intuitive and cannot be overlooked.
In an attempt to quantify these theoretical predictions, 
the thermodynamic work of adhesion and cohesion was com­
pared with adhesive and cohesive force measurements via 
A FM  experiments.
Atom ic Force Microscopy Analysis
Measurement o f pull-off forces between individual par­
ticles and substrate surfaces by A FM  and the influence of
Table III. Theoretical Values of the Thermodynamic Work of Ad­











Salbutamol-Salbutamol 13.15 19.62 49.40 69.00
Form oter ol -Form oterol 24.08 21.50 7.74 29.24
Budesonide-Budesonide 36.04 22.04 11.12 33.14
Adhesive energies
Sa lbuta m ol-Formoterol 17.79 20.54 36.82 57.34
Salbutamol-Budesonide 21.77 20.80 32.26 53.06
Budesonide-Formoterol 29.46 21.76 10.04 31.8
All values are in mJ • m 2.
complex interactive forces on particle adhesion have been 
reported previously (15,31,45). However, wider application of 
the A FM  technique for preformulation development has 
been limited by the dramatic influence of the contact area 
between contiguous surfaces on quantitative force measure­
ments. Although attempts to quantify the contact radii of the 
asperities of the colloid probes have been made (45), normal­
ization and direct comparison of cohesive and adhesive forces 
in multicomponent systems remains onerous, due to the lim ­
ited knowledge of the true contact area between probe and a 
substrate of varying surface roughness. Furthermore, efforts 
to predict adhesive interactions using theoretical approaches 
and surface energy measurements have, to date, proved un­
satisfactory (46). Theoretical estimates are often several or­
ders of magnitude greater than experimental measurements 
(47,48). The most plausible explanation for this discrepancy is 
the variation in the mesoscopic contact area between contigu­
ous surfaces from the expected macroscopic dimensions. 
These difficulties can, however, be overcome by the use o f the 
novel cohesive-adhesive balance (CAB) analysis procedure 
developed by Begat et a l (35).
Analysis o f Substrates Surfaces
Prior to adhesion studies, the surface roughness on the 
dominant crystal face of each drug substrate was investigated. 
Roughness analysis (n = 25, 5 x 5 |±m area) of the surface 
topography for each drug crystal indicated R rms values of:
Salbutamol, 1.33 nm (±0.04)
Budesonide, 0.68 nm (±0.01)
Formoterol, 1.52 nm (±0.01)
The data suggested extremely smooth surface morpholo­
gies, with surfaces exhibiting a root-mean-squared roughness 
well below 2 nm over a 25 gm2 area. Although different 
degrees o f roughness did exist between drugs (most likely 
related to differing crystal growth processes and kinetics dur­
ing crystallization), the uniform and smooth topography 
made them highly suitable for maintaining reproducible con­
tact geometry between an individual colloid probe and the 
substrate surfaces under investigation.
Measurement o f Forces o f Cohesion and Adhesion
The in situ A FM  probe technique allowed direct mea­
surements o f the cohesion and adhesion between single drug 
particulates and the dominant crystal faces of each drug ma­
terial. The integrity o f all drug probes was investigated prior 
to and post measurement using a high-magnification 500x 
long-working distance optical microscope. In all cases, the 
drug probes appeared proud of the cantilever surface, with no 
visible differences between the start and end of the experi­
mental procedure (indicating no macro/microscopic change in 
drug-probe morphology). The number distribution of each
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data set indicated a normal distribution with low variability, 
suggesting the interaction with a highly smooth substrate sur­
faces providing a uniform contact geometry for the interact­
ing probe. The specific mean values and standard deviations 
for the interaction for each drug probe and substrate are pro­
vided in Table IV . As expected, comparisons between probes 
of the same drug (probes 1-3) indicate large variations in 
adhesion force. This may be explained by the difference in 
particle size and variations in contact geometry due to the 
irregular shape o f the probes. W ithout prior knowledge o f the 
true contact area o f each probe, inter-probe variations cannot 
be quantified. However, trends can be discerned for each 
drug probe and their forces of interactions measured ranked.
Hence, the cohesive salbutamol-salbutamol force of in­
teraction was shown to be stronger than the adhesion salbu- 
tamol-formoterol, which in turn was higher than salbutamol- 
budesonide interactions. The A FM  data suggested that the 
salbutamol-formoterol interaction was approximately twice 
that o f the salbutamol-budesonide adhesion.
For the budesonide probes, the order was budesonide- 
salbutam ol, budesonide-budesonide and budesonide- 
formoterol. The quantitative AFM  data suggested that the 
adhesive (budesonide-salbutamol) interaction was nine times 
greater than the cohesive one.
Finally, for formoterol, the rank order was formoterol- 
sa lbu tam ol, fo rm o te ro l- fo rm o te ro l, and fo rm o te ro l- 
budesonide. A F M  data suggested that the form otero l- 
salbutamol interaction was approximately five times greater 
than the force o f cohesion.
Comparisons Between Thermodynamic Work o f Adhesion 
and AFM  Measurements
As previously discussed, the thermodynamic work o f ad­
hesion is directly proportional to the force of adhesion. To 
highlight this relationship and the specific role of the disper­
sive (LW ) and total (LW  + A B ) interactions, representative 
plots o f the theoretica l work o f adhesion o f the LW  
(W ad LW) interactions and the influence of acid-base interac­
tions (Wad Tot =  Wad LW + Wad AB) vs. the force measure­
ments are shown in Fig. 2 (for the case of salbutamol drug 
probe). I t  is anticipated that the work of adhesion/cohesion 
should increase with an increasing force o f adhesion/cohesion.
The plots suggest no direct relationship between the 
separation force measurements and the dispersive component 
of the work of adhesion (Wad LW) calculated from either IGC 
or CA measurements (Fig. 2, IG C and CA). However, a posi­
tive relationship was observed between the force measure­
ments and the total work o f adhesion (Wad Tot) when taking 
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Fig. 2. Plot of the theoretical thermodynamic work of adhesion vs. 
AFM force measurements for salbutamol sulfate drug probes (n = 3 
probes, •  = 1; O = 2; T  = 3). Energies were calculated from IGC 
and CA measurements. The upper two plots take into account the 
dispersive contribution only. The lower plot includes the polar as well 
as dispersive contributions. Key to the abbreviations: salbutamol 
(SS), formoterol (FFD), and budesonide (BUD).




Tip 1 Tip 2 Tip 3 Tip 1 Tip 2 Tip 3 Tip 1 Tip 2 Tip 3
Salbutamol 29.5 ± 1.5 41.5 ± 1.7 63.9 ± 2.3 10.9 ± 1.1 48.2 ± 2.9 71.9 ± 2.2 58.2 ± 2.1 15.3 ± 1.9 11.2 ±2.4
Budesonide 12.5 ± 0.9 14.8 ± 1.0 25.8 ± 1.3 0.9 ± 0.2 5.0 ± 2.2 7.9 ±4.0 13.7 ± 0.3 6.7 ± 1.9 3.7 ± 0.2
Formoterol 18.4 ± 1.9 32.1 ± 0.8 45.0 ± 3.7 1.2 ±1.1 3.7 ± 0.7 6.7 ± 1.4 13.1 ± 0.7 6.2 ± 0.9 4.1 ± 1.3
Values are ± SD, n = 3 probes. All forces are in nN.
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Similarly, analysis of the budesonide and formoterol in­
teractions indicated no correlation between the LW work of 
adhesion (from IG C and CA) and AFM measurements, while 
the total theoretical work correlated well with experimental 
AFM data. Such observations suggest that polar interactions 
between contiguous surfaces play a significant role in particle 
adhesion/cohesion in non-aqueous media and should not be 
neglected in predictive theoretical approaches.
Relationship Between CAB Plots and Theoretical 
Cohesion/Adhesion Ratios
An estimation of the separation force from theoretical 
treatm ent of the interfacial interactions via surface energy 
m easurem ents would require knowledge of the effective con­
tact area of each probe, as indicated by Eq. (8). This limita­
tion precludes direct correlation of individual AFM  force 
m easurem ents for each probe with theoretical measurements 
of the work of adhesion/cohesion. However, the determ ina­
tion of the force balance for a series of colloid probes using 
the CAB analysis procedure does allow quantification of the 
relationship between the theoretical work of cohesion and 
adhesion and corresponding AFM  measurements.
From theory, the cohesion between material 1 and adhe­
sion between material 1 and 2 in a liquid media (3) can be 
expressed as:
F i a i  m r /? f 31W 131
Fl32~ m r R ^ 2W n2  (14)
where F 131 and Fx32 are the cohesive and adhesive forces, 
respectively. Assuming that the tailoring of the substrate sur­
faces enables equivalence of the contact radii /?*31 and R f32, 
the relationship between theory and experimental measure­
ments can be discerned. From Eq. (14), the slope of a plot of 
the force of cohesion vs. the force of adhesion for a series of 
probes would yield the ratio of the thermodynamic work of 
cohesion to the work of adhesion.
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Fig . 3 . R e la tio n sh ip  be tw een  A F M  cohesion and adhesion m easu re­
m ents fo r  sa lbu tam ol su lfa te  probes (S S , n =  3 )  illu s tra te d  as a C A B  
p lo t. T h e  bisecting (s o lid ) lin e  is the e q u ilib ra tio n  o f  the cohesion and  
adhesion. D o tte d  lines a re  th e o re tic a l ratios ca lcu la ted  fro m  surface  
c o m p o n en t app ro ach  w ith  p o la r  a n d  d ispersive co n trib u tio n s . A ,  
budesonide ( B U D )  substrate; # ,  fo rm o te ro l ( F F D )  substrate.
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F ig . 4. R e la tio n s h ip  b e tw e e n  A F M  cohesion and  adhesion m easu re­
m ents fo r  bud eso n id e  probes ( B U D ,  n =  3 )  illu s tra ted  as a C A B  p lo t.  
T h e  bisecting (s o lid )  lin e  is the e q u ilib ra tio n  o f  the cohesion and  
adhesion. D o tte d  lines are th eo re tic a l ra tio s  ca lcu la ted  fro m  surface  
co m p o n en t ap p ro ach  w ith  p o la r  and dispersive c o n trib u tio n s  o f  the  
surface fre e  en e rg y  m easu rem en ts. A ,  fo rm o te ro l ( F F D )  substrate; • ,  
sa lbutam ol (S S ) substrate.
hesive-adhesive balance from the thermodynamic surface free 
energy measurem ents for salbutamol, budesonide, and for­
moterol probes are shown in Figs. 3, 4, and 5, respectively. 
The bisecting (dotted) line in each figure corresponds to the 
balance between of cohesion and adhesion (Ecoh =  Fadh, or 
Wadh =  WCOh)- The relative position of the AFM data points 
with respect to the bisector is a direct indication of the cohe­
sive and adhesive tendencies of the drug particles considered. 
D ata below the bisector indicate an affinity for the probe 
material to develop adhesive interactions (Fadh > Fcoh). Con­
versely, data above the bisector denote dom inant cohesive 
properties.
80
—' c^ohesion “  Uhoan
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F ig . 5 R e la tio n s h ip  betw een  A F M  cohesion and adhesion m easu re­
m ents fo r  fo rm o te ro l fu m a ra te  d ih y d ra te  probes (F F D ,  n =  3 ) illu s ­
tra te d  as a C A B  p lo t. T h e  b isecting  (s o lid ) lin e  is the e q u ilib ra tio n  o f  
the cohesion and  adhesion. D o tte d  lines a re  th e o re tic a l ra tio s  ca lcu ­
la te d  fro m  surface c o m p o n en t app ro ach  w ith  p o la r  and  dispersive  
c o n trib u tio n s . A  =  sa lb u ta m o l (S S ) sub strate; •  =  bud eso n id e  
( B U D )  substrate.
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Table V. Linear Regression Analysis and Measurements of Cohesive/Adhesive 
Ratios via AFM Measurements Together With the Theoretical Ratios of the 
Cohesive/Adhesive Interactions
Experimental ratio 
F /Fc^ohesion' r  adhesion
R2
F /Fr  cohesion'r  adhesion
Theoretical ratio 
W /W11 cohesion' TT adhesion
Salbutamol-Budesonide 2.41 0.9880 1.30
Salbutamol-Formoterol 1.29 0.9875 1.20
Budesonide-Salbutamol 0.11 0.9958 0.62
B udesonide-For m oter ol 1.24 0.9832 1.04
Formoterol-Salbutamol 0.21 0.9005 0.52
Formoterol-Budesonide 0.94 0.9960 0.92
Analysis of Fig. 3 suggested salbutamol to be more co­
hesive than adhesive, when interacting with formoterol and 
budesonide. This is in accordance with the theoretical predic­
tions o f the total work o f adhesion/cohesion shown in Table 
II I.
Similar analysis of CAB data for the budesonide drug 
probes (Fig. 4) suggested that budesonide was more adhesive 
with salbutamol than cohesive with itself. The theoretical ap­
proach was in agreement with this tendency for an adhesive 
interaction. Similar agreement between theory and experi­
ment was found for the budesonide-formoterol interactions.
The CAB and theoretical analysis of formoterol interac­
tions (Fig. 5) suggested that formoterol was biased toward 
adhesion. This again confirmed the experimental and theo­
retical findings.
A  linear regression analysis o f the balance of the cohe­
sive and adhesive forces as measured by AFM  was performed 
to calculate the cohesive/adhesive force ratio. These ratios are 
summarized in Table V, together with the theoretical ratio of 
the work o f cohesion to the work o f adhesion. There is a good 
correlation between the experimental and theoretical ratios, 
although absolute values are not well correlated, albeit o f the 
same order of magnitude. The two approaches suggest the 
same bias toward either adhesive or cohesive interactions. 
The discrepancy between experimental and theoretical mea­
surements, which is of greatest significance for interactions 
involving salbutamol, may relate to a slight polarity o f the 
model liquid propellant that has not been taken into account. 
This for instance is known to affect liquid-liquid surface ten­
sion predictions. Other possible reasons could be related to 
the A FM  measurements being conducted on the dominant 
face o f each drug crystal, while the surface energy values were 
calculated from contact angles measurements derived from 
compacts of micronized drug. Thus, it is reasonable to assume 
that the less dominant faces may influence the measurements. 
The relationship between face specific surface free energy 
and work o f adhesion is a subject of ongoing investigations.
The theoretical model developed in this work and its 
correlation with direct AFM  force measurement may provide 
the basis for a powerful pM D I preformulation tool. This un­
derstanding of the influence of the physicochemical proper­
ties o f colloid particles on particulate interactions may pro­
vide the formulation scientist with a guide to improving the 
stability o f pM D I suspensions and the behavior of the system 
under development.
CONCLUSIONS
Direct measurements of the interaction forces (via AFM  
measurements) responsible for the stability of colloid par­
ticles in pM D I formulations indicate a fine balance between 
adhesive and cohesive tendencies. A  relationship between the 
theoretical interfacial thermodynamics, derived from the sur­
face component approach, and experimental force measure­
ments were demonstrated. Correlation o f the experimental 
measurements with theory required the introduction of the 
polar as well as dispersive components o f surface energies of 
the interacting solids. This combined approach may provide a 
novel means of predicting suspension stability o f pM D I for­
mulations.
REFERENCES
1. D. Ganderton and T. Jones. Drug Delivery to the Respiratory 
Tract, Academic Press, London, 1987.
2. J. S. Patton. Mechanisms of macromolecule absorption by the 
lungs. Adv. Drug Deliv. Rev. 19:3-36 (1996).
3. D. L. Ross and B. J. Gabrio. Advances in metered dose inhaler 
technology with the development of a chlorofluorocarbon free 
drug delivery system. J. Aerosol Med. 12:151-160 (1999).
4. H .  D. C. Smyth. The influence of formulation variables on the 
performances of alternative propellant-driven metered dose in­
halers. Adv. Drug Deliv. Rev. 55:807-828 (2003).
5. D. Ganderton. Patients, devices and formulations. /. Aerosol 
Med. 23:441-444 (2003).
6. J. A. Ranucci, S. Dixit, R. N. J. Bray, and D. Goldman. Con­
trolled flocculation in meterd-dose aerosol suspensions. Pharma- 
cetical Technology 0:68-73 (1990).
7. Y. Michael, M. J. Snowden, B. Z. Chowdhry, I. C. Ashurst, C. J. 
Davies-Cutting, and T. Ripley. Characterisation of the aggrega­
tion behaviour in a salmeterol and fluticasone propionate inha­
lation aerosol system. Int. J. Pharm. 221:165-174 (2001).
8. E. M. Phillips, P. R. Byron, and R. N. Dalby. Axial-ratio mea­
surements for early detection of crystal-growth in suspension- 
type metered dose inhalers. Pharm. Res. 10:454-456 (1993).
9. C. J. van Oss. Interfacial Forces in Aqueous Media, Marcel Dek- 
ker, New York, 1994.
10. R. J. Good. Contact-angle, wetting, and adhesion—a critical- 
review. J. Adhes. Sci. Technol. 6:1269-1302 (1992).
11. M. D. Ticehurst, R. C. Rowe, and P. York. Determination of the 
surface properties of two batches of ss by inverse gas chromatog­
raphy. Int. J. Pharm. 111:241-249 (1994).
12. O. Planinsek and G. Buckton. Inverse gas chromatography: con­
siderations about appropriate use for amorphous and crystalline 
powders. J. Pharm. Sci. 92:1286-1294 (2003).
13. G. Binnig and C. F. Quate. Atomic force microscope. Phys. Rev. 
Lett. 56:930-933 (1986).
14. R. Ashayer, P. F. Luckham, S. Manimaaran, and P. Rogueda. 
Investigation of the molecular interactions in a pMDI formula­
tion by atomic force microscopy. Eur. J. Pharm. Sci. 21:533-543 
(2004).
15. P. Young, R. Price, D. Lewis, S. Edge, and D. Traini. Under 
pressure: predicting pressurized metered dose inhaler interac­
tions using the atomic force microscope. J. Colloid Interface Sci. 
262:298-302 (2003).
16. F. M. Fowkes. Additivity of intermolecular forces at interfaces. I. 
Determination of the contribution to surface and interfacial ten­
Model pMDI Formulations 825
sion of dispersion forces in various liquids. J. Phys. Chem. 67: 
2538-2541 (1963).
17. R. J. Good and L. A. Girifalco. A theory for estimation of surface 
and interfacial energies. III. Estimation of surface energies of 
solids from contact angle data. /. Phys. Chem. 64:561-565 (1960).
18. B. V. Derjaguin and L. D. Landau. Theory of the stability of 
strongly charged lyophobic sols and of the adhesion of strongly 
charged particles in solutions of electrolytes. Acta Physico- 
chimica. U.S.S.R. 14:663 (1941).
19. E. J. W. Verwey and J. T. G. Overbeek. Theory o f the Stability o f 
Lyophobic Colloids, Elsevier, Amsterdam, 1948.
20. C. Vervaet and P. R. Byron. Drug surfactant propellant interac­
tions in HFA formulations. Int. J. Pharm. 186:13-30 (1999).
21. R. J. Pugh, T. Matsunaga, and F. M. Fowkes. The dispersability 
and stability of carbon black in media of low dielectric constant. 
I: Electrostatic and steric contributions to colloidal stability. Col­
loids Surf. 7:183-207 (1983).
22. A. Kitahara. Zeta potential in non-aqueous media and its effect 
on dispersion stability. Prog. Organic Coatings 2:81-98 (1974).
23. D. A. Wyatt and B. Vincent. Electrical effects in non-aqueous 
systems. J. Biopharm. Sci. 3:27-31 (1989).
24. J. A. Brant and A. E. Childress. Assessing short-range mem­
brane-colloid interactions using surface energetics. J. Membr. Sci. 
203:257-273 (2002).
25. J. A. Brant and A. E. Childress. Colloidal adhesion to hydrophilic 
membrane surfaces. J. Membr. Sci. 241:235-248 (2004).
26. H. Hertz. On the contact of elastic solids. J. Reine Angew. Math. 
92:156-171 (1882).
27. K. Johnson, K. L. Kendall, and A. D. Roberts. Surface energy 
and the contact of elastic solids. Proc. R. Soc. Lond. A 324:301- 
313 (1971).
28. B. V. Derjaguin, V. M. Muller, and Y. P. Toporov. Effect of 
contact deformations on the adhesion of particles. J. Colloid In­
terface Sci. 53:314-326 (1975).
29. G. Rhodes. Crystallography—Made Crystal Clear, Academic 
Press, New York, USA, 1993.
30. W. A. Ducker, T. J. Senden, and R. M. Pashley. Direct measure­
ment of colloidal forces using an atomic force microscope. Nature 
353:239-241 (1991).
31. P. M. Young, R. Price, M. J. Tobyn, M. Buttrum, and F. Dey. The 
influence of relative humidity on the cohesion properties of mi- 
cronised drugs used in inhalation therapy. J. Pharm. Sci. 93:753- 
761 (2004).
32. P. G. A. Rogueda. HPFP, a model propellant for pMDIs. Drug 
Dev. Ind. Pharm. 29:39-49 (2003).
33. H. Mizes, M. Ott, E. Eklund, and D. Hays. Small particle adhe­
sion: measurement and control. Colloids and Surfaces A  165:11- 
23 (2000).
34. R. Price, P. M. Young, S. Edge, and J. N. Staniforth. The influ­
ence of relative humidity on particulate interactions in carrier- 
based dry powder inhaler formulations. Int. J. Pharm. 246:47-59 
(2002).
35. P. Begat, D. A. V. Morton, J. N. Staniforth, and R. Price. The 
cohesive-adhesive balances in dry powder inhaler formulations I: 
direct quantification by atomic force microscopy. Pharm. Res. 
21:1591-1597 (2004).
36. C. J. Van Oss, R. J. Good, and M. K. Chaudhury. Additive and 
non-additive surface tension components and the interpretation 
of contact angles. Langmuir 4:884-891 (1988).
37. R. J. Good and R. R. Stromberg. Surface and Colloid Science, 
Plenum Press, New York, 1979.
38. G. Buckton. Interfacial Phenomena in Drug Delivery and Target­
ing, Harwood Academic Publishers, Chur, Switzerland, 1995.
39. G. Buckton, P. Darcy, and D. McCarthy. The extent of errors 
associated with contact angles 3. The influence of surface rough­
ness effects on angles measured using a Wilhelmy plate technique 
for powders. Colloids and Surfaces A  95:27-35 (1995).
40. J. Schultz, L. Lavielle, and C. Martin. The role of the interface in 
carbon fibre-epoxy composites. J. Adhes. Sci. Technol. 23:45-60 
(1987).
41. V. Gutmann. The Donor-Acceptor Approach to Molecular Inter­
actions, Plenum Publishing Corporation, New York, 1978.
42. F. L. Riddle and F. M. Fowkes. Spectral shifts in acid-base chem- 
istry.l. Van der Waals contributions to acceptor numbers. J. Am. 
Chem. Soc. 112:3259-3264 (1990).
43. N. M. Ahfat, G. Buckton, R. Burrows, and M. D. Ticehurst. 
Predicting mixing performance using surface energy measure­
ments. Int. J. Pharm. 156:89-95 (1997).
44. O. Planinsek, A. Trojak, and S. Srcic. The dispersive component 
of the surfac fee energy of powders assessed using inverse gas 
chromatography and contact angle measurements. Int. J. Adhe­
sion Adhesives 221:211-217 (2001).
45. J. C. Hooton, C. S. German, S. Allen, M. C. Davies, C. J. Roberts,
S. J. B. Tendler, and P. M. Williams. An atomic force microscopy 
study of the effect of nanoscale contact geometry and surface 
chemistry on the adhesion of pharmaceutical particles. Pharm. 
Res. 21:953-961 (2004).
46. J. L. Parker, D. L. Cho, and P. M. Claesson. Plasma modification 
of mica: forces between fluorocarbon surfaces in water and non­
polar liquid. J. Phys. Chem. 93:6121-6125 (1989).
47. H. Yotsumoto and R.-H. Yoon. Application of extended DLVO 
theory. J. Colloid Interface Sci. 157:426-433 (1993).
48. P. M. Claesson and H. K. Christenson. Very long range attractive 
forces between uncharged hydrocarbon and fluorocarbon sur­
faces in water. J. Phys. Chem. 92:1650-1655 (1988).
Available online at www.sciencedirect.com
S C I E N C E  / W )  D I R E C T *NCE@





T h e  in f lu e n c e  o f  d o s e  o n  th e  p e r f o r m a n c e  o f  
d r y  p o w d e r  in h a la t io n  s y s te m s
Paul M. Young*, Stephen Edge, Daniela Traini, Matthew D. Jones, 
Robert Price, Dina El-Sabawi, Claire Urry, Charlotte Smith
Pharmaceutical Technology Research Group, Department o f  Pharmacy, University o f  Bath, Bath BA2 7AY, UK
Received 23 September 2004; received in revised form 7 February 2005; accepted 9 February 2005
Available online 7 April 2005
Abstract
The relationship between drug/lactose ratio and aerosolisation performance o f conventional carrier based formulations was 
investigated using the tw in  stage impinger. A  dose range o f ~ 10-450 | ig  o f drug in a 50 mg lactose carrier formulation was 
studied. Statistical differences in both the fine particle dose and fine particle fraction were observed across the dosage range 
(ANOVA,/? < 0.05). In  general, no statistically significant difference (Fishers Pairwise,/? < 0.05) in fine particle dose was observed 
between drug levels o f approximately 10 |xg and 135 p.g, whereas a linear decrease in fine particle fraction was observed across 
the same drug level range (R2 = 0.977). Increasing the dose from  ~135 |xg to 450 |xg resulted in a statistically significant increase 
in  both fine particle dose and fraction (ANOVA /?< 0.05). Such observations may be attributed to the occupation o f ‘active’ 
carrier sites by drug particles at low  drug concentration, since the quantity o f drug particles liberated from  the carrier during 
aerosolisation remains constant at the lower dosing regimes.
©  2005 Elsevier B.V. A ll  rights reserved.
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1. Introduction
Dry powder inhalers (DPI) are routinely used in 
the treatment of respiratory diseases such as asthma. 
In general, the therapeutic agents employed in such 
systems are typically processed/milled to produce
* Corresponding author. Tel.: +61 2 9036 7035; 
fax: +61 2 9351 4391.
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‘micron-sized’ particulates that are of a size range suit­
able for respiratory deposition (0.5-8 |xm, Ganderton 
and Kassem, 1992). Micron-sized particles have a 
relatively high surface area to mass ratio and conse­
quently exhibit greater cohesiveness and adhesiveness 
compared to larger, unprocessed particles. For low 
dose drugs, this high adhesivity and cohesivity can 
result in product development hindrance in regard to 
issues such as content uniformity, stability and drug 
metering.
0378-5173/$ -  see front matter © 2005 Elsevier B.V. All rights reserved, 
doi: 10.1016/j.ijpharm.2005.02.004
P.M. Young et al. /  International Journal o f Pharmaceutics 296 (2005) 26-33 27
A common approach used in order to combat these 
ever present formulation challenges, is to blend the 
micron-sized drug particles with a larger inert carrier 
material, such as lactose, to form an ‘ordered mix’ 
(Hersey, 1975). This approach results in improvement 
of handling and processing properties, accurate dosing 
by dilution of dmg to mass ratio and an increase in 
device drug emptying.
In addition to the advantages that ordered mixes can 
offer, upon inhalation, the dmg particles must be liber­
ated from the formulation so as to penetrate the lower 
respiratory airways. This is achieved by the forces gen­
erated from the patient’s inspiration and can be aided by 
device characteristics, for example, increased pressure 
drops or turbulent air flows.
The forces required to successfully remove dmg 
particles from the surfaces of the carrier will be 
dependent on the physico-chemical properties of the 
dmg and carrier, and the environmental conditions 
under which they are formulated, stored and used. 
Many studies have been conducted to investigate the 
influence of such factors on the performance of DPI 
based systems (Ganderton and Kassem, 1992). These 
include the study of carrier morphology/crystallinity 
(Kawashima et al., 1998; Zeng et al., 2000; Young et 
al., 2002; Larhib et al., 2003; Flament et al., 2004), the 
influence of carrier material, grade and size (Steckel 
and Muller, 1997; Larhrib et al., 1999; Louey et al., 
2003; Steckel and Bolzen, 2004), the influence of 
carrier fines (Lucas et al., 1998; Zeng et al., 1998, 
1999; Louey et al., 2003) and the addition of ternary 
force control agents (Young et al., 2002).
In general, the morphology and roughness of 
carrier particles are not uniform. This is in part due 
to the fact that carriers, such as lactose, are produced 
on a relatively large scale from natural sources. The 
processing and production of such organic materials 
will invariably lead to particles containing regions 
which exhibit different roughness parameters (peaks 
and troughs). Furthermore, since DPI carrier based 
systems are based on organic crystalline materials 
there may also be specific crystal faces with different 
surface free energies present (Muster and Prestidge, 
2002). In addition, production and processing methods 
may also result in the presence of surface macroscopic 
and/or microscopic amorphous regions.
Clearly, these possible inter-intra batch variations 
in physico-chemical properties in the surface of a
carrier material may lead to differences in apparent 
adhesion properties of dmg particles. Furthermore, 
during the dynamic process of mixing, the adherence 
of dmg particles to the more adhesive areas of the 
carrier surface is likely to occur. Indeed, Hersey 
(1975) proposed that the surfaces of larger particles 
consisted of distinct regions containing so-called 
‘active sites’. It was further suggested that when the 
number fine carrier particles in the mixture is below 
the saturation limit of the large particles’ adhesive 
potential, the fine particles will preferentially bind to 
these active sites. When these active sites have been 
completely occupied with fine particles a binary carrier 
system would then exist, i.e., carrier with strongly 
bound fine particles, and free or weakly bound fine 
particles.
This presence of active sites has obvious im­
plications for DPI dmg delivery, since retention of 
dmg particles on these relatively high-energy sites 
during processing and aerosolisation would result 
in a decrease in apparent respirable dmg fraction 
as suggested by Staniforth (1996). The possible 
detrimental effect of active sites may not be an issue 
for the majority of marketed DPIs since they are 
designed to deliver relatively high dmg doses (e.g. 
Ventolin Accuhaler™, Ventodisks™, Pulvinal™, 
and Cyclohaler™ > 200 fig) More recently, the 
development of DPIs which can deliver lower doses of 
dmgs has received attention. In this case, the dmg has 
a higher potency and consequently requires a lower 
dose (e.g. formoterol fumarate 6-12 fig). This may 
lead to variations in dmg delivery as a consequence of 
dmg retention in high-energy sites resulting in severe 
deviations from target doses and label claims.
Current methods for overcoming such issues include 
‘filling’ the potential active sited by increasing the fine 
particle content present on the carrier surface (Zeng 
et al., 1999) or pacifying the effects of active sites by 
the addition of so-called ‘force control agents’ such 
as magnesium stearate (Young et al., 2002). However, 
this approach does not answer questions concerning the 
role of active sites in DPI science.
As part of an ongoing study, the influence of 
dmg dose (carrier/drug ratios 100:1-5000:1) on the 
aerosolisation performance of a model DPI system 
has been investigated. The use of such a system may 
give a valuable incite into the role of active sites in the 
performance of lactose based DPI systems.
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2. Materials and methods
2.1. Materials
Micronised salbutamol sulphate was supplied by 
Aventis Pharma (Holmes Chapel, UK). a-Lactose 
monohydrate was supplied by Borculo Domo (Nether­
lands) and was sieved to produce a 63-90 fim size 
fraction. Water used was purified by reverse osmosis 
(MilliQ, Millipore, France). All solvents used through­
out the study were supplied by BDH (Poole, Dorset, 
UK) and were of at least analytical grade.
2.2. Particle size analysis
The particle size distribution of the sieve frac- 
tioned lactose and micronised salbutamol sulphate 
was determined by laser light scattering (Malvern 
Mastersizer X, Malvern, Worcs, UK). Approximately 
100 mg of sample was suspended in a 0.1% (w/v) 
lecithin-cyclohexane solution and ultra-sonicated at 
25 °C prior to analysis (experimentally determined suf­
ficient for de-agglomeration). A small volume, circu­
lating cell was used equipped either with a 100 mm 
(salbutamol sulphate) or 300 mm lens (lactose).
2.3. Scanning electron microscopy
Morphology of the lactose blends was examined by 
scanning electron microscopy (SEM) (Jeol 6310, Jeol, 
Japan) at lOkeV. Samples were gold-coated prior to 
analysis (Edwards Sputter Coater, UK).
2.4. Drug content determination
Quantification of salbutamol sulphate content 
uniformity and in vitro deposition was by high per­
formance liquid chromatography (HPLC). The HPLC 
system consisted of an AS950 intelligent sampler, 
PU-980 intelligent HPLC pump, 975 UV/VIS detector 
(all Jasco, Japan) and Spherisorb 15 cm, 5 |xm ODS1 
column.
The mobile phase used throughout the investiga­
tion was methanol/water (60:40) and acetic acid 0.1% 
(v/v). Settings were as follows: detection wavelength 
276 nm; flow rate 1.25 ml min-1 ; pressure approxi­
mately 400 kg m2; injection volume 100 fil; analysis 
time 4 min; approximate retention time 2 min.
Linearity was confirmed between 0.1 fig ml-1 and 
10 fig ml-1 (R2 = 0.99). Lactose did not interfere with 
the salbutamol sulphate response. Sample injections 
were performed in duplicate using a bracket standard 
method containing standards prepared from separate 
stock solutions.
2.5. Preparation of blends
Powder formulations containing different levels of 
salbutamol sulphate were prepared by varying the ratio 
of lactose carrier to salbutamol sulphate. Eight blends 
with ratios ranging from approximately 100:1 to 5000:1 
were prepared. Each formulation was designed so that 
50 mg of the powder blend would contain the desired 
dose. The volume of the powder in the mixing cell was 
kept constant to reduce the effect of friction.
Salbutamol sulphate was blended with the lactose 
geometrically. Briefly, an amount of lactose, equiva­
lent to about twice the total mass of salbutamol sul­
phate was used to ‘sandwich’ the drug in the blend. 
This was mixed for 1 min using a Whirlimixer (Fisons, 
UK). Lactose was then added in geometric quantities, 
mixing with a Whirlimixer for 1 min after each addi­
tion. The final blend was mixed in a Turbula (Bachofen, 
Basel, Switzerand) at 46 rev min-1 for 30 min.
The doses formulated were approximately 10 fig, 
30 fig, 40 fig, 90 (xg, 135 fxg, 190 fig, 350 fig and 
450 fig of drug.
Content uniformity (50 mg samples) across each 
blend indicated a coefficient of variation less than 5% 
(n=  10).
Each blend was stored in tightly sealed containers 
with a saturated solution of potassium carbonate (44% 
RH) for a minimum of 48 hours prior to analysis.
2.6. In vitro analysis
The influence of drug-lactose ratio on the aerosoli­
sation performance was investigated using the twin 
stage impinger (TSI) (Copley Scientific, Nottingham, 
UK). Methodology followed that of the British Phar­
macopoeia. Briefly the TSI contained 7 ml of mobile 
phase in stage one and 30 ml mobile phase in stage two, 
which at 601 min-1 produces a cut off mass median 
aerodynamic diameter of 6.4 |im between the two 
stages. The flow through the TSI apparatus was con­
trolled using a GAST rotary vein pump and solenoid
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valve timer (Copley Scientific, Nottingham, UK). Flow 
rate was tested prior to operation using a calibrated 
flow meter.
A filled (49.90 ± 0 .2 0  mg) size 3 gelatine capsule 
was placed into the dosage chamber of the Cyclohaler®. 
The mouthpiece was attached to the TSI apparatus and 
the Cyclohaler® inserted until the end met the inner 
edge of the rubber mouthpiece. The pump was turned 
on and allowed to stabilise for 10 s before starting the 
valve-timer for a 5 s period. The device was removed 
carefully, the empty capsule placed into a beaker, and 
the device was primed and tested with a second capsule. 
This procedure was repeated until five actuations had 
been conducted.
The TSI apparatus was then dismantled and each 
stage was washed with mobile phase into volumetric 
flasks. In addition, the device and capsules were washed 
into a separate volumetric flask. Appropriate sample di­
lutions were made prior to testing by HPLC. All values 
were divided by five to approximate a single dose.
The TSI aerosolisation studies were conducted in 
triplicate for each formulation and were randomised 
for dose.
3. Results
3.1. Particle size analysis
The particle size distributions for both lactose and 
salbutamol sulphate are shown in Fig. 1A and B, re­
spectively. The size distribution for the lactose sample 
(volume median diameter) indicated the majority of 
particles to be between 60 pm  and 200 pm  in diam­
eter. It is interesting to note that the upper size was 
higher than the sieve fraction value (90 pm ) and was 
most likely due to the tomahawk geometry of the lac­
tose particles. Furthermore, approximately 6% of the 
particles exhibited diameters of less than 20 pm  with 
2% less than 5 pm . These can be related to the pres­
ence of fine lactose particles attached to the large car­
rier particles which were clearly visible using SEM. 
This demonstrates that simple sieving does not pro­
vide sufficient energy to remove adhered lactose fines 
from larger carrier particles and that lactose fractions 
produced by sieving consist of a pseudo-ordered mix 
which has obvious formulation implications. Analy­
sis o f the particle size distribution of the micronised
0.01 0.1 1 10 100 1000 
(A) Particle size (Mm)
0.01 0.1 1 10 100 1000
(B) Particle size (Mm)
Fig. 1. Particle size distribution o f63-90 M-m sieve fractioned lactose 
(A) and the micronised salbutamol sulphate (B).
salbutamol sulphate suggested 90% of the particulates 
exhibited a diameter less than 9.4 pm  and 50% less 
than 3.4 pm .
3.2. Scanning electron microscopy
Representative SEM images of 12 p,g, 135 p,g and 
450 p,g dose blends are shown in Fig. 2A-C, respec­
tively. Clear variation in the degree of fine particulates 
(<5 pm ) was observed when comparing the blends. In 
general, a rank-order in particulate number matched 
that of the blend dose.
Unformulated lactose SEM images showed large 
carrier particles with some smaller adhering lactose 
particles which is in agreement with the previously de­
scribed particle size data.
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Fig. 2. Scanning electron microscope images of (A) 12 pg, (B) 
135 pg and (C) 450 pg blends.
3.3. In vitro analysis
The aerosolisation efficiency of salbutamol sulphate 
from lactose carriers was investigated using the TSI. 
Specifically, the influence of dose on the fine parti­
cle aerosolisation was investigated since this is a good 
indicator of respiratory delivery. Data were processed 
and represented as follows: loaded dose (total recov­
ered from all stages and device/capsules); emitted dose 
(total recovered from TSI stages); fine particle fraction 
(dose recovered in stage 2/loaded dose x 100); fine par­
ticle dose (dose recovered in stage 2).
The relationship between the emitted dose and 
loaded dose is shown in Fig. 3 which suggests a linear 
response (R2 = 0.998) with a device removal efficiency 
of 89 ±  4% across all doses. Since the percentage drug 
loss in the device was apparently independent of dose, 
it is reasonable to assume that such losses are due to 
drug adhered to retained lactose, since the formulation 
mass remained constant.
The relationship between fine particle fraction and 
loaded dose is shown in Fig. 4. It can be seen from 
Fig. 4 that the loaded dose has a significant effect on 
performance (ANOVA p< 0 .05). In general, a linear 
decrease (R2 =0.977) in aerosolisation (i.e., fine parti­
cle fraction) was observed on increasing the dose from 
11 |xg to 135 |_Lg followed by an increase when the dose 
was increased from 135 |xg to 450 |xg.
In comparison, the relationship between fine particle 
dose and loaded dose, shown in Fig. 5, suggested that 
the dose level only had a statistically significant effect 
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Fig. 3. Influence of loaded dose on the emitted dose.
P.M. Young et al. /International Journal o f Pharmaceutics 296 (2005) 26-33 31
20 n
V? 1 5 -
10 -
0 100 200 300 4 00 500
Loaded dose (jig)
Fig. 4. Influence of loaded dose on the fine particle fraction.
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Fig. 5. Influence of loaded dose on the fine particle dose.
p<  0.05). No significant increase in fine particle dose 
was observed between 10 |xg and 135 |xg dose.
4. Discussion
The term active site may refer to variations in mor­
phology and surface free energy (which will directly in­
fluence the thermodynamic work of adhesion). In terms 
of morphological effects, there are many possible to­
pographical features that a drug particle may encounter 
on a lactose surface as represented in Fig. 6A. It is en­
visaged that sites with ‘high energy’ (area 1 in Fig. 6A) 
in the carrier surface would be preferentially occupied 
compared to sites with low energy (area 2 in Fig. 6A) as
Fig. 6. (A) Schematic of regions on a carrier surface containing po­
tential (1) high energy and (2) low energy ‘active’ sites. (B) SEM of 
a crevice on a lactose carrier surface containing many micron-sized 
particulates. (C) Theoretical distribution and process of active site 
filling.
s ite  fill t fre c to n
d r u g - c a r r ie r  a d h e s io n
critical adhesion limit
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a consequence of a combination of increased contact 
area, high surface free energy and simple geometric 
constraints.
A possible example of this is shown in Fig. 6B, 
where micron sized particulates have accumulated in a 
recess in the surface of a large lactose carrier particle.
Furthermore, it is suggested that the active sites 
present on the surface of the carrier will have a specific 
energy distribution (Fig. 6C) with a critical, average 
adhesion point below which particles, drug or lactose, 
could be removed. This concept correlates with 
previous studies, which have suggested that surface 
roughness and carrier material directly influence 
aerosolisation of drug from lactose carriers.
Analysis of variation in FPD with loaded dose 
(shown in Fig. 5) indicates that such a critical point 
exists, since no statistical variation in FPD was ob­
served across the dose range 10-135 |xg. As expected, 
a concurrent linear decrease in fine particle fraction 
was observed, since the FPD remained constant as to­
tal dose was increased linearly. Increase in dose from 
135 |xg to 450 |xg resulted in an increase in both FPD 
and FPF, suggesting that the critical adhesion limit 
had been overcome. However, the relationship between 
loaded dose and FPF across the dose range 135^450 |xg 
was not linear. This is to be expected, however, since 
such a system would still contain a certain distribu­
tion of active sites below the critical adhesion limit and 
therefore would result in a non-uniform performance 
response (i.e., the probability of drug-particle removal 
will dependent on the filling of differing energy sites). 
Furthermore, the inherent particle size distribution of 
the micronised drug would set an upper fine particle 
fraction limit.
Another point to consider is the potential for 
formation of drug or drug-lactose fines agglomerates. 
Previous studies have reported the presence of fines 
to increase the fine particle fraction through the 
formation of agglomerates or multiplets (Lucas et al., 
1998). However, recent studies have suggested that the 
agglomeration or individual drug-carrier formation of 
a blend will be related to the balance of adhesion and 
cohesion in the system (Begat et al., 2004). It was sug­
gested that for a salbutamol sulphate-lactose system, 
adhesion would dominate, thus reducing the potential 
for agglomeration (Begat et al., 2004). Such observa­
tions correlate well with the SEM images of the blends 
in this study, which suggested many of the micronised
particulates in the salbutamol lactose system to be 
distributed as discrete entities. However, it is important 
to remember that the formulation mechanism will be 
dependent on the drug and carrier properties.
Indeed, recent studies by Louey et al. (2003) sug­
gest that increased lactose fines result in an agglom­
erate based system. This is likely, since the potential 
free carrier space would be reduced. Furthermore, it is 
envisaged that the fine particle fraction would eventu­
ally plateau and decrease due to multilayer or aggregate 
formation and formulation segregation.
However, observations across the dose range 
10-450 |xg suggested the aerosolisation performance 
to be dominated by the active site theory. Clearly 
many variables would influence this relationship and 
are worth considering for future investigation. These 
include quantifying the influence of inherent fines and 
directly relating the influence of modified carrier sur­
faces to fine particle adhesion.
5. Conclusions
Clear variations in the FPF and FPD were observed 
as a function of dose or drug/lactose ratio ( ~  10^450 |xg 
in 50 mg formulation). Furthermore, the relationship 
between drug/lactose ratio and aerosolisation perfor­
mance was related to the possibility of active sites 
present on the lactose carrier surface.
Although the investigation here suggests the pres­
ence of such regions, a fundamental understanding of 
the mechanisms and mechanics of such a dynamic 
process is required further to circumvent the empir­
ical formulation approaches used today. However, it 
is important to note, this study was conducted using 
one device, lactose and flow rate. In future, it would 
be interesting to study the influence of different car­
rier morphologies, devices (with different sheer and 
de-agglomeration mechanisms) and varied flow rates.
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